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ABSTRACT 
 
The  protein-protein  interactions  (PPIs)  occur  when  two  or  more  proteins are  bound  
together.  Also,  this  protein-protein  interactions (PPIs)  cause  the  various  biological  
processes  in  the  body.  Due  to  this  reason,  abilities  of  controlling  or  inhibiting  PPIs  can  
give  us  promising  advantages  like  (1) better  understanding  of  biological  systems,  (2) 
development  of  new  diagnostic  approaches  for  health  or  disease,  and  (3) establishment  of  
novel  molecular  therapeutics.  Many  proteins  adopt  the  secondary  structures, where  most  of  
protein-protein  interactions  take  place.  -Helices  and  -sheets  are  the  prevalent  secondary  
conformations,  but  there  are  extended  secondary  structures  such  as  -hairpins, -turns,  310  
helix,  and  so  on.  As  a  result,  construction  of  molecules  mimicking  these  protein  
secondary  structures  is  tractable  target  for  drug  design. 
Moreover,  in  drug  discovery,  designing  peptidomimetics  or  non-peptidic  mimetics  is  a  
popular  strategy  instead  using  peptides  or  truncated  peptides  because  peptides  or  truncated  
peptides  are  prone  to  proteolysis  and  degraded  in  the  body.  Also,  peptidomimetics  and  
non-peptidic  mimetics  have  not  only  the  similar  topology  as  peptides  but  also  resistance  
to  proteolysis.  Due  to  these  advantages,  in  this  study,  peptidomimetics  or  non-peptidic  
mimetics  were  synthesized  and  tested  for  different  targets:  (1)  synthesis  of  non-peptidic  
-helical  mimetics  for  p53-MDM2  inhibition,  (2)  solution-phase  synthesis  of  -hairpin  
 xi 
 
peptide  for  the  inhibition  of  multiple  myeloma  cells  (MM)  adhesion,  and  (3)  synthesis  of  
-hairpin  peptoid-peptide  hybrids. 
The  synthesis  in  all  three  different  studies  was  succeeded, but  they  still  need  some  
improvements.  For  instance,  non-peptidic  -helical  mimetics,  terpyrimidyl  derivatives,  
were  synthesized  successfully,  but  they  did  not  show  any  bioactivity  against  p53-MDM2.  
Also,  they  have  a  solubility  problem.  Based  on  these  results,  it  is  necessary  to  improve  
the  pharmacokinetic  properties  and  bioactivity  by  changing  the  substituents  on  the  rings  
or  structures. 
The  -hairpin  peptide  for  the  second  case  already  showed  good  bioactivity  against  
multiple  myeloma  (MM).  For  the  next  level  of  bio-study,  the  considerable  amount  of  a  
-hairpin  peptide  was  demanded.  In  order  to  make  the  substantial  -hairpin  peptide,  the  
solution  phase  peptide  synthesis  was  chosen  instead  of  the  solid  phase  peptide  synthesis  
because  of  the  cost-effect.  Two  methodology  were  tried  for  the  solution-phase  peptide  
synthesis:  (1)  segment  ligation  and  (2)  continuous  synthesis.  In  the  former  case,  the  -
hairpin  peptide  synthesis  was  successful,  but,  in  the  latter  case,  it  is  necessary  to  
investigate  the  appropriate  coupling  reagents  for  each  step.   
Peptoid-peptide  hybrids  has  been  one  of  the  popular  peptidomimetics  in  the  last  two  
decades.  Also,  mimicking  the  peptide  secondary  structure  in peptoids  has  been  studied  
extensively  these  days.  The  combination  of  these  two  factors  was  the  goal  for  the  third  
case.  Because  peptoid-peptide  hybrids  with  a  secondary  structure  can  be  recognizable  by  
native  proteins  and  resistant  to  proteolysis.  So  far,  three  sets  of  peptoid-peptide  hybrids  
were  synthesize  and  checked  the  secondary  structure  formation  by  using  NMR.  However,  
there  was  no  indication  of  the  secondary  structure  formation  in  the  three  sets  of  peptoid-
 xii 
 
peptide  hybrids.  This  result  suggests  that  it  is  necessary  to  introduce  the  more  
constrained  components  in  peptoid-peptide  hybrids. 
In  the  above  three  chapters,  it  has  been  tried  to  find  the  new  drug  candidates  by  
synthesizing  peptidomimetics  or  non-peptidic  mimetics.  Even  though  the  synthesis  was  
successful,  some  intended  results  such  as  the  bioactivity  or  the  secondary  structure  
formation  were  not  obtained.  However,  these  results  can  give  us  the  inspirations  to  
improve  properties  of  peptidomimetics  or  non-peptidic  mimetics  for  a  certain  purpose,  
which  leads  to  earn  the  intended  results  and  eventually  find  new  drug  candidates. 
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CHAPTER  ONE: 
INTRODUCTION 
 
1.1. Amino  acids,  peptides,  and  proteins 
Proteins  are  the  most  abundant  biological  molecules  in  every  cell.  Proteins  also  have  
diversity,  not  only  thousands  of  different  kinds,  but  also  huge  differences  in  size.  
Moreover,  their  biological  functions  in  the  cells  are  the  most  important  since  their  
outcomes  have  an  effect  on  the  biological  pathways  and  genetic  expressions.  Despite  
their  key  functions,  combinations  of  relatively  simple  monomer  subunits  is  the  
fundamental  element  of  protein  structure.  Proteins  are  built  from  a  set  of  20  amino  acids  
are  covalently  linked  in  linear  sequences.  Every  amino  acid  is  a  -amino  acid  which  has  
carboxylic  acid,  amino  group,  and  its  side  chain.  The  presence  of  carboxylic  acid  and  
amino  group  makes  amino  acids  act  as  acids  and  bases.  Also,  side  chain  of  amino  acids  
gives  different  identity  to  each  amino  acid  and  side  chains  occur  in  a  variety  of  
structure,  size,  and  electric  charge.  Two  amino  acids  can  be  covalently  linked  through  a  
peptide  bond  to  obtain  dipeptide.  The  peptide  bond  is  formed  by  removal  of  water  from  
carboxylic  acid  of  one  amino  acid  and  amino  group  of  another  amino  acid.  In  a  similar  
way,  tripeptide,  tetra peptide,  and  so  on  are  formed  from  amino  acids.  When  a  few  
amino  acids  are  involved  in  this  fashion,  the  structure  is  termed  as  an  oligopeptide.  
When  many  peptides  are  involved,  the  product  is  termed  as  a  polypeptides  which  has  
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molecular  weight  below  10,000.  Proteins  contain  thousands  of  amino  acid  residues  and  
have  larger  molecular  weights  (1). 
 
1.2. Protein  structures 
The  primary  structure  of  a  protein  is  the  linkage  of  individual  amino  acids  which  are  
joined  covalently  through  peptide  bonds.  The  peptide  bonds  in  protein  is  planar  as  a  
result  of  resonance  structure  (Figure 1).  This  prevents  the  peptide  bond  rotation  and  gives  
significant  double  bond  character.  Even  though  there  are  two  possible  configurations  for  
the  peptide  bond,  trans  configuration  is  frequently  found  out  in  proteins  due  to  benefit  
from  steric  hindrance. 
The  secondary  structure  of  protein  consists  of  the  ordered  regions  adopted  by  
polypeptide  chains.  The  secondary  structure  is  normally  about  folding  patterns  of  
polypeptide  backbone.  Moreover,  most  of  proteins  contain  secondary  structure  regions.  
There  are  three  common  types  of  secondary  structures: the  -helix,  the  -pleated  sheet,  
and  the  -turn. 
The  tertiary  structure  of  proteins  is  the  three-dimensional  layout  of  all  atoms.  As  the  
length  of  a  polypeptide  gets  longer,  it  will  fold  to  be  more  ordered  and  stable.  Because  
amino  acids  which  are  apart  can  interact  within  folded  protein  structure  through  weak  
bonding  interactions  or  covalent  bonds. 
Some  proteins  such  as  hemoglobin  consist  of  two  or  more  subunits  which  may  be  
same  or  different  types.  Only  proteins  which  contain  more  than  two  subunits  are  able  to  
have  quaternary  structures.  The  quaternary  structure  of  proteins  refers  to  the  arrangement  
of  these  subunits  in  three-dimensional  complexes  (1,2). 
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Figure 1. The resonance structure of peptide bond. 
 
1.3. -helix  mimetics  in  drug  discovery 
The  -helix  was  first  characterized  by  Linus  Pauling  in  1951  (3).  A  typical  -helix  
has  3.6  amino  acids  per  turn,  a  rise  5.4 Å /turn,  and  backbone  dihedral  angles  of   = -50   
and   = -60 .  The  helix  can  be  considered  to  have  three  distinct  faces  because  the  side  
chains  from  certain  residues  are  overlapped  vertically  every  3-4  residues.  In  other  words,  
side  chains  from   helical  residues  at  the  position  i,  i + 3,  i + 4,  and  i + 7  are  positioned  
along  the  same  face  of  -helix.  In  -helix  formation,  there  is  a  large  entropy  cost,  but  
this  can  be  cancelled  out  due  to  intramolecular  hydrogen  bonds  between  the  carbonyl  
oxygen  at  the  i  position  and  the  carboxamide  hydrogen  at  the  i + 4  position  (4).  The  
principal  character  of  -helix  is  the  conformational  hindrance  of  the  side  chains  and  
steric  restriction.  In  numerous  proteins,  -helices  are  the  bioactive  regions  which  mediate  
protein-protein  interactions  along  with  protein-DNA  and  protein-RNA  interactions  (5).   
The  protein-protein  interactions (PPIs)  plays  a  key  role  in  aspects  of  biological  processes.  
Due  to  this  reason,  abilities  of  controlling  or  inhibiting  PPIs  can  give  us  promising  
advantages  like  (1) better  understanding  of  biological  systems,  (2) development  of  new  
diagnostic  approaches  for  health  or  disease,  and  (3) establishment  of  novel  molecular  
therapeutics.  Over  30%  protein  secondary  conformation  adopts  -helices,  allowing  it  the  
most  abundant  secondary  structure  in  nature.  As  a  result,  a  number  of  PPIs  are  involved  
in  -helices  and  mimicking  -helical  templates  is  tractable  target  for  drug  design  (6, 7).   
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Azzarito  and  co-workers  classified  three  primary  design  strategies  on  the  review  paper  
based  on  helix-mediated  interactions  and  structural  features  (8):  (1) type  I  mimetics  which  
are  short  oligomers  and  copy  the  local  contour  of  -helical  structural  motif  (9),  (2)  type  
II  mimetics  which  are  small  non-peptidic  molecules  but  not  always  imitation  of  the  -
helix  structure  of  protein  receptors,  and  (3)  type  III  mimetics  which  are  non-peptide  
scaffolds  and  only  interact  with  key  residues  of  peptide  receptors  not  the  whole  -helical  
conformation  (10,  11). 
Type  I  mimetics  are  the  derivatives  of  peptide  backbone  to  replicate  the  local  region  
of  -helical  conformation  when  protein-protein  interactions  occur.  Peptides  are  not  
therapeutically  appropriate  forms  because  of  their  poor  transport  properties  and  easy  
proteolytic  degradation  (12).  However,  due  to  their  complex  structures,  small  molecules  
are  not  able  to  mimic   completely  their  functions  during  the  biological  process  (13).  
Moreover,  there  is  a  study  to  show  that  synthetic  peptides  are  not  organized  in  solution  
and  adopt  random  conformation  which  delay  the  binding  to  the  partner  proteins  (14).  
Despite  of  these  limitations,  there  have  been  several  approaches  for  oligopeptides  to  
maximize  their  -helical  properties  and  disrupt  protein-protein  interactions.   
The  first  strategy  is  stabilization  -helix  conformation  of  short  peptides  by  using  salt  
bridges,  metal  chelates,  and  covalent  cyclization  (Figure  2).  Aldert  and  Hamilton  studied  
the  restriction  of  helical  structure  of  short  peptides  through  hydrophobic  interactions.  This  
can  be  accomplished  by  incorporating  two  -(3,5-dinitrobenzoyl)Lys  residues  at  various  
positions.  They  found  that  the  helical  stability  is  the  highest  for  the  peptide  when  a  pair  
of  modified  residues  are  positioned  at  the  i  and  i + 4  (15).  Scholtz  and  co-workers  
showed  Glu-Lys  interactions  at  the  position  (i,  i + 3)  and  (i,  i + 4)  stabilize  -helical  
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structures  regardless  of  orientation  of  the  side  chains  (16).  Tsou  and  co-workers  found     
-0.4 kcal/mole  energy  decrease  for  -helical  peptide  through  Phe-Lys  cation-   interaction  
(17).   
The  Mierke  and  Spatola  groups  have  demonstrated  the  inhibition  of  disulfide-bridged  
nonapeptide  to  estrogen  receptor  /co-activator  interaction.  Even  though  circular  dichroism  
spectra  of  the  peptide  indicated  the  minimal  propensity  of  -helix  in  aqueous  condition,  
X-ray  crystal  structure  confirmed  disulfide-bridged  peptide  experienced  the  receptor-
induced  conformational  change  and  bound  to  receptor  with  -helix  conformation  (18,  19,  
20).  Rosenblatt  and  co-workers  reported  a  parathyroid-hormone-related  protein (PTHrP)  
analogue  (21)  and  Fairlie  and  co-workers  demonstrated  short  -helical  peptides  (22).  Both  
of  approaches  utilized  lactam  link  between  lysine  and  aspartic  acid  in  the  i  and  i + 4  
positions  to  stabilize  -helical  structure.   
Despite  of  the  stabilization  of  -helices  through  disulfide  or  lactam  links,  these  
natively  occurring  components  may  be  prone  to  cellular  degradation.  To  overcome  this  
disadvantage,  Grubbs  group  showed  carbon-carbon  bond  restraint  initially    via  a  ring-
closing  metathesis  reaction  from  unnatural  O-ally  serine  residues  (hydrocarbon  stapling)  
(23).  Arora  and  co-workers  also  exploited  ring-closing  metathesis  to  olefin  bearing  
residues  at  the  i  and  i + 4  positions  (hydrogen-bonding  surrogates)  (24).  However,  the  
second  approach  is  more  attractive  because  the  constraining  element  after  ring-closing  
metathesis  does  not  block  any  faces  of  -helix  conformation  unlike  the  result  of  first  
approach  (Figure 3).   
Even  though  all  the  above  strategies  have  developed  the  promising  peptide-based  
inhibitors  with  -helix  conformation,  it  is  impossible  to  control  the  activity  of  these  
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restrained  peptides.  Alleman  group  established  that  external  stimuli  can  govern  the  
protein-binding  activity  in  a  reversible  way.  This  can  be  achieved  by  cis/trans  
isomerization  of  azobenzene  under  radiation  exposure.  An  azobenzene  bridge  was  places  
through  cystein  residues  at  the  i,  i + 4,  i + 7  or  i +  11  positions  and  this  bridge  makes  
the  peptides  switch  between  random  coil-like  and  -helical  conformations  under  photon  
emission  (25).   
Another  approach  for  generation  of  type  I  mimetics  is  the  use  of  foldamers.  Gellman  
and  co-workers  design  -peptides  by  adding  methylene  unit  to  -amino  acids  to  cure  
human  cytomegalovirus (HCMV,  alternatively  know  as  herpesvirus-5)  infection.  They  
identified  a  12-helical  inhibitor  derived  from  the  HCMV  protein  gB  with  an  IC50  of  30 
M  (26).  The  -peptides  have  not  only  better  resistance  to  proteolysis  but  also  more  
favorable  pharmacodynamic  properties.  This  is  because  an  additional  degree  of  freedom  
form  extra  methylene  group  makes  -peptides  more  flexible  and  suitable  for  folding  into  
more  defined  secondary  structures  than  -peptides  (27).  There  are  two  well-known  
secondary  structures  in  -peptides,  the  14-haelix  and  the  12-helix  (named  after  the  
number  of  backbone  atoms  per  hydrogen-bond  ring)  (28).  The  group  of  Schepartz  
showed  3-homodecamer  14-helical  peptide  originated  from  p53  with  slightly  lower  
affinity  than  that  of  the  original  peptide  to  hDM2  (2.5-fold  lower)  (29).  Other  than  -
peptide  design,  mixed  /-peptides  were  used  to  mimic  the  -helical  conformation.  
Gellman  and  co-workers  designed  -foldamers  for  inhibition  of  anti-apoptotic  and  pro-
apoptotic  members  of  the  Bcl-2  family  and  gp41  (30,  31,  32,  33,  34,  35,  36).  One  of  
examples  is  the  development  of  gp41  inhibitors  (35).  The  form  of  repetition  was  
prepared  through  the  insertion  of  3-residues  into  the  -sequence  of  the  C-terminal  
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heptads  repeat  domain  (CHR)  of  gp41.  Later,  recurrent  3-residues  were  replaced  by  
constrained  -residues  to  compensate  the  entropic  penalty  originated  from  the  pre-
organization  of  more  flexible  analogues.  This  approach  produced  the  structural  mimetics  
of  10  turns  of  an  -helical  CHR  domain  and  the  most  potent  peptide  with  a  Ki  of  9 nM  
improved  the  ability  of  inhibition  more  (~380-fold)  than  that  of  the  acyclic  -peptide  
analogue  (35).  Afterwards,  the  Gellman  group  transformed  cyclic  constraints  to  the  ion  
pairings  on  i,  i + 3,  and/or  i,  i + 4  positions  to  stabilize  helical  structures  (36). 
Type  II  mimetics  are  the  small  non-peptidic  molecules  which  bind  to  the  protein  
receptors.  However,  molecules  of  this  class  are  more  like  functional  mimetics,  not  
necessarily  mimicry  of  the  original  helix  structure.  Even  though  it  is  difficult  to  identify  
inhibitors  in  this  class  due  to  different  occupation  or  layout  from  traditional  drug  
molecules,  there  have  been  several  discoveries  of  compelling  inhibitors  of  PPIs  (37-45)  
(Figure  4).   
One  of  examples  is  the  finding  of  Nutlins,  a  family  of  tetra-substituted  imidazoles  
after  a  high-throughput  screen.  These  compounds  were  optimized  to  inhibit  p53-murine  
double  minute  2  (p53-MDM2)  interactions  and  the  most  effective  compound,  Nutlin-3  
showed  IC50  value  of  90 nM  (37).  Shaomeng  Wang  and  co-workers  demonstrated  potent  
inhibitors  based  on  a  spirooxindole  template  after  virtual  screening.  They  found  
compounds  from  this  family  selectively  bound  to  MDM2  protein  (10,000-fold)  over  
mDMX  (murind  double  minute  X)  as  well  as  MI-219  is  the  most  potent  inhibitor  (Ki =  
5 nM)  among  this  pool  of  compounds  (39).   
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Figure 2. Examples of helical stabilization: -  interaction (1), salt-bridge (2), cation-   
interaction (3), disulfide (4), lactam (5), azobenzene (6), olefin (7). 
 
 
Figure 3. Schematics of hydrocarbon stapling and hydrogen-bonding surrogates. 
 
Abbott  laboratories  discovered  the  inhibitors  of  the  Bcl-xL/Bak  via  fragment-based  SAR  
(structure-activity  relationship),  a  modern  drug  discovery  tool.  Despite  of  the  highest  
affinity  of  ABT-737  (Ki = 0.6 nM)  for  Bcl-xL  among  all  the  derivatives  (42),  ABT-737  
was  not  suitable  for  clinical  use  due  to  poor  pharmacokinetic  properties.  Improvement  of  
oral  availability  resulted  in  the  discovery  of  ABT-283  with  the  comparable  affinity  (Ki  
1 nM)  as  that  of  ABT-737  (43).  In  a  recent  reports,  optimized  analogues  of  this  inhibitor  
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showed  suppression  of  cell  growth  in  cancer  cell  lines  with  IC50  values  of  60 - 90 nM  
(44,  45) 
 
  
Figure 4. Examples of type II mimetics. 
 
Type  III  mimetics  are  the  non-peptidic  scaffolds  which  mimic  the  spatial  orientation  of  
the  critical  recognition  residues  from  the  original  helix  instead  of  recapping  the  helical  
structure  like  type  I  mimetics  (46).  Compounds  of  this  class  have  not  only  a simple  rod  
shaped-like    pharmacophore  with  side  chains  oriented  in  a  similar  way  to  that  of  a  
native  -helix  but  also  the  comparable  protein-protein  interaction  areas  unlike  that  of  
type  II  mimetics.   
The  groups  of  Rees  and  Willems  pioneered  this  concept  by  building  trisubstituted  
indanes  as  inhibitors  of  tachykinnin  receptors  (47,  48).  However,  the  first  true  -helix  
mimetic  was  built  by  the  Hamilton  group  (49).  They  showed  the  synthesis  and  
conformational  analysis  of  trisubstituted  3,2´,2´´-terphenyl  derivatives  via  alternating  alkyl  
or  aryl  groups  on  ortho-positions  of  the  aryl  cores.  The  side  chains  on  ortho-position  
were  projected  in  a  similar  way  of  i,  i + 4,  and  i + 7  positions  of  the  -helix.  Analogues  
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of  this  family  were  shown  inhibition  to  calmodulin / phosphodiesterase,  Bcl-xL / Bak,  and  
gp41  interactions  with  IC50  values  of  nanomolar  ranges  (49 - 51).   
Despite  the  potent  inhibition  results,  derivatives  of  this  series  have  a  poor  polarity.  
In  order  to  overcome  this  disadvantage,  Hamilton  and  co-workers  reported  the  
terephthalamide  and  4,4-dicarboxamide  templates  (Figure  5a, b)  which  have  easier  
synthesis  procedure  and  more  drug-like  property  (52,  53).  The  inhibition  results  of  these  
derivatives  against  Bcl-xL / Bak  interaction  were  close  or  lower  than  the  terphenyl  family  
(Ki = 0.78 M  5a1,  1.8 M  5b2,  and  0.11 M  terphenyl).   
 
 
Figure 5. Examples of type III mimetics. 
 
The  group  of  Rebek  demonstrated  a  series  of  oxazole-pyridazine-piperazines  with  
hydrophobic  side  chains  to  mimic  the  i,  i + 4,  and  i + 7  positions  of  the  helix  (Figure  
5c).  The  incorporation  of  heterocyclic  rings  increased  the  hydrophilicity  and  this  surface  
would  project  to  the  solvent  exposed  area.  This  simultaneously  allowed  surface  of  
hydrophobic  side  chains  to  turn  toward  recognition  area  of  protein  receptor  (54).  In  a  
similar  concept  of  pre-rigidity  conformation,  Hamilton  and  co-workers  reported  a  
trispyridylamide  scaffold  by  using  aromatic  oligoamides  which  are  easy  to  synthesize  via  
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amide  bond  formation  (Figure  5d)  (55).  X-ray  crystallography  study  confirmed  this  
template  showed  pre-organized  conformation  because  of  hydrogen-bonding  among  the  NH  
group  of  the  amides,  the  ortho-alkoxy  of  pyridyl  rings,  and  nitrogen  on  pyridyl  rings.  
This  made  side  chains  of  the  scaffold  project  to  the  same  face  as  i,  i + 4,  and  i + 7  
positions  of  the  helix  (56).   
Although  structural  rigidity  is  helpful  to  stabilize  -helix  conformation,  a  degree  of  
flexibility  can  improve  interactions  with  the  target  protein  via  'induced  fit'.  Based  on  
Hamilton`s  original  pyridyl  carboxamide  derivatives,  several  groups  demonstrated  a  
oligobenzamide  scaffold  by  replacing  pyridine  rings  to  benzene  rings,  which  potentially  
decrease  the  number  of  hydrogen-bonds  within  this  structure  of  mimetics  (57 - 60).  
Fletcher  and  co-workers  reported  distribution  of  pyridine  and  benzene  rings  can  control  
intramolecular  hydrogen  bonding  and  inhibition  activity  against  Bak  (Figure  5e)  (61). 
The  Wilson  group  described  the  first  solid-phase  synthesis  for  -helix  mimetics.  They  
built  N-alkylated  oligobenzamides  via  this  method  (Figure  5f)  and  tested  against  to  p53 / 
hDM2  interaction  (62,  63).  The  development  of  this  strategy  can  bring  the  diversity  
libraries  for  -helix  mimetics  with  easy  and  effective  way. 
Although  there  have  been  significant  progress  for  design  and  development  of  -helix  
mediated  protein-protein  inhibitors,  it  is  still  essential  to  understand  -helix  mediated  
interactions   and  generate  therapeutically  relevant  molecules  with  higher  affinity  and  
selectivity  to  protein  receptors.  
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1.4. -sheets,  -turns,  and  -hairpins  in  drug  discovery 
Although  tertiary  structures  of  folded  proteins  are  diverse,  only  limited  secondary  
structures  are  observed  with  long-range  order:  helices  ( and  310)  and  sheets  (parallel  
and  anti-parallel)  (64).  As  a  result,  it  is  critical  to  study  the  characteristic  propensity  of  
helix  and  sheet  conformational  stability  in  order  to  predict  protein  folding  preferences.  
The  -helix  has  been  examined  extensively  to  determine  variables  for  helix  stability  such  
as  the  effects  of  sequence,  side  chain - side  chain  interactions,  solvent,  length,  and  other  
factors.  This  was  possible  because  of  the  development  of  model  system  which  adopts  
-sheet  
structure  and  stability  are  less  well-documented  due  to  the  difficulty  of  model  system  
development  in  aqueous  solution  (66,  67).  There  was  a  first  discovery  of  modest  -
hairpin  model  system  in  1993.  This  resulted  in  the  development  of  recent  well-defined  -
-secondary  structures  (68).   
A  polypeptide  with  lack  of  side  chains  (poly-glycine)  adopts  a  fully  extended  
conformation  or  "zig - zag"  conformation  that  every  peptide  bond  is  located  in  a  common  
plane  and  a  repeat  distance  between  Ci   and  Ci+2  is  7.4  Å   (69).  However,  polypeptides  
with  non-glycyl  residues  relieve  the  steric  tension  by  rotating  slightly  in  both  the  N – C   
and  C  -  C  ´ bonds.  A  repetition  of  this  fold  in  a  regular  fashion  results  in  -structure,  
one  of  the  most  common  structures  in  proteins.  In  -structure,  N – H  and  C = O  of  the  
backbone  are  aligned  approximately  perpendicular  to  the  direction  of  the  chain  and  
involved  in  inter-strand  hydrogen  bonding.  There  are  two  layouts  depending  on  hydrogen  
bonding  arrangement  between  strands  of  polypeptide.  When  hydrogen  bonding  interaction  
between  N – H  and  C = O  occurs  collinear,  -strands  are  arrayed  in  an  anti-parallel  
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fashion.  However,  deviation  from  co-linearity  of  hydrogen  bonding  leads  to  parallel  
arrangement  of  strands  (Figure  6).  The  determinant  of  parallel  or  anti-parallel  
arrangement  is  the  side  chain  interactions  between  strands  (70).  The  side  chains  of  -
conformation  are  toward  to  right  angles  alternatively  above  and  below  the  plane  and  this  
characteristic  alignment  results  in  a  -sheet.  Also,  manipulating  polar  or  non-polar  
residues  provides  an  amphiphilic  property.     
 
 
Figure 6. Hydrogen bonding in parallel and anti-parallel of -sheet. 
 
  When  -strand  changes  its  overall  direction,  a  few  residues  are  involved  in  a  chain  
reversal.  The  chain  reversal,  known  as  -turn  is  formed  with  two  corner  residues  (i + 2  
and  i + 3)  and  hydrogen  bonding  between  i  and  i + 3  (Figure 7).  This  hydrogen  bond  
constrains  the  incoming  and  outgoing  -strands  to  maintain  the  -sheet.  The  -turn  was  
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found  initially  in  silk  proteins  by  Geddes  and  co-workers  (71)  and  defined  
stereochemically  by  Venkatachalam  group  (72).   
Based  on  the  stereochemistry  and  conformation  of  -turns,  they  can  be    classified  into  
seven  different  types:  type  I,  type  II,  type  I ,  type  II ,´  type  III,  type  VI,  and  IG1  (G1  
-bulge  type  I)  (73  -  81).  Type  I,    most  frequently  occurring  in  native  proteins  has  L-
residues  on  both  i + 1  and  i + 2  positions  (76,  77).  However,  proline  favors  to  be  located  
on  i + 2  position.  In  type  II  turns,  proline  as  well  as  L-residue  is  inclined  to  be  found  
on  position  i + 1.  For  the  i +2  position,  glycine,  small  polar  L-residue,  or  D-residue  is  
found  because  of  steric  hindrance  caused  by  a  side  chain  in  the  L-configuration.  As  a  
result,  the  differences  between  type  I  and  type  II  is  the  location  of  proline  due  to  the  
tension  on  the    angle  from  the  cyclic  side  chain. 
 
 
Figure 7. -Turn. 
 
Type  I  ´ and  type  II  ´ are  the  mirror  images  of  type  I  and  type  II and  they  have  the  
opposite  stereochemistry  on  the  equivalent  positions.  For  example,  D-proline  instead  of  L-
proline  would  appear  frequently  on  i + 1  for  type  I  ´ or  on  position  i + 2  for  type  II .´  
Also,  if  residues  with  different  chirality  take  up  the  corresponding  sequence  position,  
their  energy  level  is  comparable. 
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  There  is  a  unique  turn  feature  of  310  helix  (82,  83).  It  still  maintains  hydrogen  bonding  
between  i  and  i + 3,  but  the  incoming  and  outgoing  strands  are  twisted  seriously  as  
regards  to  each  other.  The  turn  in  this  feature  is  called  a  type  III  turn. 
Although  the  peptide  bond  of  polypeptide  prefers  trans-configuration  because  of  benefits  
from  steric  effect,  it  is  also  able  to  accommodate  cis-configuration.  The  type  VI  turn  is  
one  of  the  instances.  The  type  VI  turn  has  hydrogen  bond  (i  and  i + 3)  with  ability  to  
link  two  -strands,  but  mediating  peptide  bond  between  i + 2  and  i + 3  adopts  cis  
conformations. 
The  last  turn  type,  as  known  G1  bulge  type  I,  has  three  corner  residues  instead  of  
typical  two  corner  residues  (Figure  8).  This  results  in  the  hydrogen  bond  between  i  and  
i + 4  and  L  conformation  in  the  i + 3  position  (84).  Sibanda  and  Thorton  reported  that  
-bulge  over  a  
tighter  two-residue  turn  (75).  Normally,  -bulge  turn  is  less  related  to  cross-strand  
interactions  (85)  which  are  crucial  for  peptides  and  proteins  folding  pattern  (86).  This  
propensity  considers  -bulge  turn  type  as  an  element  of  negative  design  (87). 
 
 
Figure 8. G1 -bulge type I turn. 
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The  stereochemical  type  of  side  chains  in  -turns  can  be  defined  in  a  similar  way  
as  R-group  arrangements  on  cyclohexyl  rings  (73).  When  side  chain  exists  in  the  same  
plane  as  polypeptide  backbone,  it  has  equatorial  orientation.  However,  side  chains  exists  
out  of  plane  as  polypeptide  backbone,  it  can  be  defined  as  axial.  Depending  on  turn  
type  and  amino  acids  configuration  in  the  turn  position,  orientation  of  side  chains  can  be  
predicted  (Table  1). 
 
Table 1. Side Chain Orientation of Corner Residues in -Turns (71) 
Turn  Type Position i + 1
a
 Position i + 2
a
 
L-Residue D-Residue L-Residue D-Residue 
I eq ax (down) ax (up) eq 
I  ´ ax (up) eq eq ax (down) 
II eq ax (down) eq ax (down) 
II  ´ ax (up) eq ax (up) eq 
III intermed intermed intermed intermed 
VI (cis peptide bond) eq eq ax (down) ax (down) 
a
  Eq:  equatorial;  ax:  axial;  intermed:  intermediate. 
 
-hairpin  motifs  are  consisted  of  -strands  and  -turns  and  structurally diverse  because  
of  variations  in  the  hairpin  constraints,  variations  in  sequences,  variations  in  the  loop  size,  
and  variations  in  the  appearance  of  -bulges  in  the  -strands  (Figure  9).  Also,  -hairpins  
are  occurring  widely  not  only  in  native  polypeptides  and  proteins  but  also  bioactive  
cyclic  acids  such  as  gramicidin  S  and  peptide  hormones  oxytocin  and  vasopressin.   
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Figure 9. -Hairpin structure. 
 
There  have  been  several  studies  about  stability  factors  of  isolated  -hairpins  (88  -  95)  
and  they  proposed  two  key  elements:  cross-strand  interactions  and  interactions  within  turn  
residues.  Cross-strand  interactions  include  aromatic-aromatic  (96),  electrostatic  (97),  or  
hydrophobic  packing  interactions  (88,  98).  The  one  of  important  interactions  within  turn  
residues  is  combination  of  type  I  -turn  and  a  G1  bulge  which  appears  to  stabilize  in  
many  peptide  hairpins  (99  -  103).  Recently,  it  is  found  that  strands  length  of  five  or  
more  resides  are  required  for  -hairpin  stability  (104).  Despite  of  these  discoveries,  many  
studies  are  still  undergoing  to  determine  the  relative  contribution  of  these  factors  to  -
hairpin  stability. 
Santiveri  et  al  compared  the  contributions  of  turn,  strand,  and  cross-strand  side  chain  -  
side  chain  interactions  via  mutations  on  both  loop  and  strand  and  residue  swapping  
within  a  strand  (105).  They  found  that  side  chain  -  side  chain  interactions  across  the  
strand  may  be  more  important  for  the  hairpin  stability.  This  result  is  crucial  because  
statistical  analyses  of  protein  structure  have  not  considered  these  effects.   
Perez-Paya  group  reported  favor  for  an  aromatic  versus  aliphatic  residue  at  the  i + 3  
position  in  a  type  I  ´ turn  (106).  They  used  the  sequence  Tyr - Asn - Gly - X  as  a  type  I  ´ 
-hairpin  most  stable  despite  of  the  
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appearance  of  tyrosine  on  the  cross-strand  from  X.  This  result  does  not  follow  a  typical  
-sheet  character,  but  the  author  explained  this  with  context  dependence.  In  another  study,  
Balaram  and  co-workers  studied  aromatic  side  chain  -  side  chain  interactions  in  organic  
solvent  in  order  to  examine  their  importance  without  hydrophobic  driving  force  (107).  
They  found  that  aromatic  interactions  contribute  to  hairpin  stability  through  weak  
electrostatic  effects  instead  of  the  hydrophobic  effects.   
Hughes  and  Waters  investigated  the  role  of  lysine  methylation  in mediating  protein  –  
protein  interactions  within  a  -hairpin  system  (108).  Methylation  of  lysine  in  histone  tails  
causes  the  binding  of  chromodomain  proteins  and  eventually  regulates  chromatin  
condensation.  This  can  be  achieved  by  packing  the  methylated  lysine  within  an  aromatic  
pocket.  Based  on  this  interaction,  the  interaction  of  a  trimethylated  lysine  and  tryptophan  
within  -hairpin  was  investigated  to  resolve  the  nature  of  this  type  of  cation  -    
interaction  (Figure  10a).  They  found  that  trimethylation  of  lysine  improves  the  interaction  
with  tryptophan  by  approximately  0.7 kcal/mol  and  hairpin  structure  shows  the  compelling  
thermal  stability.  This  interaction  can  contribute  to  structural  stability  for  hairpin  loops  
within  designed  proteins. 
The  groups  of  Cochran,  Wu,  and  Eidenschink  suggested  tryptophan  zipper  motif  to  
stabilize  -hairpin  structure  (109  -  111).  This  motif  can  resolve  the  disadvantage  of  a  
disulfide  bridge  constraint.  Even  though  using  a  disulfide  bridge  has  been  valuable  to  
select  specific  peptide  loop  structures  for  certain  protein  targets  in  phage-display  
technology  (112),  this  bridge  is  susceptible  to  be  cleaved  in  vivo  in  the  presence  of  a  
free  thiol  group.  Also,  the  disulfide  link  is  not  able  to  stabilize  -hairpin  structure  due  
to  many  degrees  of  rational  freedom  which  cost  the  loss  of  other  stabilizing  interactions  
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(113).  However,  tryptophan  zipper  motifs  induce    stacking  interactions  between  
cross-strand  tryptophans  at  non-hydrogen  bonding  positions  and  make  -hairpins  stable  
(Figure  10c). 
Many  groups  have  investigated  two-residue  turn  sequences  to  stabilize  -hairpin  
structures.  For  example,  Asn – Gly,  D-Pro – Gly,  Aib – Gly,  D-Pro – L-Pro,  and  Aib – D-
Pro  turns  promote  the  formation  of  -hairpins  because  of  their  character  to  form  type  I  ´ 
or  type  II  ´ turn  (114,  115).  Even  though  three-residue  turn  is  considered  as  an  element  
of  negative  design  (87),  there  have  been  a  few  successful  three-residue  turn  design  
recently  in  a  -hairpin  structure.  One  of  examples  is  G1  bulge  in  a  ubiquitin-based  
hairpin  sequence  that  resulted  in  a  non-natural  strand  registry  (116).  However,  Balaram  
and  co-workers  reported  a  three-residue  turn  which  maintains  native  strand  registry  in  
methanol  (Figure  10b).  This  can  be  achieved  by  insertion  of  D-Ala  after  L-Pro  in  a  two-
residue  type  II  -turn,  D-Pro  -  L-Pro  that  leads  to  a  left-handed  helical  conformation  
(117). 
So  far,  the  factors  which  are  naturally  occurring  and  stabilizing  -hairpin  structure  
have  been  discussed.  Recently,  many  groups  have  investigated  the  possibility  of  
incorporation  of  peptidomimetics  into  -sheet  or  -hairpin  structures  because  these  
artificial  elements  may  improve  the  proteolytic  resistance.  Many  groups  have  examined  
all  aspects  of  -hairpin  structure  including  the  turn,  strands,  backbone,  hydrogen  bonding,  
side  chain  -  side  chain  interactions,  and  chirality  and  found  the  tolerance  of  -hairpins  
from  the  a  wide  range  of  alterations. 
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Figure 10. Structures of -hairpin sequences. 
 
Bartlett  and  co-workers  have  suggested  an  amide  isostere  consisting  of  a  1,6-dehydro-
3(2H)pyridinone  ring  for  templation  of  -strands,  known  as  @-tide  (118  -  120).  This  @-
tide  provides  not  only  rigid  template  but  also  a  characteristic  CD  signal  at  280  nm  
(Figure  11a).  This  signal  produced  by  vinylogous  amide  is  sensitive  to  conformational  
changes  that  acts  as  an  indicator  of  sequence  and  side  chain  effects  on  -hairpin  folding.  
Based  on  the  CD  signal  at  280  nm,  the  authors  determined  intrinsic  stability  of  each  
residue  and  contribution  of  the  side  chain  -  side  chain  interaction  (120). 
Another  example  of  a  template  b-sheet  is  the  introduction  of  a  guanidine-pyrrole  
moiety  at  the  N  terminus  of  a  tripeptide  (Figure  11b).  Schmuk  and  colleagues  found  that  
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this  peptidomimetic  model  was  bound  to  a  tetra peptide  in  water  through  electrostatic  and  
hydrogen  bonding  between  the  guanidinopyrrole  and  the  terminal  carboxylate  of  tetra 
peptide  (121).  This  study  showed  sequence  selectivity  regarding  charge  pairing  along  the  
strands. 
 
 
Figure 11. Structures of peptidomimetics. 
 
Kelly  and  co-workers  have  showed  the  replacement  of  strand  residues  in  Apeptide  
with  alkene  functionality.  They  switched  Cand  the  NH  to  alkene  moiety  and  
investigated  the  effect  of  backbone  hydrogen  bonding  in  protein  aggregation  (Figure  11c).  
Even  though  formation  of  spherical  aggregates  was  observed,  they  found  that  alkene  
isostres  on  the  Phe  19  and  Phe  20  in  A peptide  prevent  amyloid  formation  (122). 
Last  example  of  incorporation  of  peptidomimetic  to  -hairpin  structure  is  the  utilization  
of  a  photoswithchable  azobenzene  as  the  turn  sequence  (Figure  11d).  Two  groups  studied  
and  found  -hairpin  structure  was  maintained  in  the  presence  of  cis-azobenzene  
configuration  (123-125).  However,  depending  on  the  difference  in  the  strand  sequences,  
two  groups  showed  different  result:  the  system  designed  by  Hilvert  and  co-workers  was  
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shown  aggregation  in  the  trans- configuration,  but  the  model  made  by  Renner  and  
colleagues  was  not  shown  any  sign  of  aggregation  in  either  configuration. 
As  discussed  in  the  previous  topic,  -helix,  the  design  of  protein  epitope  mimetics  is  
considered  as  an  innovative  approach  for  the  development  of  protein  -  protein  and  
protein  -  nucleic  acid  interaction  inhibitors.  This  is  because  molecular  recognition  of  
proteins  is  normally  occurring  on  the  surface  exposed  secondary  structure  motifs  such  as  
-hairpins  and  -helices.  There  have  been  many  studies  about  the  -hairpin  structure,  
that  contributed  to  the  development  of  -hairpin  motifs  which  can  mimic  the  partial  
contour  of  the  restrained  macro cyclic  molecules  (126,  127).  Also,  using  parallel  synthetic  
chemistry  in  solid-phase  promotes  the  diversity  of  -hairpin  mimetics  as  well  as  
optimization  of  their  propensities  (128). 
The  group  of  Fasan  found  that  the  distance  between  the  Catoms  of  two  residues  i  
and  i  +  2  along  one  strand  of  a  -hairpin  is  comparable  to  the  -helical  side  chains  at  
the  i  and  i  +  4  residues  (129).  In  order  to  test  this  design  against  HDM2,  a  series  of  -
hairpins  with  different  peptide  sequences  was  prepared.  After  a  surface  Plasmon  
resonance  (SPR)  assay,  -hairpin  with  a  sequence  of  Phe1,  Trp3,  and  Leu4  showed  
inhibition  of  p53  binding  to  HDM2  (IC50  =  125   8 M)  (Figure  12).  For  further  
investigation,  Phe  or  Trp  residue  was  replaced  by  Ala  and  it  was  found  that  -hairpin  
lost  the  inhibition  ability  of  p53  binding.  This  result  indicated  the  significance  of  the  
side  -  chain  complementarily.   
In  many  organisms,  it  is  found  that  the  large  family  of  cationic  host-defense  peptide  is  
involved  in  anti-infective  defense  mechanism  (130).  These  short  cationic  peptides  
typically  have  10-50  residues  and  a  net  positive  charge  of  +2  to  +10.  They  have  
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amphipathic  properties,  but  different  sequences  and  secondary  structures.  Due  to  their  
participation  in  immune  response,  this  family  of  peptides  has  been  considered  as  a  
potential  pool  for  development  of  novel  antibiotics.   
 
 
Figure 12. -Hairpin inhibitor disrupting the HDM2-P53 interaction. 
 
Among  many  cationic  peptides,  PG-1  was  taken  as  a  initial  model  for  -hairpin  
mimetic  design  (131).  Because  PG-1  not  only  adopts  -hairpin  structure  via  two  cross-
strand  disulfide  bridges  but  also  displays  wide  spectrum  of  antimicrobial  activity  in  
micromolar  range.  However,  due  to  its  weak  potency,  it  is  necessary  to  modify  
sequences  or  propensity  of  the  peptide.  Recently,  a  family  of  protein  epitope  mimetic  
(PEM)  based  on  PG-1  was  demonstrated  that  show  the  improvement  of  their  potency  
including  the  lead  compound  L27-11  (Figure  13)  which  shows  nanomolar  range  activity  
(132).  These  PEM  compounds  have  the  stabilized  -hairpin  structure  through  a  D-Pro-L-
Pro  turn  template  and  attract  to  the  negatively  charged  bacterial  surface  because  of  their  
positive  charges  in  the  strands.  After  discovery  of  L27-11,  another  optimization  was  
followed  to  improve  drug-like  properties  such  as  the  plasma  stability,  target  stability,  and  
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toxicology.  This  resulted  in  the  discovery  of  compound  POL7001  (Figure  14)  and  the  a  
clinical  lead  candidate  POL7080  (132).  The  safety  of  POL7080  is  under  testing  in  
healthy  humans  in  a  phase  I  clinical  study,  but  it  is  already  considered  as  the  first  in  a  
new  class  of  antibiotics  against  Gram-negative  bacteria  (133). 
 
 
Figure 13. The template of -hairpin antibiotic L27-11. 
 
Figure 14. The template of -hairpin antibiotic POL7080. 
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CXCR4  is  characterized  as  the  class-A  family  of  G-protein  coupled  receptors  (GPCRs)  
and  plays  a  role  as  a  co-receptor  for  CD4-dependent  HIV  infection  of  human  T-cells  as  
well  as  a  helper  in  hematopoietic  stem  cells  (HSCs)  mobilization  from  the  bone  marrow  
(BM)  to  peripheral  blood.  Since  CXCR4  appears  on  the  surface  of  the  majority  of  HSCs  
and  interacts  with  its  native  ligand  SDF-1  in  BM,  CXCR4  antagonist  are  considered  as  
promising  novel  therapeutic  for  the  efficient  mobilization  and  harvest  peripheral  blood  
HSCs  by  interruption  of  the  SDF-1/CXCR4  interaction  (134)  both  in  cancer  therapy  as  
antimetastatic  agents  (135)  and  in  inflammation  and  tissue  repair  (136).   
Polyphemusin  II  isolated  from  the  American  horseshoe  crab  (Limulus  polyphemus)  has  
-hairpin  structure  with  18-amino  acid  residues  and  shows  inhibition  to  CXCR4.  This  
peptide  was  taken  as  a  starting  point  and  a  few  of  PEM  molecules  were  designed  and  
optimized  in  biological  assays.  For  example,  POL3026  (Figure  15),  POL5551,  and  
POL6326  are  highly  potent  and  selective  CXCR4  antagonists  (127,  137).  POL6326  
showed  very  limited  or  no  mobilization  of  tumor  cells  in  the  leukapheresis  and  has  
already  moved  into  a  phase  II  clinical  trial  for  the  transplantation  of  autologous  stem  
cells  in  newly  diagnosed  multiple  myeloma  patients.   
Also,  based  on  the  recent  X-ray  structure,  the  -hairpin  is  bound  to  CXCR4  through  
residues  in  the  inward-facing  projecting  walls  of  the  seven  transmembrane  helical  bundle,  
a  few  extracellular  loops,  and  the  N-terminal  segment  (138).  For  the  selective  high  
affinity,  a  network  of  polar,  hydrogen  bonding,  and  hydrophobic  interactions  is  important  
between  the  ligand  and  the  receptor.  According  to  the  structural  similarity  between  this  
bound  ligand  and  POL3026,  the  macro cyclic  b-hairpin  mimetic  may  interact  with  
CXCR4  in  a  fundamentally  identical  way. 
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Figure 15. Structure of CXCR4 antagonist (POL 3026). 
 
The  fundamental  understanding  of  -hairpin  structure  and  folding  has  been  improved  
with  the  discovery  of  well-defined  -hairpin  model  systems.  Based  on  this  improvement,  
protein  epitope  mimetics  (PEM)  with  -hairpin  structures  have  come  to  the  light  in  drug  
discovery.  With  some  early  success,  this  field  is  now  well  on  its  way  to  discovering  
well-folded  -hairpin  structure  with  high  therapeutic  potency  against  diverse  disease. 
 
1.5. Solid-phase  peptide  synthesis 
The  first  synthesis  of  peptides  was  tried  by  Theodor  Curtius  in  1882  (139).  He  made  
a  dipeptide,  Bz-Gly-Gly,  by  mixing  benzoyl  chloride  and  the  silver  salt  of  glycine.  
However,  Emil  Fisher  was  generally  considered  as  the  first  scientist  who  demonstrated  
the  total  chemical  synthesis  of  proteins  (140).  In  1907,  Fisher  reported  an  
octadecapeptide  comprising  of  fifteen  glycine  and  three  leucine  residues  (141).  Another  
improvement  of  peptide  synthesis  after  Fischer`s  era  was  built  by  Bergmann  and  Zervas  
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(142).  They  suggested  a  reversible  protecting  groups  for  the  -amino  groups  in  early  
1930s.  This  discovery  allowed  to  control  the  sequences  in  peptide  synthesis  as  well  as  to  
avoid  the  racemization  of  amino  acid  in  the  amide  coupling.  With  the  carbodiimide  
coupling  methods  (143)  along  with  protecting  group  strategies,  small  peptides  were  able  
to  be  synthesized  in  solution-phase  such  as  glutathione  (144)  and  carnosine  (145).  The  
group  of  du  Vigneaud  showed  the  synthesis  of  oxytocin  in  1954  (Figure  16)  (146). 
Although  the  above  approaches  of  peptides  and  proteins  have  been  performed  in  
solution-phase,  the  majority  of  peptide  synthesis  have  been  accomplished  in  solid-phase  
by  using  the  solid  support  such  as  resin  bead.  This  is  because  solid-phase  synthesis  has  
several  advantages  in  comparison  with  the  solution-phase  methods  (147).  First,  since  the  
synthetic  intermediate  is  always  bound  to  the  resin,  the  excess  reagents  or  unbound  by-
products  can  be  washed  away  easily.  This  leads  to  minimize  the  handling  losses  and  
avoid  further  purification.  Second,  the  use  of  large  excess  of  reagents  can  force  the  
reaction  to  the  completion.  As  a  result,  the  couplings  are  fast  and  close  to  quantitative.  
Last,  depending  on  cleavage  conditions  and  appropriate  anchor  or  linker  groups,  the  
polymeric  resins  are  occasionally  able  to  be  regenerated  and  recycled. 
Solid  phase  peptide  synthesis  (SPPS)  was  introduced  by  Merrifield  first  in  1963  (148).  
In  SPPS,  the  C-terminal  amino  acid  of  the  intended  peptide  is  bound  covalently  to  a  
solid  support.  The  elimination  of  N()-protecting  group  is  followed  in  the  attached  
peptide  and  the  next  amino  acid  in  N()-and  side-chain  protected,  carboxyl-activated  
form  is  added  after  washing  the  resin-bound  amino  acid  (Figure  17).  Once  the  expected  
peptide  bond  is  formed  successfully,  the  excess  reagents  and  by-products  are  removed  via  
filtration  and  washing.  These  steps  are  repeated  until  the  desirable  peptide  is  formed  on  
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the  resin.  In  the  last  step,  every  protecting  group  is  eliminated  in  the  presence  of  
hydrofluoric  acid  (HF)  or  trifluoroacetic  acid  (TFA).  During  this  process,  the  linker  
bound  to  the  solid  support  covalently  is  also  cleaved  to  give  the  crude  peptide  which  
needs  to  be  purified  through  diverse  methods.   
 
 
Figure 16. Synthesis of small peptide. 
 
Although  the  synthesis  of  peptides  containing  about  40-50  amino  acids  is  still  limited  
through  the  most  optimized  SPPS,  the  invention  of  SPPS  has  changed  the  history  of  
peptides  and  protein  chemistry.  Even  the  SPPS  is  extended  its  application  for  the  
synthesis  of  small  non-peptide  compounds.  Despite  of  its  useful  usage,  a  few  of  essential  
conditions  are  required  for  the  successful  solid  phase  peptide  synthesis  (149). 
The  first  requirement  is  cross-linked  insoluble  polymeric  supports  such  as  resin  beads  
are  stable  to  the  synthetic  conditions.  The  initial  resin  form  used  by  Merrifield  was  
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polystyrene  beads  where  the  styrene  is  fractionally  cross  linked  with  1%  divinylbenzene  
and  the  chloromethyl  group  acts  as  an  anchor  or  a  linker  (Figure  18).  The  next  amino  
acid  can  be  coupled  to  the  linker  through  an  ester  group.  This  ester  group  is  stable  to  
the  reaction  conditions  during  the  peptide  synthesis  and  cleaved  by  using  harsh  acidic  
condition  at  the  last  step  of  the  synthesis.  One  disadvantage  of  polystyrene  beads  is  its  
hydrophobicity.  Because  the  growing  peptide  is  hydrophilic,  the  growing  peptide  is  not  
solvated  well  and  folds  itself  to  form  internal  hydrogen  bonds.  This  eventually  prevents  
the  next  amino  acid  from  accessing  to  the  end  of  growing  peptide  chains.  To  resolve  
this  problem,  it  is  necessary  to  develop  more  polar  solid  supports  such  as  Sheppard`s  
polyamide  resin.  In  addition,  the  conditions  for  the  non-peptide  synthesis  are  different  
from  those  of  the  peptide  synthesis.  This  demands  for  the  development  of  new  class  of  
resins  like  Tentagel  resin  consisting  of  80 %  polyethylene  glycol  implanted  to  cross-
linked  polystyrene.  Regardless  which  polymer  resin  is  chosen  for  the  synthesis,  they  have  
to  be  swelling  well  and  robust  to  the  synthetic  conditions  for  the  better  synthesis  
efficiency. 
The  second  requirement  is  about  a  linker  or  an  anchor  which  is  bound  to  the  
polymer  chain  of  the  solid  support.  It  should  contain  the  reactive  functional  group  to  the  
starting  material  in  the  intended  synthesis  and  the  resulting  linker  should  be  inert  
throughout  the  whole  synthetic  process.  However,  it  can  be  cleaved  readily  to  give  the  
final  molecule.  Depending  on  the  functional  groups  on  the  starting  material  or  the  final  
product,  different  linkers  are  used.  The  Wang  resin  has  the  suitable  linker  for  the  
addition  and  release  of  carboxylic  acids.  An  N-protected  amino  acid  is  bound  to  the  
 30 
 
linker  via  an  ester  link  and  this  link  is  robust  to  the  coupling  and  deprotection  steps  
during  the  peptide  synthesis. 
Once  the  synthesis  is  completed,  the  final  peptide  is  cleaved  from  the  bead  by  using  
trifluoroacetic  acid  (Figure  19a).  However,  starting  materials  with  carboxylic  acid  are  
bound  to  the  Rink  resin  through  an  amide  link.  After  all  the  aimed  reactions  are  
finished,  the  final  product  is  released  with  a  primary  amide  group  instead  of  the  original  
carboxylic  acid  under  the  TFA  treatment  (Figure  19b).  If  a  starting  material  has  the  
primary  or  secondary  alcohol  group,  a  linker  on  a  dihydropyran  derivatized  resin  is  
suitable.  The  alcohol  group  can  be  linked  to  the  resin  in  the  presence  of  pyridinium  4-
toluenesulfonate  in  dichloromethane  and  the  cleavage  of  final  product  will  be  done  with  
the  treatment  of  TFA  (Figure  19c). 
The  last  requirement  is  protecting  functional  groups,  which  are  not  involved  in  any  
synthetic  reactions  during  SPPS.  The  selection  of  appropriate  protecting  groups  is  very  
crucial.  Not  only  are  protecting  groups  stable  to  the  reaction  conditions  during  the  whole  
synthetic  process  but  also  they  can  be  removed  efficiently  under  the  mild  conditions.  
Regarding  the  peptide  synthesis,  two  primary  protecting  group  strategies  are  used.  The  
first  strategy  is  the  use  of  Boc/benzyl  protecting  pair  useful  for  the  Merrifield  resin  
(Figure  18).  The  Boc-N()-protected  amino  acid  is  attached  to  the  growing  peptide  chain  
in  the  synthesis  and  the  Boc  (tert-butyloxycarbonyl)  group  is  deprotected  with  TFA  to  
make  amino  group  available  for  the  next  coupling  with  another  Boc-N()-protected  
amino  acid.  Other  functional  groups  on  the  amino  acid  residues  also  need  to  be  
protected  during  the  synthesis.  However,  this  protecting  group  should  be  robust  to  TFA.  
Normally,  benzyl-type  protecting  groups  are  used  because  they  are  stable  to  TFA  but  
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susceptible  to  hydrofluoric  acid.  In  addition,  the  bond  between  the  growing  peptide  chain  
and  the  linker  is  affected  by  hydrofluoric  acid.  As  a  result,  treatment  with  hydrofluoric  
acid  cleaves  the  final  product  as  well  as  deprotects  functional  groups  on  the  residues  at  
the  last  step.  However,  this  strategy  has  one  major  disadvantage  which  is  the  use  of  
hydrofluoric  acid.  Because  hydrofluoric  acid  is  a  corrosive  chemical  which  might  
jeopardize  human  health.  To  avoid  the  serious  health  risk,  Fmoc/t-Bu  strategy  is  used  as  
an  alternative.  In  this  case,  N()-terminus  of  every  amino  acid  involved  in  couplings  to  
the  growing  peptide  chain  is  protected  by  9-fluorenylmethoxycarbonyl  (Fmoc)  group  
instead  of  Boc-group.  Because  Fmoc-group  can  be  deprotected  with  a  mild  base  such  as  
piperidine.  Other  functional  groups  on  amino  acid  residues  are  protected  by  t-butyl  group  
which  can  be  removed  easily  with  TFA  rather  than  hydrofluoric  acid.  Moreover,  the  
suitable  resin  (e.g.  Wang  resin)  is  chosen  where  the  bond  between  linker  and  the  
growing  peptide  is  cleaved  with  TFA. 
Protein  synthesis  has  been  challenging  subject  in  organic  chemistry,  but  it  is  a  very  
critical  topic  in  synthetic  biology.  There  have  been  numerous  modifications  and  changes,  
such  as  invention  of  SPPS  for  the  generation  of  proteins.  Despite  of  huge  efforts,  the  
efficiency  of  protein  synthesis  is  still  relatively  low.  To  resolve  this  problem,  it  is  
necessary  to  develop  more  efficient  and  flexible  peptide  chemical  synthesis  which  
contributes  to  the  further  study  in  biology  and  drug  discovery. 
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Figure 17. The key process of solid-phase peptide synthesis. 
 
1.6. Solution-phase  peptide  synthesis 
As  mentioned  in  the  previous  chapter,  Curtius  and  Fisher  are  the  first  pioneers  in  
simple  peptide  chemical  synthesis  in  early  twentieth  century.  Since  then,  the  chemistry  
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has  been  developed  based  on  selection  of  protecting  groups  for  amino  acids,  their  
deprotection,  and  peptide  bond  formation.  These  days,  two  main  peptide  synthesis  
approaches  are  applied. One  is  solution-phase  peptide  synthesis  and  the  other  is  solid-
phase  peptide  synthesis  that  have  the  fundamentally  same  principles.  In  this  chapter,  
principles  for  the  peptide  synthesis  in  solution  will  be  covered. 
 
 
Figures 18, 19. Merrifield resin (a) and types of resins (b, c, d). 
 
It  is  important  to  prepare  optically  pure  products,  but  racemization  can  occur  during  
amino  acid  deprotection  as  well  as  amino  acid  activation  steps.  Two  racemization  
mechanisms  were  considered:  (1)  direct  proton  abstraction  (150)  and  (2)  racemization  
through  oxazol-5(4h)-ones  (151,  152).  In  the  former  case,  it  is  a  very  rare  situation  such  
as  the  rapid  racemization  of  phenylglycine  derivatives.  The  strong  base  triggers  the  
racemization  by  abstracting  the  -proton  on  amino  acid  (Figure  20).  This  can  be  solved  
with  the  application  of  suitable  conditions  like  the  use  of  a  tertiary  amine  (153,  154).  In  
the  latter  case,  the  formation  of  oxazol-5(4H)-ones  is  involved  in  racemization  mechanism  
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(151).  When  the  carbonyl  moiety  of  N-acyl  amino  acids  (acyl = acetyl,  benzoyl,  piperidyl,  
and  so  on)  is  activated,  oxazol-5(4H)-ones  is  formed  which  gives  chirally  unstable  
intermediates  through  tautomerization  of  the  oxazol-5(4H)-ones  (Figure  20).  In  order  to  
avoid  the  formation  of  oxazol-5(4H)-ones,  urethane-protected  amino  acids  (e.g.  
benzyloxycarbonyl,  tert-butyloxycarbony  etc)  has  been  used  for  the  peptide  chemical  
synthesis  because  of  their  resistance  to  racemization  during  activation  and  coupling. 
As  mentioned  earlier,  suitable  protecting  groups  on  amino  acids  is  critical  to  avoid  
recamization.  Not  only  that,  they  are  also  important  to  control  the  peptide  formation.  
N()-protected  amino  acid  and  C()-protected  amino  acid  are  used  to  control  the  peptide  
bond  formation.  After  peptide  formation,  protected  dipeptide  can  be  isolated,  purified,  and  
characterized.  For  the  next  coupling,  N()-protecting  group  is  removed  and  another  N()-
protected  amino  acid  is  coupled  to  this  dipeptide.  As  a  result,  in  order  to  obtain  desired  
peptide,  appropriate  protecting  groups  should  be  selected  for  the  N()-amino,  carboxyl  
moiety,  or  side-chain  functional  groups.  In  the  following  chapters,  different  kinds  of  
protecting  groups  and  their  deprotection  remedy  are  described  in  detail. 
Bergmann  and  Zervas  introduced  Cbz-group  (Figure  21)  for  the  protection  of  amino  
groups  (155).  Z-amino  acid  can  be  prepared  via  the  reaction  between  benzyloxycarbonyl  
chloride  and  amino  acid  under  the  Schotten-Bauman  condition.  This  protecting  group  can  
be  removed  by  hydrogenolysis,  reduction  with  sodium  in  liquid  ammonia,  liquid  HF  and  
so  on.  However,  hydrogenolysis  (155)  and  acidolysis  with  HBr  (156)  are  the  most  
conventionally  used  procedures.  However,  if  a  peptide  chain  accomdates  sulfur-containing  
amino  acids  such  as  Cys  and  Met,  the  hydrogenolysis  of  Cbz-group  fails  due  to  catalyst  
poisoning.  To  overcome  this  problem  many  attempts  were  made,  for  example  use  an  
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additive  (e.g.  BaSO4  (157),  boron  trifluoride  etherate  (158))  or  a  proton  donor  (e.g.  1,4-
cyclohexadiene  (159),  ammonium  formate  (160),  cyclohexene  (161)).  This  was  reported  to  
improve  hydrogenolysis  only  for  the  Met-containing  peptides.  Kuromizu  and  Meienhofer  
demostraned  catalytic  hydrogenolysis  of  Cbz-group  from  Cys-containing  peptide  in  liquid  
ammonia  (162).  This  method  was  applied  for  the  somatostatin  synthesis  (163).  There  are  
a  few  protecting  groups  which  structurally  similar  to  Cbz-group,  but  more  stable  in  
acidic  condition  (Figure  21).  The  incorporation  of  an  electron-donating  group  on  the  
aromatic  ring  improves  the  acid  liability  of  the  Cbz-group.  (164  -  170).  These  groups  
can  be  removed  by  hydrogenolysis  or  mild  acid. 
McKay  and  Albertson  was  introduced  Boc  group  (Figure  22)  as  another  amino  
protecting  group  (171).  Di-tert-butyl  bicarbonate  is  preferably  used  to  prepare  for  Boc-
amino  acids  (172,  173)  and  the  Boc  group  can  be  removed  under  mild  acidic  conditions  
like  TFA.  During  the  Boc  cleavage  by  acidic  treatment,  tert-butyl  cation  is  formed  which  
causes  many  side  reactions  such  as  alkylation.  To  prevent  the  side  reaction,  anisole  is  
used  as  a  cation  scavenger. 
When  Lys(Boc),  Glu(OtBu),  and  Asp(OtBu)  as  well  as  sulfur-containing  amino  acids  
(Met  and  Cys)  are  involved  in  the  peptide  chain,  both  Cbz-  and  Boc-protecting  groups  
cannot  be  applied  for  -amino  groups.  In  order  to  avoid  the  dilemma,  triphenylmethyl  
(trityl : Tri)  group  (174  -  176)  can  be  employed  as  a -amino  protecting  group  because  
this  group  is  able  to  be  removed  with  milder  acids  such  as  dilute  acetic  acid  or  1 
equivalent  hydrochloric  acid  (Figure  22). 
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Figure 20. Two racemiztion mechanisms. 
 
 
Figure 21. Structures of the Cbz and substituted Cbz groups. 
. 
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Protecting  groups  removed  by  strong  bases  are  not  suitable  for  the  peptide  synthesis  
due  to  possibility  of  recamization.  However,  protecting  groups  removable  under  mild  
basic  conditions  is  very  valuable  because  selective  cleavage  of  Bpoc  or  Tri  group  is  
especially  difficult  in  the  presence  of  Lys (Boc).  Among  diverse  base-labile  protecting  
groups,  the  9-fluorenylmethyloxycarbonyl  (Fmoc)  group  (Figure  22)  is  the  most  well-
known  protecting  group  in  solid  phase  synthesis  (177).  Fmoc-amino  acid  can  be  
prepared  by  reaction  between  free  amino  acid  and  Fmoc-Cl,  but  a  side  product,  
Fmoc-dipeptides,  can  be  also  formed  in  the  course  of  this  reaction  (178).  This  
resulted  in  the  development  of  several  additional  Fmoc  reagents  such  as  Fmoc-OSu  
(179,  180),  Fmoc-OPCP  (179),  and  Fmoc-OBt  (179).  Deprotection  of  Fmoc  group  
occurs  easily  by  various  amines  like  piperidine  (181,  182)  via  -elimination  
mechanism.  The  cleavage  of  Fmoc  group  by  piperidine  leads  formation  of  a  fulvene-
piperidine  adduct  difficult  to  remove  in  reaction  mixture  in  solution-phase  synthesis.  
In  order  to  resolve  the  disadvantage,  polymer-bonded  amines  (183  -  186)  have  been  
use  to  remove  Fmoc  group  in  solution. 
The  allyloxycarbonyl  (Alloc)  group  can  also  provide  an  effective  N()-protectin  
(187,  188).  The  Alloc  group  (Figure  22)  can  be  removed  in  the  presence  of  
palladium  catalyst  in  neutral  conditions  and  the  tBu  group  and  fluorine-9-ylmethyl  
(Fm)  groups  are  intact  during  the  deprotection  process.  The  2,2,2-
trichloroethoxycarbonyl  (Troc)  group  (Figure  22)  is  also  one  of  very  useful  N()-
protecting  groups  (189  -  192)  because  it  is  stable  in  both  acid  and  base  presence.  It  
can  be  removed  by  mild  conditions  such  as  zinc  dust  in  acetic  acid. 
As  described  earlier,  protecting  the  C-terminus  on  amino  acids  is  also  important  as  
much  as  protecting  the  N-terminus  due  to  controlling  peptide  bond  formation.  
Regarding  C-terminal  protection,  there  are  major  difference  between  solid-phase  
 38 
 
synthesis  and  solution  phase  synthesis.  In  the  former,  the  insoluble  polymeric  support  
may  act  as  a  C-terminal  protecting  group,  whereas  in  the  latter,  more  typical  
protecting  groups  are  used.  The  most  commonly  used  C-terminus  protecting  groups  
are  alkyl  ester,  aryl  ester,  hydrizides,  or  protected  hydrazides. 
 
Figure 22. Amino moiety protecting groups. 
 
Methyl  ester  (-OMe)  and  ethyl  ester  (-OEt)  (Figure  23)  can  be  prepared  by  two  
steps:  (1)  activation  alcohol  (e.g.  methanol,  ethanol)  by  thionyl  chloride  and  (2)  
reaction  between  a free  amino  acid  and  a  previously  activated  species.  Methyl  and  
ethyl  ester  can  be  removed  by  saponification  and  modified  to  different  functional  
groups  for  further  couplings.  Preparation  of  amino  acid  tBu  esters  (Figure  23)  can  be  
proceeded  by  a  couple  of  different  methods  (193  -  198).  For  example,  reaction  
between  amino  acids  and  isobutylene  can  provide  amino  acid  tBu  ester  in  the  
presence  of  sulfuric  acid  as  a  catalyst  (193).  tBu  esters  are  inert  to  base-catalyzed  
hydrolysis,  hydrogenolysis,  and  nucleophiles.  However,  they  can  be  removed  by  
acidolysis  with  moderately  strong  acid  such  as  TFA  or  solutions  of  HCl  in  organic  
solvents.  The  1-adamantyl  esters  of  amino  acids  has  the  similar  characters  as  tBu  and  
it  can  be  also  deblocked  by  TFA. 
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The  benzyl  ester  (-OBzl)  of  amino  acids  is  prepared  by  a  couple  of  mild  
conditioned  methods  (199  -  201).  Cleavage  of  the  benzyl  ester  (Figure  23)  can  be  
proceeded  through  acidolysis  with  strong  acid  or  hydrogenolysis  (202).  Amino  acid  
phenacyl  ester  (Figure  23)  are  obtained  by  the  treatment  of  N-protected  amino  acid  
carboxylates  with  bromoacetophenone  (203).  The  phenacyl  group  is  very  stable  to  
acidic  condition  even  to  liquid  HF.  Due  to  this  propensity,  the  phenacyl  group  is  
used  along  with  the  Boc  group  as  N-protection.  The  phenacyl  group  can  be  removed  
with  zinc  in  acetic  acid  (203)  or  sodium  thiophenoxide  in  an  inert  solvent  (204).   
Peptidic  hydrazides  are  prepared  by  reacting  peptide  methyl,  ethyl,  or  benzyl  esters  
to  hydrazine  hydrates  (205,  206).  The  hydrazide  can  act  as  a  C-terminal  protecting  
group  as  well  as  maybe  be  transferred  into  the  acyl  azide  with  suitable  treatments  
(207,  208).  However,  if  the  protected  peptide  alkyl  ester  contains  Arg(NO2),  
Asp(OBzl),  Asp(OtBu),  or  Glu(OBzl),  treatment  of  hydrazine  hydrates  causes  side  
reactions  like  hydrazinolysis  of  side  chain  functional  groups.  In  order  to  suppress  this  
side  reactions,  it  is  more  suitable  to  synthesize  protected  peptide  hydrazides  from  the  
comparable  substituted  hydrazide. 
 
Figure 23. C-terminus protecting groups. 
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Some  native  amino  acids  have  a  third  functional  groups.  As  a  result,  in  the  
synthesis  of  peptides,  it  is  necessary  to  protect  the  -amino  group  of  Lys  (or  -amino  
group  of  Orn)  in  either  carbonyl  or  amino  component  and  the  -mercapto  group  of  
Cys  in  either  component.  However,  this  rule  is  not  applied  to  some  functional  groups  
on  amino  acids  such  as  the  carbonyl  groups  of  Asp  and  Glu,  the  guanidine  group  of  
Arg,  the  phenolic  hydroxyl  group  of  Tyr,  the  aliphahatic  hydroxyl  group  of  Ser  and  
Thr,  the  imidazole  of  His,  the  primary  carboxamide  of  Asn  and  Gln,  the  aliphatic  
thioether  of  Met,  and  the  indole  ring  of  Trp.  The  group  of  Okada  demonstrated  the  
synthesis  of  eglin  c  containing  70  amino  acid  residues  by  following  the  minimum  
protection  method  (209,  210).  In  contrast,  Sakakibara  recommended  “solution  synthesis  
of  peptides  by  the  maximum  protection  procedure"  via  the  DCC  coupling  method  and 
a  HF  final  deprotection  method  (211).  "Maximum  protection"  strategy  represents  
protecting  maximum  numbers  of  functional  groups  to  avoid  the  side  reactions.  Despite  
less  occurrence  of  side  reaction,  it  is  challenging  to  build  highly  soluble  segments  
with  full  protection.  Nakao  and  co-workers  showed  the  synthesis  of  osteocalcin  
containing  40  amino  acid  residues  by  the  maximum  protection  approach  (212). 
There  are  two  main  strategies  to  construct  peptide  molecules  in  solution:  (1)  
stepwise  elongation  and  (2)  segment  condensation.  Even  though  their  approaches  are  
different,  the  chemical  methods  used  on  both  are  fundamentally  similar.   
It  is  critical  to  prevent  epimerization  during  the  peptide  synthesis.  Stepwise  
elongation  from  the  C-terminal  by  one  amino  acid  at  a  time  using  urethane-protected  
amino  acids  such  as  Z-amino  acids  and  Boc-amino  acids  is  beneficial  to  avoid  
epimerization  while  the  peptide  bond  is  dormed  (212  -  214).  The  stepwise  elongation  
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method  is  suitable  for  small  peptide  synthesis  and  preparation  peptide  segments  to  
build  larger  peptides  and  proteins. 
In  1952,  Khorana  used  DCC  for  nucleotide  synthesis  (215)  and  Sheehan  and  Hess  
employed  DCC  for  peptide  synthesis  in  1955  (216).  Since  then,  DCC  (Figure  24)  has  
been  the  most  effective  and  attractive  coupling  reagent  both  in  solid  phase  peptide  
synthesis  and  solution  phase  peptide  synthesis  because  of  its  high  reactivity  and  high  
efficiency  within  short  time.  The  defect  of  the  use  of  DCC  is  the  production  of  the  
insoluble  dicyclohexylurea  during  activation/coupling.  To  overcome  this  disadvantage,  
diisopropylcarbodiimide  (DIPCDI)  has  been  utilized  and  is  comparably  effective  and  
forms  a  more  soluble  urea  by-product  (216). 
 
 
Figure 24. Structures of carbodiimides. 
 
Another  principle  applied  to  stepwise  elongation  is  mixed  anhydride  method  which  
was  reported  by  Curtius  over  100  years  ago,  but  Wieland  was  the  first  to  use  this  
approach  for  peptide  synthesis  (217).  This  method  has  an  regioselective  problem  due  
to  the  use  a  mixed  anhydride,  containing  two  carbonyl  groups,  formed  from  protected  
amino  acids  or  peptides  and  carboxylic  acids.  In  order  to  obtain  the  desired  product,  
the  amino  component  has  to  attack  to  the  correct  carbonyl  group  (Figure  25).  As  a  
result,  the  success  of  this  approach  depends  on  the  reduced  the  possibility  of  
undesired  attack  on  the  carbonyl  group.  This  can  be  achieved  by  using  sterically  
hindered  carboxylic  acids  or  their  analogues.  The  most  effective  coupling  reagents  for  
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this  case  is  containing  isovaleryl  (218)  or  pivaloyl  residues  (219).  Also,  another  
popular  type  of  mixed  anhydrides  is  formation  of  carbonic  acids  rather  than  
carboxylic  acids  as  intermediates.  Generally,  ethyl  chloroformate  (220,  221)  and  
isobutyl  chloroformate  (222)  are  used.  The  advantage  of  this  approach  is  easy  
removal  of  by-products  made,  carbon  dioxide  and  the  corresponding  alcohol,  from  the  
reaction  mixture. 
Based  on  the  principle  of  the  mixed  anhydride  method,  Wieland  and  colleagues  
showed  an  amino  acid  thiophenyl  ester  (223),  activated  the  ester  moiety  that  has  a  
tendency  to  form  the  peptide  bond  under  mild  conditions  (224).  The  fundamental  
concept  of  this  principle  is  making  the  carbonyl  carbon  more  vulnerable  to  the  amino  
component  attack  by  increasing  the  electron-withdrawing  character  of  the  alcohol  
moiety  of  the  ester.  This  can  be  achieved  by  using  phenols  with  electron  withdrawing  
group  at  ortho  or  para  positions  such  as  p-nitrophenyl  ester  (223),  2,4,5-
trichlorophenyl  ester  (225),  pentachlorophenyl  ester  (226),  or  penafluorophenyl  ester  
(227).  Anderson  group  demonstrated  N-hydroxysuccinimide  (HOSu)  ester  as  one  
example  of  N-hydroxylamine  type  active  ester  (Figure  26)  (228).  The  advantages  of  
the  N-hydroxylamine  derivative  are  the  suppression  of  epimerization  and  the  easy  
removal  with  water.  Another  N-hydroxylamine  analogue  is  N-hydroxybenzotriazole  
(HOBt)  which  is  widely  used  in  peptide  synthesis  (Figure  26)  (229,  230).   
 
 
Figure 25. Two possible products via a mixed anhydride. 
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The  group  of  Kenner  first  postulated  the  use  of  acylphosphonium  salts  as  reactive  
intermediates  for  the  amide  bond  formation  (231).  However,  this  method  was  not  used  
widely  until  Castro  developed  (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium  
hexafluorophosphate  (BOP)  reagent  (232).  Since  then,  phosphonium  salts  has  been  
used  widely  in  peptide  chemistry.  BOP  (Figure  27)  is  easy  to  handle  and  promotes  
fast  coupling,  but  produces  the  toxic  byproduct,  hexamethylphosphorotriamide  (HMPA).  
In  order  to  avoid  the  toxic  byproduct  formation,  Castro  replaced  dimethylamine  by  
pyrrolidine and developed (benzotriazol-1-yloxy)tripyrrolidinophosphonium  
hexafluorophosphate  (PyBOP)  (Figure  27)  (233,  234). 
The  related  uronium  salts  have  also  been  employed  in  solid  phase  peptide  synthesis.  
The  use  of  uronium  salts  reduces  the  occurrence  of  side  reaction  such  as  
epimerization  (235).  The  group  of  Dourtoglou  introduced  2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium  hexafluorophosphate  (HBTU)  reagent  (Figure  27)  (234,  236).  
Subsequently,  a  few  other  uronium  salts  were  developed.  Knorr  and  coworkers  
showed  the  2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium  tetrafluoroborate  
(HBTU)  (Figure  27)  (235).  Later,  the  aza  derivative  of  HBTU,  2-(1H-7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium  hexafluorophosphate  (HATU)  (Figure  
27)  was  reported  (237).  For  years,  HBTU  and  HATU  were  considered  as  uronium  
salts,  but  X-ray  crystallography  analysis  confirmed  their  true  structure  as  guanidium  
salts  (238).   
The  condensation  of  peptide  segments  is  an  attractive  approach  for  the  larger  
peptides  or  proteins  synthesis  in  solution.  The  separation  of  the  peptide  from  
truncated  or  deleted  sequences  is  relatively  easy.  The  main  problem  of  this  method  is  
the  epimerization  of  C-terminal  residue  of  carboxylic  segment  except  glycine  or  
proline.  As  a  result,  the  most  critical  requirement  for  coupling  is  reducing  
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epimerization  of  the  C-terminal  amino  acid  of  the  carboxyl  moiety.  The  appropriate  
coupling  methods  to  diminish  epimerization  in  segment  condensation  are:  (1)  the  azide  
procedure,  (2)  DCC  methodology  using  an  acidic  additive,  and  (3)  native  chemical  
ligation  (239). 
 
Figure 26. Structures of the active esters. 
 
The  azide  procedure  is  favorably  applied  when  the  C-terminus  does  not  contain  a  
Gly  or  Pro  residue.  With  certain  precautions,  the  amount  of  epimerization  can  be  
maintained  at  very  low  levels  (240).  Another  advantage  of  this  approach  is  minimum  
protection  principle  can  be  employed  because  the  azides  do  not  acylate  hydroxyl  
groups.  However,  its  major  defect  is  the  low  efficiency  of  coupling  which  leads  to  
the  rearrangement  reaction  to  give  carbamide  peptides  difficult  to  remove  (208).  The  
group  of  Shioiri  introduced  diphenylphosphoryl  azide  (DPPA)  as  an  acyl  azide  
forming  reagent  that  constructs  a  peptide  bond  without  any  side  chain  functional  
groups  protection  as  well  as  produces  a  low  level  of  the  epimeric  peptide  (241  -  
243). 
It  was  found  that  the  coupling  of  protected  peptide  segments  experienced  a  
significant  epimerization  of  the  C-terminal  amino  acid  when  carbodiimides  were  used  
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alone  (244).  The  group  of  Weygand  reported  the  segment  coupling  with  the  
combination  of  DCC  and  HOSu  dramatically  reduced  epimerization  (less  than  1%)  
(245,  246)  and  Wuensch  and  colleagues  employed  this  approach  to  the  synthesis  of  
glucagon  (247  -  249).  Later,  Koenig  and  Geiger  demonstrated  a  more  powerful  
reagent  than  HOSu,  as  known  as  HOBt  (230)  and  3,4-dihydro-3-hydroxy-4-oxo-1,2,4-
benzotriazine  (HOOBt)  (250,  251).  The  DCC/HOBt  procedure  was  successfully  applied  
to  the  synthesis  of  human  adrenocorticotropic  hormone  (ACTH)  (252). 
Native  chemical  ligation  is  the  most  useful  method  to  produce  long  peptide  chains.  
Native  chemical  ligation  is  remarkably  chemoselective  reaction  between  unprotected  
peptides  containing  a  C-terminal  thioester  and  N-terminal  Cys  residue  under  mild  
conditions  in  aqueous  solution  (253)  (Figure  28).  After  ligation,  treatment  of  selective  
desulfurization  with  H2/metal  reagents  converts  Cys  to  Ala  (254).  Since  Ala  residue  is  
one  of  the  common  amino  acids  in  proteins,  ligation  at  Ala  residues  can  be  utilized  
broadly. 
The  final  step  of  peptide  synthesis  is  removing  all  protecting  groups.  As  mentioned  
earlier,  all  protecting  groups  on  -amino,  carboxyl  component  or  side  chain  of  amino  
acids  have  characteristic  propensities.  As  a  result,  it  is  important  to  choose  suitable  
deprotecting  reagents  to  remove  every  protecting  group.  The  final  deprotection  
procedures  are  mainly:  (1)  catalytic  hydrogenolysis  with  palladium  (152,  255),  (2)  
sodium  treatment  in  liquid  ammonia  (256  -  258),  (3)  TFA  treatment  (259,  260),  (4)  
HF  treatment  (261,  262),  or  (5)  the  "hard-soft  acid-base"  remedy  (HSAB)"  (263  -  
270). 
Solution  phase  peptide  synthesis  has  been  a  classical  approach  in  peptide  synthesis.  
Even  though  solid  phase  peptide  synthesis  has  replaced  in  most  labs,  it  is  still  useful  
to  produce  peptide  in  large-scale  for  industrial  purposes. 
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1. 7. Peptoids 
There  have  been  many  cases  that  short  peptide  and  nucleic  acid  oligomers  with  
great  affinity  to  various  molecular  targets  suffered  from  poor  pharmacokinetic  
properties.  As  a  result,  developing  peptidomimetics  close  to  poly  peptide  structure  
with  the  chemical  diversity,  spacing  of  side  chains,  a  polar  backbone,  and  the  
resistance  to  proteolysis  is  one  of  crucial  tasks  in  drug  discovery  (271).  In  late  1980s,  
a  new  class  of  peptidomimetics  was  introduced  as  known  as  pepoids  where  
connectivity  of  side  chain  point  was  moved  from  the  alpha  carbon  to  the  amide  
nitrogen  (272).  In  other  words,  the  resulting  structures  are  repetition  of  N-substituted  
glycine  units,  essentially  regioisomer  of  peptides  (Figure  29).  This  slight  change  of  
structures  leads  to  the  loss  of  a  hydrogen  bond  donor  (the  NH  group)  and  chiral  
center  at  the  -carbon  and  the  gain  of  flexibility.  Also,  it  gave  peptoids  a  defiance  to  
the  proteolysis. 
 
 
Figure 27. Structures of Phosphonium, uronium, and guanidium salts. 
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The  initial  approach  of  peptoid  synthesis  was  Merrifield  method  of  solid-phase  
peptide  synthesis  (273)    by  using  N-substituted  monomer  units.  The  monomer  units  of  
peptoids  have  secondary  amines,  which  is  more  hindered  than  the  primary  amines  of  
peptides,  so  their  coupling  reaction  time  is  longer  in  SPPS.  Also,  preparation  of  the  
monomer  units  is  challenging  because  SPPS  demands  the  considerable  amount  of  N-
substituted  glycine.  In  order  to  resolve  these  problems,  submonomer  method  was  
employed  for  peptoid  synthesis.  The  submonomer  concept  was  originally  utilized  by  
Emil  Fischer  who  conceived  peptide  synthesis  by  using  ammonia  to  displace  
haloalkylamides  (274),  but  the  group  of  Kent  actually  inspired  the  application  of  
submonomer  method  for  the  peptoid  synthesis. They  demonstrated  the  ligation  and  
cyclization  of  peptide  fragments  based  on  coupling  nucleophiles  to  peptidic  
bromoacetamides  (275).  Based  on  the  suggestion,  the  idea  of  peptoid  synthesis  was  to  
grow  the  main  chain  by  an  acylation  reaction  with  a  haloacetic  acid  and  then  attach  
the  side  chain  with  a  primary  amine  (Figure  30).  This  approach  avoids  the  
preparation  of  fully  protected  monomer  units  and  uses  smaller  submonomer  units  
instead.  The  first  step  is  acylation  of  a  secondary  amine,  which  can  be  slower  as  
compared  to  a  primary  amine  in  peptide  synthesis.  However,  using  an  activating  agent  
such  as  DIC  can  promote  the  reaction  speed.  The  second  step  is  a  simple  SN2  
reaction  to  incorporate  the  peptoid  side  chain  functionality.  The  advantages  of  this  
step  are  that  primary  amines  have  not  only  good  reactivity  but  also  commercially-
available  diversity. 
-helices  and  -sheets  are  the  most  prevalent  secondary  structures  for proteins,  but  
various  other  secondary  structures  are  also  well-defined  for  proteins,  including  
alternative  types  of  helices  (-helix,  -helix,  310  helix,  polyproline-helix,  and  collagen  
helix),  extended  structures  (-sheets,  -hairpins,  and  -bulges),  and  different  kinds  of  
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turns  (-turn,  -turn,  -turn,  and -turn)  (276).  These  secondary  structures  are  
normally  characterized  according  to  one  of  two  ordinary  methodologies:  (1)  hydrogen  
bonding  pattern  (277)  and  (2)  the  values  of  the  three  bond  angles  of  the  peptide  
backbone  (,  ,  and  )  (278).  In  peptoids,  it  is  impossible  to  define  the  secondary  
structure  based  on  the  former  criteria  due  to  the  lack  of  the  amide  hydrogen,  but  
assessing  constrained  backbone  ,  ,  and    angles  and  the  side  chain  conformations  
can  contribute  to  the  classification  of  peptoid  secondary  structures.  The  secondary  
structure  of  peptoid  is  generally  evaluated  by  circular  dichroism  (CD)  spectroscopy  
which  enables  rapid  analysis  relative  to  characterization  of  NMR.  Moreover,  due  to  
the  flexible  structure  of  peptoids,  their  crystallization  has  been  very  difficult.  
Excessive  CD  studies  has  been  established  in  order  to  correlate  relationship  between  
CD  spectra  and  bioactivity  changes  and  evaluate  the  peptoid  structures.  However,  it  is  
careful  when  comparing  CD  data  for  peptoids  because  different  side  chain  
compositions,  especially  aromatic  side  chains,  affect  on  the  CD  spectra  shape. 
In  peptoids,  the  polyproline-type-I-like  helix  is  the  most  commonly  reproductive  
secondary  structure  component  by  using  the  chiral  and  steric  side  chains,  as  already  
predicted  by  computational  considerations  (279).  There  are  two  available  structures  of  
this  type  of  peptoid  helix  (280,  281)  and  their  pitch  differs  by  10%.  With  the  
absence  of  the  regular  backbone  hydrogen  bonding  effect  in  peptoids,  the  variation  of  
the  helical  pitch  may  be  attributed  by  the  different  side  chain  used  (Nspc  and  Nrch)  
(Figure  31).  Since  the  length  of  the  peptoid  backbone  is  fixed,  a  difference  in  helical  
pitch  directly  affect  on  varying  numbers  of  residues/turn. 
Despite  of  the  original  effect  of  sterically  bulky  side  chains  such  as  Nspe-  and  
Nsch-  (Figure  31)  on  the  structure  generating  properties,  further  studies  reported  
depending  on  side  chains,  n- *  interactions  can  affect  on  the  cis/trans  amide  ratios  
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(282,  283).  For  example,  one  side  chain  (Nsna,  Figure  31)  preferred  the  cis-amide  
conformation,  that  likely  results  in  more  highly  structured  peptoid  helices  (282).  In  
contrast,  incorporation  of  aniline  in  peptoid  side  chains  forces  cis/trans  amide  
equilibrium  to  over  90  %  trans  according  to  the  measurement  of  NMR  spectroscopy  
(284).  By  using  these  side  chains  and  a  monomer  capable  of  backbone-side  chain  
hydrogen  bonding,  the  characteristic  acyclic  peptoid  reverse  turn  have  been  generated  
recently  (285). 
Besides  backbone  constraints,  Nspe  derivatives  with  para-substitutents  can  create  the  
contacts  (e.g.  disulfide  bonds,  salt  bridges,  and  hydrogen  bonds)  which  are  able  to  
stabilize  specific  tertiary  and  quaternary  structures  (286).  Alternatively,  Nspe  analogues  
with  ortho-  and  para-substitutents  can  stabilize  the  peptoid  helix  via  intramolecular  
i i+3  interactions.  For  instance,  Wetzler  and  Barron  proposed  that  the  a  pyridine  
Nspe  analogue  on  position  i  of  a  peptoid  helix  would  be  protonated  at  close  to  pH  7  
because  hydrogen  bond  acceptor  on  the  para-position  of  a  substituted  Nspe  at  i+3  
position  could  form  hydrogen  bonding  with  the  protonated  pyridine  ring  (276,  Figure  
32). 
More  recently,  turn  components  have  been  revealed  that  can  be  achieved  either  by  
macrocyclization  (287)  or  by  utilization  of  heterocyclic  turn-inducing  unit  (288).  
Kirshenbaum  and  colleagues  showed  head-to-tail  macrocyclization  of  achiral  peptoid  
oligomers  and  found  macrocyclic  hexamer  or  octamer  peptoids  are  alike  as  peptide -
turns  (287).  The  configurations  of  the  turn  region  in  each  macrocycle  were  cis  and  
the  rest  of  amides  were  trans.   The  superposition  of  hexamer  and  octamer  peptoids  
are  highly  similar  to  each  other  in  the  turn  regions  as  well  as  the  original  peptide  -
turns.  Appella  and  co-workers  demonstrated  a  triazole  monomer  acting  as  a  turn  
mimic  in  2007  (288).  The  triazole  moiety  is  able  to  constrain  the  peptoid  backbone  
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similar  to  a  cis  double  bond  that  leads  to  a  rigid  turn  in  the  peptoid  structures.  This  
outcome  can  facilitate  the  design  of  biomimetic  peptoids  using  turn  motif  stabilization.  
 
 
Figure 28. Native chemical ligation for peptide synthesis. 
 
 
Figure 29. structures of peptide and peptoid. 
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Figure 30. The solid-phase submonomer method. 
 
 
Figure 31. Peptoid secondary structure inducing side chains. 
 
Even  though  peptides  and  proteins  are  involved  in  important  biological  processes,  
they  have  not  been  developed  for  clinical  use  due  to  their  poor  oral  bioavailability,  
short  half-life  in  the  body,  and  an  immune  response  induction  (289).  These  
disadvantages  of  peptides  gave  the  great  opportunity  for  the  peptoid  therapeutics  
because  peptoids  are  resistant  to  proteolysis  and  prepared  in  large  scale  with  low  cost  
relative  to  -peptides.  Also,  as  mentioned  earlier,  peptoids  can  adopt  the  folded  
conformations  such  as  helices  (290),  loops  (291,  292),  and  turns  (287,  288)  in  
peptoids.  Many  researchers  have  taken  these  advantages  of  peptoids  and  developed  
diverse  peptoid  mimetics. 
The  group  of  Liskamp  showed  peptoid  mimetics  of  peptide  amylin  which  is  
involved  in  the  beginning  of  type  II  diabetes  (293).  Amylin  generates  amyloid  fibrils  
and  easily  aggregates  in  the  insulin-forming  islet  -cells  (294)  through  cross  -sheet  
topology  (295).  Peptoid  1  and  retropeptoid  2  (residues  in  reverse  order)  as  analogs  of  
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the  amylin  core  region  (20-29)  were  synthesized  and  studied  their  structures  and  
inhibition  of  amylin  aggregation  (Table  2).  In  order  to  evaluate  the  structures  of  
amylin  (20-29),  peptoid  1,  and  retropeptoid  2,  CD  spectroscopy  was  used:  amylin  (20-
29)  showed  characteristic  CD  spectrum  of  -sheet,  but    peptoid  1  and  retropeptoid  2  
displayed  weak  or  random  CD  spectra  indicating  no  defined  secondary  structure.  
Based  on  these  CD  spectra  difference,  the  ability  of  the  peptoids  was  studied  whether  
peptoids  can  inhibit  -sheet  and  amyloid  fibril  formation  in  amylin  (20-29).  A  1:1  
(w/w)  mixture  of  amylin  (20-29)  and  peptoid  1  did  not  show  any  unique  CD  
spectrum  of  -sheet,  that  support  peptoid  1  was  able  to  disrupt  the  -sheet  formation  
of  amylin  (20-29).  Also,  this  mixture  was  ~20  %  opaque  in  a  comparison  of  that  of  
amylin  (20-29)  alone,  that  represents  inhibition  of  amyloid  aggregation.  However,  the  
retropeptoid  12  showed  moderate  inhibition  of  aggregation  by  displaying  ~50  %  
turbidity  in  a  mixture  (w/w)  of  amylin  (20-29)  and  retropeptoid.  This  may  be  
attributed  from  the  supramolecular  assemblies  of  retropeptoid  2  which  interfered  the  
effective  inhibition  of  aggregation. 
 
 
Figure 32. Proposed model of intrahelix stabilizing hydrogen bond between ortho- and 
para-substituted Nspe analogues (X=Cl, OCH3, etc.). 
 
Kodadeck  and  colleagues  found  out  three  peptoids  (3-5)  bound  to  the  coactivator  
CREB-binding  protein  (CBP)  in  vitro  with  a  low  micromolar  range  among  a  library  
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of  ~100,000  peptoid  hexamers  (296,  297).  This  coactivator  protein  plays  a  key  role  in  
mammalian  genes  transcription.  After  further  studies,  among  three  peptoids,  only  
peptoid  3  was  selective  for  CBP  while  peptoids  4  and  5  were  selective  for  bovine  
serum  albumin  (Figure  33).  In  other  words,  peptoid  4  and  5  failed  to  induce  
transcription,  but  peptoid  3  managed  to  activate  transcription  by  serving  as  an  
activation  domain  (EC50  =  8 ).  Moreover,  the  cell  permeability  of  all  three  peptoids  
was  evaluated.  The  peptoid  3  showed  good  cell  permeability,  which  correlated  well  to  
its  relative  hydrophilicity.  Surprisingly,  peptoid  4  is  most  hydrophobic  among  three  
peptoids,  but  its  cell  permeability  was  moderate.  Although  peptoid  5  has  intermediate  
hydrophobicity,  it  showed  the  poor  cell  permeability.  Based  on  this  permeability  result,  
the  researchers  explained  the  reason  of  the  transcription  induction  failure  by  peptoid  5  
due  to  no  accumulation  inside  cells  (Figure 33). 
  Peptoid  mimetics  play  an  important  role  in  drug  discovery  because  of  the  fast  
synthesis  and  structural  similarity  to  polypeptides.  Many  researchers  already  have  
worked  on  the  design  and  application  of  peptoid  mimics  of  bioactive  molecules  and  
will  continue  to  pursue  the  same  goal 
 
Table 2. Structures of Amylin (20-29), Peptoid 1, and Retropeptoid 2
289 
Oligomer Sequence  (N-  to  C-terminus) 
Amylin  (20-29) SNNFGAILSS 
Peptoid  1 NSer-NAsn-NAsn-NPhe-Gly-NAla-NIle-NLeu-Nser-NSer 
Retropeptoid  2 NSer-NSer-NLeu-Nile-NAla-Gly-NPhe-NAsn-NAsn-NSer 
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Figure 33. Peptoid hexamers 3, 4, and 5. 
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CHAPTER  TWO: 
DESIGN  OF  NON-PEPTIDIC  OLIGO-PYRIMIDINES  
MIMICKING  i,  i+4(3),  i+7  POSITIONS  OF  -HELICES 
 
2. 1. Introduction 
P53  is  a  tumor  suppressor  which  is  inactive  or  mutated  in  tumor  cells (1).  In  
unstressed  normal  cells,  p53  is  expressed  in  low  levels  by  MDM2  (murine double 
minute protein 2)  through  two  ways (2).  P53  is  a  transcription  factor  inhibited  by  
MDM2.  This  can  be  achieved  by  binding  to  N-terminal  domain  of  p53  and  
preventing  transcriptional  activity.  P53  can  be  also  decreased  via  ubiquitin-dependent  
proteasome  pathway.  MDM2  promotes  ubiquitination  of  lysine  residues  of  p53  C-
terminal  region  by  acting  as  an  ubiquitin  E3  ligase.  However,  stresses  such  as  DNA  
damage,  ultra  violet  light,  and  oncogenes  induce  the  activation  of  wild  type  of  p53  
protein  (3, 4).  This  results  in  the  presence  of  target  genes  in  different  regulatory  
regions.  These  target  genes  lead  to  various  effects  like  inhibition  of  angiogenesis,  cell  
cycle arrest,  or  apoptosis  (Fig 1).  Hence,  over expression  of  MDM2  makes  wild-type  
p53  disabled  and  tumor  cells  elongate  their  lives  (5). 
Due  to  the  negative  feedback  between  MDM2  and  p53,  MDM2  is  an  attractive  
therapeutic  target  for  anti-cancer  treatment.  Two initial  approaches  were  validated  as  
cancer  targets,  MDM2,.  MDM2  expression  was  inhibited  by  antisense  oligonucleotides.  
This  results  in  strong  activation  of  p53  and  cell  cycle  arrest  or  apoptosis  (6,  7).  Also,  
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injecting  a  monoclonal  antibody  to  MDM2  leads  to  activation  of  p53  and  cell  growth  
arrest  by  disrupting  interaction  between  p53  and  MDM2  (8).  These  studies  promote  
development of antagonists of MDM2, leading p53 active. 
 
 
Figure 34. A negative feedback loop between p53 and MDM2. 
 
Prior  to  antagonists  synthesis,  it  is  important  to  check  key  interactions  between  p53  
and  MDM2.  According  to  the  crystallography,  the  region  of  MDM2  that  binds  to  
NH2-terminal  peptide  of  p53  showed  characteristic  interactions  between  these  two  
proteins. Two  pairs  of  -helices  from  p53  and  MDM2  form  a  hydrophobic  cleft  
where  p53  binds  like  a  pocket-ligand  (9).  Stabilization  of  p53-MDM2  complex  is  
achieved  through  interactions  between  hydrophobic  cleft  and  hydrophobic  residues  
(Phe19,  Trp23,  Leu26)  along  with  one-faced  p53  helical  peptide.  Further  experimental  
(10,  11)  and  computational  (12,  13)  studies  have  confirmed  the  important  binding  
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residues  of  p53-MDM2  complex  and  this  leads  to  study  the  possibility  that  small  
molecules  can  be  an  anti-cancer  alternative  by  competing  for  MDM2  binding  (14). 
Several  strategies  have  been  studied  to  develop  MDM2  antagonists. Peptides  which  
can  inhibit  MDM2  were  discovered  after  phage  display  at  the  100  nmol/L  of  IC50  
level  in  vitro  (15).  A  recent  study  showed  an  improved  peptide  which  has  better  
binding  affinity  and  p53  activation  (15).  A  high-throughput  screen  of  chemical  
libraries  has  been  used  to  identify  Nutlins,  a  group  of  cis-imidazoline  derivatives  
which  were  able  to  inhibit  p53-MDM2  binding  with  high  affinity  (16).  This  study  has  
promoted  development  of  small  molecules  that  act  as  p53-MDM2  inhibitors. 
Recently,  the  group  of  Dr.  Hamilton  has  showed  terphenyl  scaffold  which  is  small  
non-peptidic  molecules  and  mimics  of  the  NH2-terminal  -helix  of  p53  (17).  In  order  
to  make  -helix  structure  of  terphenyl  derivatives,  side  chains  on  the  phenyl  rings  are  
projected  like  i,  i+4,  and  i+7  fashion.  This  mimic  of  structure  can  be  achieved  by  
substituting  appropriate  alkyl  or  aryl  groups  on  ortho-position  of  each  phenyl  ring.  
These  terphenyl  analogues  also  showed  inhibition  of  p53-MDM2  interaction  in  vitro  
and  p53  activation  in  cell  culture.  This  study  showed  the  possibility  to  develop  a  
novel  -helical  mimetics  as  MDM2  antagonists.. 
  Here,  terpyrimidine  derivatives  which  have  a  -helical  mimetic  structure  and  better  
polarity  based  on  terphenyl  scaffold. 
 
2. 2. Results  and  discussion 
From  the  previous  study,  terphenyl  scaffold  with  mimic  of  -helical  structure  
showed  inhibition  p53-MDM2  interaction  and  activation  p53.  Despite  of  the  potential,  
these  terphenyl  derivatives  have  poor  solubility  or  polarity.  Not  only  improving  this  
disadvantage  but  also  finding  better  potency,  a  new  group  of  -helical  mimetics  of  
 99 
 
the  NH2-terminal  p53  -helix  was  developed  by  using  pyrimidyl  rings  instead  of  
phenyl  rings.  The  terpyrimidyl  derivatives  project  their  side  chains  in  a  similar  
geometry  of  those  of  a-helices.  Also,  containing  nitrogens  on  pyrimidyl  rings  results  
in  the  increase  of  polarity  (Scheme 1). 
 
Scheme 1. General synthesis procedure of terpyrimidyl derivatives. 
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Initially,  various  R  groups  (e.g.  -Ph,  -NH2,  -S-CH3,  -S-CH2-C6H5)  were  used  to  
make  terpyrimidyl  derivatives.  Every  terpyrimidyl  product  was  obtained  as  a  
precipitate  except  when  R  is  phenyl  group.  Due  to  easy  purification,  more  
terpyrimidyl  libraries  were  built  for  the  case  of  NH2,  S-CH3,  S-CH2-C6H5  as  R  groups. 
Monomeric  pyrimidyl  analogues (1a-1j)  were  prepared  by  Michael  addition  (Scheme 
2;  Table 1).  Pyrimidyl  monomers  were  obtained  as  a  precipitate. 
 
 
Scheme 2. Synthesis of 1a-1j. 
 
Table 3. Percent Yield of Monomeric Pyrimidyl Derivatives Synthesis 
Entry Compound R R1 Yield 
1 1a S-CH3 iPr 51% 
2 1b S-CH3 Ph 92% 
3 1c S-CH3 iBu 13% 
4 1d S-CH2-C6H5 1-Naphthalene 13% 
5 1e NH2 iPr 29% 
6 1f NH2 1-Naphthalene 90% 
7 1g NH2 tBu 55% 
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8 1h NH2 iBu 21% 
9 1i NH2 Ph 88% 
10 1j NH2 Benzyl 50% 
 
Dimeric  pyrimidyl  derivatives  were  synthesized  from  compounds,  1a-1j  (Scheme 3).  
Depending  on  which  atom  of  hydroxylamine  is  involved  in  SN2  reaction,  monomeric  
pyrimidines  (1)  were  transformed  into  mixture  of  2  and  2´.  Under  controlled  condition,  
derivatives  of  2  were  only  reduced  to  compounds  3.  The  Michael  addition  of  3  with  
different  Michael  acceptors  followed  and  afforded  a  novel  group  of  terpyrimidyl  
dimers,  4a-4j  (Table 2).  Dimeric  terpyrimidyl  analogues  were  formed  as  a  precipitate. 
 
 
Scheme 3. General synthesis of terpyrimidyl dimers. 
 
Table 4. Percent Yield of Terpyrimidyl Dimers Synthesis 
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Entry Compound R R1 R2 Yield 
1 4a S-CH3 iPr tBu 13% 
2 4b S-C6H5 1-Naphthalene iBu 86% 
3 4c NH2 iBu Benzyl 25% 
4 4d NH2 Benzyl 1-Naphthalene 8% 
5 4e NH2 iBu 1-Naphthalene 58% 
 
Nucleophilic  substitution  reaction  (SN2)  of  dimeric  terpyrimidyl  derivatives with  
hydroxylamine  hydrochloride  afforded  the  mixture  of  5  and  5´.  Analogues  of  5  were  
transformed  into  compounds  6  when  reduction  reaction  was  carried  out  in  methanol  
using  potassium  formate,  acetic  anhydride,  and  10% palladium/carbon  as  reducing 
reagents.  Addition  reaction  with  Michael  donors  6  in  the  presence  of  Michael  
acceptors  and  triethylamine  occurred  and  afforded  trimeric  oligo-pyrimidyl  derivatives  
7a-7d  (Scheme 4).  Oligo-pyrimidyl  trimers  7a-7d  were  precipitated  after  reaction  was  
done  (Table 3). 
Terminal  groups  (-CN,  and  -NH2)  of  oligo-pyrimidyl  analogues  were  transformed  
into  carboxylic  acid  derivatives  in  order  to  elevate  their  polarity  and  dissolve  better  in  
aqueous  solution  (Scheme 5).  Terminal  cyano  group  was  hydrolyzed  in  methanol  
(reflux)  using  NaOH.  Another  terminal  group  -NH2  was  involved  in  nucleophilic  
substitution  reaction  (SN2)  when  succinic  anhydride  was  employed  in  THF.  Products  
after  hydrolysis  or  SN2  reaction  were  obtained  as  precipitation  (Table 4). 
  In  conclusion,  terpyrimidyl  compounds  were  synthesized  successfully  after  SN2  
reaction,  reduction,  and  Michael  addition.  Despite  of  nitrogen  atoms  on  pyrimidyl  
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rings,  oligo-pyrimidyl  derivatives  have  solubility  problems  in  aqueous  solution.  Based  
on  this  result,  development  of  novel  MDM2  antagonists  based  on  different  scaffolds  
need  modifications  which  are  in  a  compliance  with  therapeutic  properties. 
Scheme 4. General synthesis of trimeric oligo-pyrimidine derivatives. 
 
Table 5. Percent Yield of Terpyrimidine Trimers Analogues 
Entry Compound R R1 R2 R3 Yield 
1 7a NH2 iBu 1-
Naphthalene 
iBu 57% 
2 7b NH2 Benzyl 1-
Naphthalene 
iBu 28% 
3 7c NH2 iBu 1- iPr 51% 
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Naphthalene 
4 7d NH2 iBu Benzyl iBu 37% 
 
 
Scheme 5. Synthesis of 8-10. 
 
Table 6. Percent Yield of synthesis 8-10 
Entry compound R R1 R2 R3 Yield 
1 8 NH2 iBu Benzyl - 5% 
2 9 - iBu Benzyl - 37% 
3 10 NH2 iBu Benzyl iBu 14% 
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2. 3. Experimental section 
2. 3. 1. General comments  
The  chemicals  were  purchased  from  Aldrich-Sigma  and  Acros.  
1
H (400 MHz)  and  
13
C (100 MHz)  NMR  spectra  were  obtained  in  deuterated  solvents  using  Inova-400.  
For  high  resolution  mass  spectrometry (HRMS)  spectra,  Agilent  1100  series  was  used  
in  the  ESI-TOF  mode.   
 
2. 3. 2. Synthesis  of  monomeric  pyrimidyl  derivatives, 1a-1j 
4-isopropyl-2-(methylthio)pyrimidine-5-carbonitrile (1a) 
 A  mixture  of  Michael  acceptor  (6.02 mmol, 1 g),  NaOEt  ( 6.02 mmole, 0.45g)  and  2-
methyl-2-thiopseudourea  sulfate  (2.04 mmol, 1.67 g)  in  methanol  (absolute, 200 proof, 
10mL)  was  located  under  microwave  conditions  until  the  TLC  indicated  completion  of  
the  reaction.  The  mixture  was  brought  to  room  temperature  and  the  formed  precipitate  
was  filtered  by  vacuum  and  rinsed  with  ice  cold  methanol  (5 mL x 3).  Yield: 51%.  
1
H 
NMR (CDCl3, 400 MHz):  1.32-1.34 (d, 6H, J = 0.02),  2.60 (s, 3H),  3.33-3.38 (m, 1H),  
8.60 (s, 1H).  
13
C NMR (CDCl3, 400 MHz): 14.61,  21.15,  29.93,  159.83.  HR-MS:  m/z 
= 194 [M+H]
+
. 
 
2-(methylthio)-4-phenylpyrimidine-5-carbonitrile (1b) 
 A  mixture  of  Michael  acceptor  (4.99 mmol, 1 g),  triethylamine  ( 6.48 mmole, 0.9 ml)  
and  2-methyl-2-thiopseudourea sulfate  (9.98 mmol, 1.39 g)  in  methanol  (absolute, 200 
proof, 10mL)  was  stirred  under  refluxing  conditions  until  the  TLC  indicated  
completion  of  the  reaction.  The  mixture  was  brought  to  room  temperature  and  the  
formed  precipitate  was  filtered  by  vacuum  and  rinsed  with  ice  cold  methanol  (5 mL x 
3).  Yield: 92%.  
1
H NMR (CDCl3, 400 MHz):  2.66 (s, 3H),  7.54-7.59 (m, 3H),  8.09-8.11 
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(m, 2H),  8.78 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):  14.75,   129.19,  132.41,  161.56.  
HR-MS:  m/z = 228.05 [M+H]
+
. 
 
 
4-isobutyl-2-(methylthio)pyrimidine-5-carbonitrile (1c) 
 A  mixture  of  Michael  acceptor  (11.1 mmol, 2 g),  triethylamine  ( 14.4 mmole, 2.0 ml)  
and  2-methyl-2-thiopseudourea sulfate  (11.1 mmol, 1.54 g)  in  methanol  (absolute, 200 
proof, 10mL)  was  stirred  under  refluxing  conditions  until  the  TLC  indicated  
completion  of  the  reaction.  The  mixture  was  brought  to  room  temperature  and  the  
formed  precipitate  was  filtered  by  vacuum  and  rinsed  with  ice  cold  methanol  (5 mL x 
3).  Yield: 13%.  
1
H NMR (CDCl3, 400 MHz):  0.91-0.93 (d, 6H),  2.17 (m, 1H),  2.62-
2.64 (d, 2H),  3.49 (s, 3H),  8.25 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):  8.87 29.95,  
44.59,  45.77,  121.60.  HR-MS:  m/z = 208 [M+H]
+
. 
 
2-(benzylthio)-4-(naphthalene-1-ylmethyl)pyrimidine-5-carbonitrile (1d) 
 A  mixture  of  Michael  acceptor  (6.43 mmol, 1.70 g),  triethylamine  ( 9.64 mmole, 1.3 ml)  
and  2-benzyl-2-thiopseudourea sulfate  (9.64 mmol, 1.96 g)  in  methanol  (absolute, 200 
proof, 10mL)  was  stirred  under  refluxing  conditions  until  the  TLC  indicated  
completion  of  the  reaction.  The  mixture  was  brought  to  room  temperature  and  the  
formed  precipitate  was  filtered  by  vacuum  and  rinsed  with  ice  cold  methanol  (5 mL x 
3).  Yield: 13%.  
1
H NMR (CDCl3, 400 MHz):  4.17 (s, 2H),  2.21 (s, 2H),  7.10-8.17 (m, 
12H),  8.64 (s, 1H).  
13
C NMR  (CDCl3, 400 MHz):  44.59,  45.58,  123.98,  125.53,  
125.91,  126.28,  126.48,  127.40,  129.03,  134.94,  159.91,  160.16,  161.62,  162.53,  
168.76,  172.27,  176.63.  HR-MS:  m/z = 383 [M+NH4]
+
. 
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2-amino-4-isopropylpyrimidine-5-carbonitrile (1e) 
A  mixture  of  guanidine  hydrochloride (7.23 mmol, 0.69 g)  and  potassium  carbonate 
(7.23 mmol, 1 g)  in  ethanol (5 mL) was  added  Michael  acceptor (4.82 mmol, 0.8 g)  
suspended  in  ethanol (1 mL).  The  reaction  mixture  was  placed  on  a  microwave  reactor  
for  25 min  at 125 ºC.   A  colorless  crystal-like  precipitate  formed  in  the  solution  upon 
cooling  to  rt.  The  precipitate  was  filtered  and  rinsed  with  ice  cold  ethanol (3 mL x 2)  
to  isolate  compound.  Yield:  29%.  HR-MS:  m/z = 163.09 [M+H]+. 
 
2-amino-4-(naphthalene-1-ylmethyl)pyrimidine-5-carbonitrile (1f) 
  To  a  mixture  of  Michael  acceptor (3.03 mmol, 0.8 g)  and  guanidine hydrochloride 
(4.55 mmol, 0.43 g)  in  ethanol (absolute, 200 proof, 12 mL)  was  added  triethylamine 
(4.55 mmol, 0.6 ml).   The  mixture  was  stirred  under  refluxing  conditions  until  the  
TLC  indicated  the  complete  consumption  of  starting  materials.  The  mixture  was  
brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  vacuum  and  
rinsed  with  ice  cold  methanol  (5 mL x 3).  Yield: 90%.  HR-MS:  m/z = 261.11 [M+H]
+
. 
 
2-amino-4-(tert-butyl)pyrimidine-5-carbonitrile (1g) 
A  mixture  of  Michael  acceptor  (5.56 mmol, 1 g),  triethylamine  ( 8.34 mmole, 1.2 ml)  
and  guanidine  hydrochloride  (8.34 mmol, 0,8 g)  in  methanol  (absolute, 200 proof, 
10mL)  was  stirred  under  refluxing  conditions  until  the  TLC  indicated  completion  of  
the  reaction.  The  mixture  was  brought  to  room  temperature  and  the  formed  
precipitate  was  filtered  by  vacuum  and  rinsed  with  ice  cold  methanol  (5 mL x 3).  
Yield: 55%. 
13
C NMR (CDCl3, 400 MHz):  
HR-MS:  m/z = 177.11 [M+H]+. 
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2-amino-4-isobutylpyrimidine-5-carbonitrile (1h) 
 A  mixture  of  guanidine  hydrochloride (8.91 mmol, 0.85 g)  and  triethylamine (8.91 
mmol, 1.2 ml)  in  ethanol (5 mL) was  added  Michael  acceptor (5.94 mmol, 1.07 g)  
suspended  in  ethanol (1 mL).  The  reaction  mixture  was  placed  on  a  microwave  reactor  
for  25 min  at 125 ºC.   A  colorless  crystal-like  precipitate  formed  in  the  solution  upon 
cooling  to  rt.  The  precipitate  was  filtered  and  rinsed  with  ice  cold  ethanol (3 mL x 2)  
to  isolate  compound.  Yield:  20%.  HR-MS:  m/z = 177.11 [M+H]
+
. 
 
2-amino-4-phenylpyrimidine-5-carbonitrile (1i) 
 Microwave-assisted  reactions  were  also  done  in  the  presence  of  potassium carbonate  
(6.00 mmole, 0.83g)  to  obtain  the  desired  pyrimidines. Michael  acceptor  (4.00 mmol, 0.8 
g)  and  guanidine hydrochloride  (6.00 mmol, 0.57 g)  was  mixed  in  ethanol  (5 mL).  The  
reaction  mixture  was  placed  on  a  microwave  reactor  for  40 min  at  120 ºC.  A  colorless  
crystal-like  precipitate  formed  in  the  solution  upon  cooling  to  rt.  The  precipitate  was  
filtered  and  rinsed  with  ice  cold  ethanol  (3 mL x 2)  to  isolate  compound 1i  as  needle-
like  crystals.  Yield: 88%.  
1
H NMR (CDCl3, 400 MHz):6.89 (s, 2H),  7.42-7.60 (m, 5H),  
7.87 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):  128.30,  128.45,  131.76,  159.60.  HR-MS:  
m/z = 197.08 [M+H]
+
. 
 
2-amino-4-benzylpyrimidine-5-carbonitrile (1j) 
 To  a  mixture  of  Michael  acceptor (3.92 mmol, 0.8 g)  and  guanidine hydrochloride 
(5.88 mmol, 0.56 g)  in  ethanol (absolute, 200 proof, 12 mL)  was  added  triethylamine 
(5.88 mmol, 0.8 ml).   The  mixture  was  stirred  under  refluxing  conditions  until  the  
TLC  indicated  the  complete  consumption  of  starting  materials.  The  mixture  was  
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brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  vacuum  and  
rinsed  with  ice  cold  methanol  (5 mL x 3).  Yield: 50%.  HR-MS:  m/z = 211.09 [M+H]
+
. 
 
 
 
2. 3. 3. Synthesis  of  dimeric  pyrimidyl  derivatives, 4a-4e 
4-(tert-butyl)-4´-isobutyl-2´-(methylthio)-[2,5´-bipyrimidine]-5-carbonitrile (4a) 
A  mixture  of  compound 1a (2.07 mmol, 0.4 g) ,  hydroxylamine (5.18 mmol, 0.36 g) and  
triethylamine (5.18 mmol, 0.7 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  evaporate  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid 2 (0.36 mmol, 0.11 g),  start  
reduction  reaction.  Dissolve  solid 2  with  methanol  and  add  acetic  anhydride (0.47 mmol, 
0.04 ml).  After  five  minutes,  add  potassium  formate (1.44 mmol, 0.12g)  and  
palladium/carbon (0.11 g).  Heat  the  reaction  solution  and  keep  stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 3  can  be  observed.  With  compound 3,  start  another  coupling  reaction.  
Dissolve  solid  3  with  methanol  and  add  acetic  anhydride (0.47 mmol, 0.04 ml).  After 
five  minutes,  add  potassium  formate (1.44 mmol, 0.12g)  and palladium/carbon (0.11 g).  
Heat  the  reaction  solution  and  keep  stirring  overnight.  By  using  diatomaceous  earth,  
filter  the  reaction  solution  and  evaporate  every solvent.  White  compound  3  can  be  
observed. With compound 3, start another coupling reaction.  A mixture of compound 3 and  
2´ (1.90 mmol, 0.4 g)  and  Michael  acceptor (2.85 mmol, 0.29 g)  in  ethanol (absolute, 200 
proof, 10mL)  was  stirred  under  refluxing  conditions  until  the  TLC  indicated  
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completion  of  the  reaction.  The  mixture  was  brought  to  room  temperature  and  the  
formed  precipitate  was  filtered  by  vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 
3).  Yield: 13%.  
1
H NMR (CDCl3, 400 MHz):  1.30 (d, 6H),  1.57 (s, 9H),  2.64 (s, 3H),  
4.05 (m, 1H),  8.98 (s, 1H),  9.14 (s, 1H).   
13
C NMR (CDCl3, 400 MHz):  14.53,  22.05,  
29.93,  32.24,  40.28,  104.28,  116.77,  121.65,  159.96,  162.34,  164.54,  174.27,  175.47,  
179.55.  HR-MS: m/z = 328 [M+H]
+
. 
 
2´-(benzylthio)-4-isobutyl-4´-(naphthalen-1-ylmethyl)-[2,5´-bipyrimidine]-5-carbonitrile (4b) 
A  mixture  of  compound 1d (0.76 mmol, 0.28 g) ,  hydroxylamine (1.90 mmol, 0.13 g)  
and  triethylamine (1.90 mmol, 0.3 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  remove  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid 2 (0.75 mmol, 0.13 g),  start 
reduction  reaction.  Dissolve  solid 2  with  methanol  and  add  acetic  anhydride (0.98 mmol, 
0.1 ml).  After  five  minutes,  add  potassium  formate (3.00 mmol, 0.25g)  and  
palladium/carbon (0.30 g).  Heat  the  reaction  solution  and  keep stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 3  can  be  observed.  With  compound 3,  start  another  coupling  reaction.  
Dissolve  solid  3  with  methanol  and  add  acetic  anhydride (0.98 mmol, 0.1 ml).  After  
five  minutes,  add  potassium  formate (3.00 mmol, 0.25g)  and  palladium/carbon (0.30 g).  
Heat  the  reaction  solution  and  keep  stirring  overnight.  By  using  diatomaceous  earth,  
filter  the  reaction  solution  and  evaporate  every  solvent.  White  compound  3  and  2  ´ 
can  be  observed.  With  mixture  of  3  and 2 ,´  start  another  coupling  reaction.  A  mixture  
of  compound 3  and  2  ´ (0.75 mmol, 0.288 g),  triethylamine (1.13 mmole, 0.2 ml)  and  
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another  Michael acceptor (1.13 mmol, 0.23 g)  in  ethanol (absolute, 200 proof, 10mL)  was  
stirred  under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  
The  mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  
by  vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  Yield: 86%.  
1
H NMR (CDCl3, 
400 MHz):  0.79-0.81 (d, 6H),   1.98 (m, 1H),  2.67-2.69 (d, 2H),  4.15 (s, 2H),  5.12 (s, 
2H),  6.98-7.50 (m, 12H),  8.86 (s, 1H),  9.32 (s, 1H).  
13
C NMR (CDCl3, 400 
MHz):22.36,  28.89,  35.34,  40.17,  45.55,  115.19,  121.61,  124.16,  125.18,  125.54,  
125.87,  126.25,  126.64,  127.31,  127.40,  128.60,  128.97,  129.12, 132.44,  133.96,  134.73,  
160.09 .  HR-MS:  m/z = 502 [M+H]
+
. 
 
2´-amino-4-benzyl-4´-isobutyl-[2,5´-bipyrimidine]-5-carbonitrile (4c) 
A  mixture  of  compound 1h (2.09 mmol, 0.368 g) ,  hydroxylamine (5.23 mmol, 0.36 g)  
and  triethylamine (5.23 mmol, 0.7 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  evaporate  every  ethanol  under  the  
reduced  pressure. White  solid  are  formed.  With  this  solid 2 (2.09 mmol, 0.44 g),  start  
reduction  reaction.  Dissolve  solid 2  with  methanol  and  add  acetic  anhydride (2.72 mmol, 
0.3 ml).  After  five  minutes,  add  potassium  formate (8.36 mmol, 0.70g)  and  
palladium/carbon (0.44 g).  Heat  the  reaction  solution  and  keep stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 3  can  be  observed.  With  compound 3,  start  another  coupling  reaction.  
A  mixture  of  compound 3 (2.09 mmol, 0.403 g),  triethylamine (3.13 mmole, 0.4 ml)  and  
Michael  acceptor (3.13 mmol, 0.64 g)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions until  the  TLC  indicated  completion  of  the  reaction.  The  
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mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  
1
H NMR (CDCl3, 400 MHz):  
0.79 (d, 6H),  1.98 (m, 1H),  2.97 (d, 2H),  4.26 (s, 2H),  5.30 (s, 2H),  7.22-7.34 (m, 5H),  
8.83 (s, 1H),  9.00 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):    22.72,  28.66,  43.35,  45.05,  
127.68,  129.16,  129.51,  160.41,  162.29.  HR-MS:  m/z = 345.18 [M+H]
+
. 
2´-amino-4´-benzyl-4-(naphthalene-1-ylmethyl)-[2,5´-bipyrimidine]-5-carbonitrile (4d) 
A  mixture  of  compound 1j (1.90 mmol, 0.40 g) ,  hydroxylamine (7.60 mmol, 0.52 g)  
and  triethylamine (7.60 mmol, 1.1 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  remove  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid 2 (1.90 mmol, 0.46 g),  start 
reduction  reaction.  Dissolve  solid 2  with  methanol  and  add  acetic  anhydride (2.47 mmol, 
0.2 ml).  After  five  minutes,  add  potassium  formate (7.60 mmol, 0.64g)  and  
palladium/carbon (0.44 g).  Heat  the  reaction  solution  and  keep stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 3  can  be  observed.  With  compound 3,  start  another  coupling  reaction.  
A  mixture  of  compound 3 (1.90 mmol, 0.43 g),  triethylamine (2.85 mmole, 0.4 ml)  and  
Michael  acceptor (2.85 mmol, 0.60 g)  in  ethanol (absolute, 200 proof, 10mL) was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  
1
H NMR (CDCl3, 400 MHz): 
.21 (s, 2H),  4.69 (s, 2H),  5.25 (s, 2H),  6.82-8.07 (m, 12H),  8.82 (s, 1H),  8.93 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):    40.41,  42.11,  124.19,  125.72,  126.13,  126.32,  126.69,  
128.33,  128.67,  128.79,  129.12,  162.60.  HR-MS: m/z = 429 [M+H]
+
. 
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2´-amino-4´-isobutyl-4-(naphthalene-1-ylmethyl)-[2,5´-bipyrimidine]-5-carbonitrile (4e) 
A  mixture  of  compound 1h (1.02 mmol, 0.18 g) ,  hydroxylamine (2.55 mmol, 0.18 g)  
and  triethylamine (2.55 mmol, 0.4 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  evaporate  every  ethanol.  White  solid  
are  formed.  With  this  solid 2 (1.02 mmol, 0.21 g),  start reduction  reaction  under  the  
reduced  pressure.  Dissolve  solid 2  with methanol  and  add  acetic  anhydride (1.33 mmol, 
0.1 ml).  After  five  minutes,  add  potassium formate (4.08 mmol, 0.34g)  and  
palladium/carbon (0.21 g).  Heat  the  reaction  solution  and  keep  stirring overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 3  can  be  observed.  With  compound 3,  start  another  coupling  reaction.  
A  mixture  of  compound 3 (1.02 mmol, 0.19 g),  triethylamine (1.33 mmole, 0.2 ml)   and  
Michael  acceptor (1.33 mmol, 0.35 g)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  
1
H NMR (CDCl3, 400 MHz):   
0.71 (d, 6H),  1.91 (m, 1H),  2.85 (d, 2H),  4.80 (s, 2H),  5.28 (s, 2H),  7.50-8.10 (m, 7H),  
8.91 (s, 1H),  8.93 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):  2.58,  28.58,  40.56,  44.79,  
124.33,  125.76,  126.17,  126.69,  128.68,  128.75,  129.12,  132.09,  132.17,  134.22,  
160.54.  HR-MS: m/z = 395 [M+H]
+
. 
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2. 3. 4. Synthesis  of  trimeric  terpyrimidyl  derivatives, 7a-7d 
2 ´ ´ -amino-4,4 ´ ´ -isobutyl-4 ´ -(naphthalene-1-ylmethyl)-[2,5 ´ :2 ´ ,5 ´ ´ -terpyrimidine]-5-
carbonitrile (7a) 
A  mixture  of  compound 4e (0.73 mmol, 0.288 g) ,  hydroxylamine (2.92 mmol, 0.20 g)  
and  triethylamine (2.92 mmol, 0.4 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  remove  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid (0.73 mmol, 0.31 g),  start 
reduction  reaction.  Dissolve  solid  with  methanol  and  add  acetic  anhydride (0.95 mmol, 
0.1 ml).  After  five  minutes,  add  potassium  formate (2.92 mmol, 0.25g)  and  
palladium/carbon (0.31 g).  Heat  the  reaction  solution  and  keep  stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 6  can  be  observed.  With  compound 6,  start  another  coupling  reaction.   
A  mixture  of  compound 6 (0.73 mmol, 0.30 g),  triethylamine (2.92 mmole, 0.4 ml)   and  
Michael  acceptor (1.09 mmol, 0.20 g)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.   The  
mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  Yield:  57%.  
1
H NMR (CDCl3, 
400 MHz):    0.71-0.77 (d, 6H),  0.77-0.81 (d, 6H),  1.85-2.00 (m, 2H),  2.68-2.70 (d, 2H),  
2.89-2.91 (d, 2H),  5.17 (s, 1H),  5.24 (s, 1H),  6.97-8.03 (m, 7H),  8.90 (s, 1H),  8.91 (s, 1H),  
9.53 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):    22.37,  22.62,  28.77,  28.96,  40.15,  44.60,  
45.58,  115.11,  123.98,  125.91,  126.28,  126.48,  129.03,  132.27,   134.94,  159.91,  160.16,  
161.63,  162.53,  164.63,  168.75,  172.26,  173.63.  HR-MS: m/z = 529 [M+H]
+
. 
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2 ´ ´-amino-4 ´ ´-benzyl-4-isobutyl-4 ´-(naphthalene-1-ylmethyl)-[2,5 ´:2 ´ ,5 ´ ´-terpyrimidine]-5-
carbonitrile (7b) 
A  mixture  of  compound 4d (0.11 mmol, 0.05 g) ,  hydroxylamine (0.44 mmol, 0.03 g)  
and  triethylamine (0.44 mmol, 0.1 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  evaporate  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid 5 (0.11 mmol, 0.05 g),  start 
reduction  reaction.  Dissolve  solid 5  with  methanol  and  add  acetic  anhydride (0.14 mmol, 
0.01 ml).  After  five  minutes,  add  potassium  formate (0.44 mmol, 0.04g)  and  
palladium/carbon (0.05 g).  Heat  the  reaction  solution  and  keep stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 6  can  be  observed.  With  compound 6,  start  another  coupling  reaction.  
A  mixture  of  compound 6 (0.11mmol, 0.05 g),  triethylamine (0.28 mmole, 0.04 ml)  and  
Michael  acceptor (0.17 mmol, 0.03 g)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  Yield:  28%.  
1
H NMR (CDCl3, 
400 MHz):    0.82 (d, 6H),  2.05 (m, 1H),  2.73 (d, 2H),  4.29 (s, 2H),  5.15 (s, 2H),  5.21 (s, 
2H), 6.98-7.97 (m, 12H),  8.91 (s, 1H),  9.01 (s, IH),  9.52 (s, 1H).  
13
C NMR (CDCl3, 400 
MHz):    22.40,  28.96,  40.16,  41.46,  45.60,  104.99,  105.36,  107.25,  115.12,  116.34,  
121.60,  123.99,  125.44,  125.86,  126.12,  126.77,  128.24,  129.03,  129.27,  132.28,  
133.99,  134.84,  141.20,  154.44,  159.90,  160.18,  162.11,  162.79,  164.61,  168.85,  
170.71,  173.61,  173.88.  HR-MS: m/z = 563 [M+H]
+
. 
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2´´-amino-4´´-isobutyl-4-isopropyl-4´-(naphthalene-1-ylmethyl)-[2,5´:2´,5´´-terpyrimidine]-5-
carbonitrile (7c) 
A  mixture  of  compound 4e (0.40 mmol, 0.158 g) ,  hydroxylamine (1.60 mmol, 0.11 g)  
and  triethylamine (1.60 mmol, 0.2 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  remove  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid 5 (0.40 mmol, 0.17 g),  start 
reduction  reaction.  Dissolve  solid 5  with  methanol  and  add  acetic  anhydride (0.52 mmol, 
0.05 ml).  After  five  minutes,  add  potassium  formate (1.60 mmol, 0.26g)  and  
palladium/carbon (0.17 g).  Heat  the  reaction  solution  and  keep stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 6  can  be  observed.  With  compound 6,  start  another  coupling  reaction.  
A  mixture e of  compound 6 (0.40 mmol, 0.164 g),  triethylamine (1.60 mmole, 0.2 ml)  and  
Michael  acceptor (0.52 mmol, 0.086 g)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  Yield: 51%.  
1
H NMR (CDCl3, 
400 MHz):    0.68-0.69 (d, 6H),  1.21-1.24 (d, 6H),  1.91 (m, 1H),  2.83-2.85 (d, 2H),  3.42 
(m, 1H),  5.19 (s, 4H),  7.03-7.86 (m, 7H),  8.85 (s, 1H),  8.92 (s, 1H),  9.54 (s, 1H).  
13
C 
NMR (CDCl3, 400 MHz):    21.16,  22.58,  28.71,  35.21,  40.06,  124.14,  125.54,  125.58,  
126.27,  126.95,  127.50,  128.99,  159.95,  160.49.  HR-MS: m/z = 515 [M+H]
+
. 
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2´´-amino-4´-benzyl-4,4´´-diisobutyl-[2,5´:2´,5´´-terpyrimidine]-5-carbonitrile (7d) 
A  mixture  of  compound 4c (0.43 mmol, 0.15 g) ,  hydroxylamine (1.72 mmol, 0.12 g)  
and  triethylamine (1.72 mmol, 0.2 ml)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing  conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  evaporate  every  ethanol  under  the  
reduced  pressure.  White  solid  are  formed.  With  this  solid 5 (0.43 mmol, 0.16 g),  start 
reduction  reaction.  Dissolve  solid 5  with  methanol  and  add  acetic  anhydride (0.56 mmol, 
0.1 ml).  After  five  minutes,  add  potassium  formate (1.72 mmol, 0.15g)  and  
palladium/carbon (0.16 g).  Heat  the  reaction  solution  and  keep stirring  overnight.  By  
using  diatomaceous  earth,  filter  the  reaction  solution  and  evaporate  every  solvent.  
White  compound 6  can  be  observed.  With  compound 6,  start  another  coupling  reaction.  
A  mixture  of  compound 6 (0.43 mmol, 0.15 g),  triethylamine (1.72 mmole, 0.2 ml)  and  
Michael  acceptor (0.65 mmol, 0.12 g)  in  ethanol (absolute, 200 proof, 10mL)  was  stirred  
under  refluxing conditions  until  the  TLC  indicated  completion  of  the  reaction.  The  
mixture  was  brought  to  room  temperature  and  the  formed  precipitate  was  filtered  by  
vacuum  and  rinsed  with  ice  cold  methanol (5 mL x 3).  Yield: 37%.  
1
H NMR (CDCl3, 
400 MHz):    0.83 (d, 6H),  1.00 (d, 6H),  1.61 (s, 2H),  2.01 (m, 2H),  2.91 (d, 2H),  3.15 (d, 
2H),  4.72  (s, 2H),  5.27 (s, 2H),  7.82 (m, 2H),  7.86 (m, 3H),  8.99 (s, 1H),  9. 02 (s, 1H),  
9.44 (s, 1H).  
13
C NMR (CDCl3, 400 MHz):    14.10,  14.81,  22.79,  22.83,  25.80,  43.92,  
48.82,  53.45,  121.61,  128.60,  129.29,  155.52,  157.58.  HR-MS: m/z = 479 [M+H]
+
. 
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2. 3. 5. Synthesis of  8-10 
2´-amino-4-benzyl-4´-isobutyl-[2,5´-bipyrimidine]-5-carboxylic acid (8) 
A  mixture  of  compound 4c (0.58 mmol, 0.2 g)  and  sodium  hydroxide (5.8 mmol, 0.23 
g)  in  methanol (absolute, 200 proof, 10mL)  was  stirred  under  refluxing  conditions.  
Check  TLC  and  remove  every  solvent  under  the  reduced  pressure.  Dissolve  the  white  
solid  with  water  and  add  1M  HCl  until  pH  reaches  to  2~3.  Extract  the  product  with  
ethyl  acetate  and  recrystalize  the  product  with  ether  and  ethyl acetate.  The  yield  is  
5 %.  
1
H NMR (MeOH, 400 MHz):    0.73-0.77 (d, 6H),  1.90-1.94 (m, 1H),  2.94-2.98 (d, 
2H),  4.39 (s, 2H),  4.61 (s, 2H),  7.17-7.32 (m, 5H),  8.79-8.85 (t, 2H),  9.19 (s, 1H).  
13
C 
NMR (MeOH, 400 MHz):    21.57,  28.56,  40.93,  41.37,  43.99,  44.15,  104.98,  126.34,  
126.51,  128.26,  128.36,  129.23,  129.32,  155.86,  156.01,  164.51.  HR-MS: m/z = 364 
[M+H]
+
. 
 
4-benzyl-2´-(3-carboxypropanamido)-4´-isobutyl-[2,5´-bipyrimidine]-5-carboxylic acid (9) 
Dissolve  compound 8 (0.13 mmole, 0.05 g)  with  THF  add  succinic  anhydride (0.13 
mmole, 0.013 g)  and  triethylamine ( 0.26 mmole, 0.1 ml)  into  the  same  flask. Reflux  the  
mixture  and  check  TLC.  Evaporate  every  solvent  under  the  reduced  pressure  and  
perform  the  column  to  purify  the  compound 9. (ethyl acetate -> MeOH : ethyl acetate 
(1:4)). The  yield  is  37 %.
  1
H NMR (MeOH, 400 MHz):  0.66-0.67 (d, 6H),  0.82-0.84 (d, 
2H),  1.01-1.03 (d, 2H),  1.80-1.85 (m, 1H),  2.84-2.86 (d, 2H),  4.54 (s, 2H),  6.93 (s, 2H),  
7.13-7.29 (m, 5H),  8.68 (s, 1H),  8.94 (s, 1H).  
13
C NMR (MeOH, 400 MHz):    22.93,  
23.16,  28.56,  29.82,  30.63,  32.82,  128.79,  129.90,  151.75,  174.72,  202.97,  203.02,  
204.18,  205.50,  205.57,  205.59,  206.21.  HR-MS: m/z = 464 [M+H]
+
. 
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2´´-amino-4´-benzyl-4,4´´-diisobutyl-[2,5´:2´,5´´-terpyrimidine]-5-carboxylic acid (10) 
A  mixture  of  compound 7d (0.43 mmol, 0.2 g)  and  sodium  hydroxide (5.8 mmol, 0.23 
g)  in  methanol (absolute, 200 proof, 10mL)  was  stirred  under  refluxing  conditions.  
Check  TLC  and   remove  every  solvent  under  the  reduced  pressure.  Dissolve  the white  
solid  with  water  and  add  1M  HCl  until  pH  reaches  to  2~3. Extract  the  product  with  
ethyl  acetate  and  recrystalize  the  product  with  ethyl  acetate.  The  yield  is  14 %.  
1
H 
NMR (MeOH, 400 MHz):    0.73-0.77 (m, 12H),  0.91-0.93 (d, 2H),  1.08-1.13 (m, 1H),  
1.29-1.30 (d, 2H ),  1.89-1.99 (m, 1H),  4.72-4.76 (d, 2H),  4.39 (s, 1H),  4.61 (s, 1H),  7.13-
7.31 (m, 5H),  9.21 (s, 1H),  9.31 (s, 1H),  9.35 (s, 1H).  
13
C NMR (MeOH, 400 MHz):    
20.92,  21.57,  21.69,  28.53,  28.55,  28.60,  40.94,  41.28,  41.32,  41.39,  43.81,  43.98,  
44.16,  126.22,  126.35,  126.50,  128.26,  128.35,  128.97,  129.00,  129.22,  129.32,  159.57,  
160.80,  165.35.  HR-MS: m/z = 498.27 [M+H]
+
. 
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CHAPTER THREE: 
SOLUTION-PHASE  SYNTHESIS  OF  -HAIRPIN  PEPTIDE  
INHIBITING  MULTIPLE  MYELOMA  CELLS  ADHESION 
 
3. 1. Introduction 
Many  classes  of  blood  cells  are  formed  from  blood  stem  cells  in  bone  marrow.  
Plasma  cells,  a  type  of  white  cell,  can  make  antibodies  which  fight  against  infections.  
Plasma  cells  follow  the  normal  cell  cycle. When  genes  of  plasma  cells  are  changed,  
they  turn  into  myeloma  cells  In  contrast  to  plasma  cells,  myeloma  cells  do  not  follow  
normal  cell  cycle.  Overtime,  myeloma  cells  outgrow  plasma  cells  and  form  a  mass  of  
myeloma  cells  which  is  called  a  solitary  plasma  cytoma  in  bone  marrow.  This  can  
result  in  invading  bone  tissue  and  spreading  throughout  the  body.   
Multiple  myeloma (MM)  is  a  cancer  of  plasma  cells.  Even  though  treatment  for  
multiple  myeloma (MM)  has  been  highly  improved,  the  disease  still  remains  incurable  
because  myeloma  cells  can  develop  drug-resistance  by  being  exposed  to  chemotherapy  
over  long  periods  of  time.  There  have  been  numerous  studies  of  both  solid  and  
hematological  cancer  cells  from  different  tissues  showed  drug  resistance  (1-8).  Even  
though  dominant  or  multiple  factors  are  involved  in  multidrug  resistance,  a  few  drug  
transporters  (e.g. P-glycoprotein,  multidrug resistance-associated protein,  breast  cancer  
resistant  protein)  and  proteins  which  control  or  regulate  cell  growth  or  cell  death  (e.g.  
Bcl-2  family)  as  cellular  drug-resistant  factors  were  studied  intensively  (9). Despite  of  
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the  fact  that  current  standard  therapy  for  cancers,  including  MM,  is  targeting  apoptotic  
pathway,  these  studies  suggested  that  activating  multiple  cell  death  pathways  may  
avoid  cancer  drug  resistance  and  cure  cancers  better  (10).  Also,  Jason  et  al  found  out  
cell-adhesion  mediated  drug  resistance  (CAM-DR)  of  multiple  myeloma  cells  is  not  
related  to  two  well-known  factors  of  drug  resistance,  active  drug  transport  and  
increased  expression  of  Bcl-2  family  members  which  activate  the  apoptotic  pathway  
(11).   
There  are  three  different  types  of  cell  death  based on  the  morphological  appearance  
(12).  According  to  characteristic  morphological  aspects,  apoptosis  (type 1  cell  death)  
shows  nuclear  pyknosis (chromatin  condensation)  and  karyorthexis (nuclear  
fragmentation)  (13).  Autophagy  (type  2  cell  death)  includes  the  massive  autophagic  
vacuolization  and  the  digestion  of  partial  cytoplasm  by  lysosomal  hydrolases  (14).  
Necrosis  (type  3  cell  death)  is  characterized  by  rupture  of  the  plasma  membrane  by  
deflation  of  cell  volume  and  the  random  dismantle  of  swollen  organelles. Currently,  
most  conventional  anticancer  drug  discovery  strategy  is  inducing  apoptosis  because  of  
plethora  knowledge  of  molecular  mechanism  of  apoptosis  regulation  (15). A  delicate  
balance  between  proapoptotic  and  antiapoptotic  proteins  of  apoptosis  pathways  plays  
an important  role  to control  the  survival  of  long-lived  cells  and  termination  of  short-
lived  cells  in  a  number  of  tissues,  including  the  bone  marrow.  However,  imbalance  of  
proapoptotic  and  antiproptotic  regulators  causes  various  diseases.  Especially,  for  
cancers,  cells  which  facilitate  neoplasia  and  malignance  can  prolong  their  survival  by  
thwarting  action  of  antiapoptotic  proteins.  Although  in  a  variety  of  accumulating  
evidences  validate  that  apoptosis  induction  can  be  a  potential  drug  discovery  strategy,  
it  is  necessary  to  optimize  selectivity  of  compounds  which  interact  with  more  than  
two  members  of  apoptosis  protein  families  along  with  improving  pharmacokinetic  
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properties.  This  disadvantage  is  another  reason  to  induce  alternative  cell  death  for  
anti-cancer  therapy.   
Previously,  it  was  reported  that  HYD-1  (kikmviswkg),  a  synthetic  D-amino  acid  
peptide,  can  act  as  a  ligand  mimetic  and  block  tumor  cell  adhesion  (16).  This  
cascades  preventing  migration  of  prostate  tumor  cells  on  laminin  322  (laminin  5)  and  
changing  the  cellular  signals  coming  from  a  laminin  322  (laminin  5)  matrix  (17, 18).  
Later,  Rajesh  et  al  discovered  HYD-1  can  block  binding  41 integrin-dependent  
multiple  myeloma  cells  to  extracellular  matrix,  fibronectin,  as  well  as  induce  cell  
death  in  H929,  8226,  and  U266  multiple  myeloma  (MM)  cell  lines  but  not  in  
CD34+  normal  hematopoietic  progenitor  cells  or  surrounding  blood  mono-nuclear  
cells  (19).  HYD-1  induced  necrosis  (type  3  cell  death)  in  MM  cells  that  is  different  
from  apoptosis  or  autophagy by  observing  the  loss  of  Δψm,  total  cellular  ATP  
decrease,  increased  ROS  expression.  However,  because  of  modest  antitumor  activity  
of  HYD-1  (IC50 = 33 µM)  in  vivo,  it  was  necessary  to  modify  HYD-1  to  improve  
bioavailablity  or  antitumor  activity (e.g.  PEGylation,  cyclization).   
 
 
Figure 35. Structure of HYD-1. 
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Hazlehurst  and  co-workers  discovered  that  MVISW  were  the  minimal  elements  of  
HYD-1  for  bioactivity  after  creating  N-  and  C-terminal  deletion  peptides  and  
replacement  isoleucine  to  valine  increased  bioactivity.  Based  on  these  findings,  first  
modification  was  designing  -hairpin  structure  by  applying  MVVSW  in  the  
recognition  strand  and  KLKLK  in  the  non-recognition  strand  (20).  Advantages  of  -
hairpin  design  that  contribute  to  better  bioactivity  include:  (1) amphiphilic  
functionality  and  (2) rigid  conformational  structure.  After  a  structure-activity  
relationship (SAR)  study,  methionine (M)  was  changed  to  norleucine  and  serine (S)  
was  replaced  by  alanine (A).  For  further  optimization,  conformational  search  and  
energy  minimization  for  -turn  promoters  were  studied  by  using  the  macromodel  
and  the  GLIDE  software  distributed  by  Schrodinger,  Inc..  This  result  indicated  that  
ether-peptidomimetic  proline  derivative  at  one  turn  and  methylsulfonamide  amino  
ethyl  glycine  at  the  other  turn  showed  an  impressive  bioactivety.  By  applying  every  
optimization  condition,  a  cyclic  peptide  referred  as  MTI-101  showed  1.08 µM 
(=IC50)  bioactivity  after  TOPRO3  assay.   
 
 
Figure 36. -Hairpin structure. 
 
Due  to  the  promising  bioactivity  of  MTI-101  in  vitro,  it  is  necessary  to  produce  a  
massive  amount  of  MTI-101  to  investigate  whether  the  same  effect  will  reproduce  in  
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vivo.  The  mass  production  of  peptides  can  be  carried  out  through  either  continuous  
solid-phase  synthesis  or  conventional  solution-phase  synthesis.  Each  method  has  its  
own  disadvantages,  for  example,  classic  solution-phase  synthesis  needs  to  isolate  and  
purify  intermediates  and  continuous  solid-phase  synthesis  demands  to  handle  large  
amount  of  pricy  resins  or  large  excess  of  reagents.  In  order  to  scale  up  the  
production  of  the  biologically  active  peptides  successfully,  it  seems  better  to  combine  
the  strong  aspects  of  both  methods  to  overcome  their  disadvantages  (21).  
In  this  study,  solution-phase  synthesis  which  has  advantages  of  solution-phase  and  
solid-phase  methods  was  examined  for  the  production  of MTI-101.  We  approached  in  
two  different  ways:  (1)  combination  of  recognition  strand  and  non-recognition  strand  
and  (2)  continuous  solution-phase  synthesis.  The  data  suggested  the  possibility  of  
larger-scale  production  for  MTI-101  with  simple  purification  and  less  use  of  reactants  
or  reagents  in  solution  phase.  
 
 
Figure 37. Structure of MTI-101. 
 
Table 7. Comparison of Solid-phase Synthesis and Solution-phase Synthesis 
  
Advantages 
 
 
Disadvantages 
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Solid –phase 
synthesis 
 
 
 
 
 
 
- Rapid  purifiction 
- Fast  synthesis 
 
 
 
 
- Limited  workable  reactions  for  
coupling  or  linking 
- Difficulty  of  monitoring  the  
reaction  process 
- Solvation problems 
 
 
 
 
 
Solution-phase 
synthesis 
 
 
 
 
- Many  documented  solution-phase  
synthesis 
- Many  commercially  available  
protecting  groups 
- More  economical  for  mass  
production 
 
 
 
Purification problems 
 
 
 
 
 
3. 2. Results and discussion 
Previously,  continuous  solution  methods  have  utilized  Fmoc-  chemistry  to  build  
small-scaled  short  peptides  which  consist  of  six  to  eight  amino  acids  (22).  Because  of  
inconvenience  of  by-product  removal  after  Fmoc-  deprotection,  in  this  study,  Cbz-  or  
Boc-  protecting  groups  were  used.  In  addition,  in  contrast  to  solid-phase  approach,  the  
reaction  can  be  monitored  and  analyzed  at  any  stage.  MALDI-TOF  and  LC-MS  
techniques  were  used  for  the  analysis. 
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Synthesis  of  MTI-101  was  approached  in  two  different  ways.  One  is  recognition  
strand  and  non-recognition  strand  were  synthesized  separately  and  combined  later.  The  
other  is  the  whole  peptide  structure  was  built  in  a  continuous  way.  We  investigated  
the  former  case  first  since  short  peptides  of  six  to  eight  amino  acid  units  were  
synthesized  successfully  in  solution  (22).   
Before  building  the  recognition  strand,  -turn  promoter  was  synthesized.  Scheme 6  
shows  synthesis  procedures  of  -turn  promoter,  derivative  of ether-peptidomimetic  
proline.  Boc-D-proline  was  reduced  to  Boc-D-prolinol  by  using  NaBH4.  SN2  reaction  
was  followed  to  convert  Boc-D-prolinol  to  Boc-D-pyrrolidine  derivative.  For  the  next  
coupling,  Boc-  group  was  deprotected  selectively  under  0 °C.  The  sequence  of  
recognition  strand  (WAVVN)  was  attached  to  the  -turn  promoter.  Three  different  
coupling reagents  were  used  for  the  better  yield.  In  order  to  proceed  the  next  coupling,  
Cbz-  group  was  deprotected  in  the  presence  of  10 % Pd/C  and  high  N2 (55 psi).  After  
each  coupling,  the  product  was  purified  by  column  chromatography.  The  final  
deprotection  step  was  completed  via  treatment  with  TFA  (Scheme 7).   
 
 
Scheme 6. Synthesis of -turn promoter. 
 
Building  non-recognition  strand  was  started  with  the  synthesis  of  methylsulfonamide  
amino  ethyl  glycine  linker.  Excess  of  1,2-ethylenediamine  was  reacted  to  di-tert-butyl  
dicarbonate  to  give  one side  protected  product.  In  the  next  step,  the  unprotected  amino  
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group  attacked  sulfur  atom  of  methanesulfonyl  chloride  in  a  fashion  of  SN2  reaction.  
Due  to  slightly  more  neucleophilic  property  of  nitrogen  of  methylsulfonamide  side,  
nucleophilic  substitution  reaction  occurred  only  one  side  in  the  presence  of  methyl  
bromoacetate  and  NaH.  The  Boc-  group  was  deprotected  for  the  next  coupling  
(Scheme 8).  Scheme  9  shows  all  the  coupling  and  deprotection  steps  for  non-
recognition  strand.  Five  amino  acids  were  coupled  to  the  linker  by  using  T3P  in  an  
order  of  K(Boc)LK(Boc)LK(Boc).  Boc-  protected  lysine  was  used  to  avoid  side  
reactions  in  coupling  and  deprotection  steps.  Deblocking  Cbz-  group  was  processed  
under  10 %  Pd/C  and  H2 (55 psi).  After  every  coupling,  the  pure  product  was  obtained  
through  recrystallization  in  ether  (Scheme 9).   
 
 Scheme 7. Recognition strand synthesis of MTI-101. 
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Scheme 8. Synthesis of linker. 
 
 
Scheme 9. Non-recognition strand synthesis of MTI-101. 
 
The  last  step  for  MTI-101  synthesis  is  cyclization  of  recognition  strand  and  non-
recognition  strand  in  solution.  Linear  peptide  was  formed  between  -NH2  from  non-
recognition  strand  and  -COOH  from  recognition  strand  under  the  condition  of  T3P,  
DIEA,  and  anhydrous  THF.  For  the  final  cyclization,  Cbz-  deprotection  was  proceeded  
earlier  than  that  of  methyl  ester  group.  Because  free  carboxylic  acid  was  transformed  
back  into  methyl  ester  in  the  presence  of  excess  methanol  which  is  solvent  for  the  
Cbz-  deprotection  step.  After  Cbz-  deprotection,  methyl  ester  group  was  deblocked  by  
using  5 %  lithium  hydroxide.  Cyclization  of  linear  peptide  occurred  via  treatment  with  
T3P.  The  pure  product  was  obtained  as  precipitation  in  ether.  The  final  Boc-  
deprotection  of  MTI-101  was  completed  with  TFA/DCM  (Scheme 10). 
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Scheme 10. Cyclization between recognition strand and non-recognition strand. 
 
Even  though  cyclization  of  recognition  strand  and  non-recognition  strand  was  
successful  in  solution,  this  approach  suffered  from  economical  problem.  Because  
recognition  strand  synthesis  demands  column  chromatograph  purification  after  every  
coupling.  This  would  eventually  cost  more  for  the  large-scale  peptide  synthesis.  In  
order  to  overcome  this  deficiency,  continuous  solution-phase  synthesis  was  examined  
since  every  product  of  non-recognition  strand  was  able  to  be  recrystallized  in  ether.  
Before  launching  continuous  solution-phase  synthesis,  it  is  necessary  to  modify  
protecting  group  from  previously  synthesized  -turn  promoter  due  to  involvement  of  
Boc-  protected  lysine.  Instead  of  Boc-D-proline,  Cbz-D-proline  was  reduced  to  Cbz-D-
prolinol  in  the  presence  of  N-methylmorpholine,  isobutyl chloroformate,  and  NaBH4.  
Cbz-D-prolinol  was  transformed  into  Cbz-pyrrolidine  derivative  by  using  tert-butyl  
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bromoacetate.  tert-Butyl  group  was  deprotected  for  the  coupling  in  two  different  ways: 
(1) TFA/DCM  and  (2) H3PO4/toluene.  Even  though  the  combination  of  TFA  and  DCM  
is  the  typical  method  for  deblocking  Boc-  group,  coupling  reagent, T3P,  enabled  
trifluoroacetic  acid  active  and  caused  uncontrolled  side  reaction.  Moreover,  this  side  
product  was  impossible  to  remove  after  recrystallization  (Scheme 11).  
 
Scheme 11. Synthesis of -turn promoter. 
 
  In  the  beginning,  continuous  solution-phase  synthesis  followed  the  same  procedure  
of  non-recognition  strand  synthesis.  A  sequence  of  K(Boc)LK(Boc)LK(Boc)  was  
coupled  to  the  linker  by  using  combination  of  N-methylmorpholine  and  
isobutylchloroformate  or  T3P  as  coupling  reagents.  Except  percent  yield  of  dipeptide 2,  
the  most  of  percent  yields  were  comparable  for  both  coupling  reagents.  This  is  
because  the  linker  contained  trifluoroacetic  acids  as  counter  ions  after  Boc-  
deprotection  and  they  were  activated  by  T3P.  This  resulted  in  undesirable  reactions  
and  decreased  percent  yield.  Between  coupling  steps,  Cbz-  group  was  deprotected  
under  the  condition  of  Pd/C  and  H2  or  Pd/C  and  triethylsilane.  A  combination  of  
Pd/C  and  triethylsilane  made  Cbz-  deprotection  faster,  however,  the  efficiency  of  
deblocking  completion  decreased  as  the  peptide  became  longer.  After  hexapeptide 6,  
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two  more  couplings  (-turn  promoter  and  trypthophan)  were  proceeded.  However,  
because  of  facing  a  couple  of  problems,  for  example,  side  reactions  or  low  percent  
yield,  it  is  implausible  to  proceed  the  rest  of  coupling  and  cyclization.  (Scheme 12, 
Table 6, 7) 
 
Table 8. Percent Yield of Continuous Solution-phase Synthesis 
Entry Compound Yield 
1 2a1 45% 
2 3c1 89% 
3 4a1 95% 
4 5c1 88% 
5 6a1 96% 
6 7d - 
*T3P as coupling reagent 
 
Table 9. Percent Yield of Continuous Solution-phase Synthesis 
Entry Compound Yield 
1 2a2 98% 
2 3c2 95% 
3 4a2 89% 
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4 5c2 86% 
5 6a2 91% 
6 7d 73% 
7 8e 51% 
*N-methylmorpholine and isobutylchloroformate as coupling reagent 
 
 
Scheme 12. Continuous solution-phase synthesis of MTI-101. 
 
In  summary,  it  is  shown  the  possibility  of  MTI-101  synthesis  in  solution  by  using  
two  different  approaches: (1) cyclization  of  recognition  strand  and  non-recognition  
strand  and  (2) continuous  synthesis.  In  the  former  case,  synthesis  of  MTI-101  was  
successful  in  solution,  however,  column  chromatography  purification  was  necessary  for  
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recognition  strand  that  causes  more  cost  for  the  large-scale  synthesis.  In  the  latter  
case,  even  though  products  after  each  coupling  were  recrystallized  in  ether,  synthesis  
of  MTI-101  was  unable  to  be  completed  due  to  side  reactions  or  low  yield.  Large-
scale  synthesis  of  MTI-101  would  be  refined  by  using  appropriate  coupling  reagents  
or  methods. 
 
3. 3. Experimental section 
3.3.1. General  comments 
All  peptides  were  identified  by  mass  spectral  analysis  (Bucker)  and  all  new  
compounds  showed  consistent  
1
H,  
13
C  NMR  (INOVA-400),  and  high  resolution  mass  
spectral  data  (Agilent  1100  series). 
 
3.3.2. -turn  promoter  synthesis 
3.3.2.1. Tert-butyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-carboxylate 
N-Boc-D-prolinol (1 g, 4.96 mmol)  was  dissolved  in  20 ml  of  toluene  and  cooled 
down   to  0 °C.  Tetrabutylammonium iodide (0.92 g, 2.49 mmol),  30 % NaOH  solution (12 
ml, 90 mmol),  and  tert-butylbromoacetate (1.46 ml, 9.93 mmol)  were  added  subsequently  
into  the  cooled  solution.  The  reaction  mixture  was  brought  to  room  temperature  after  
5  hours  and  left  overnight.  20 ml  of  toluene  was  added  and  the  mixture  was  extracted.  
The  organic  layer  was  washed  with  1 N HCl (15 ml)  and  brine (15 ml).  The  organic  
layer  was  concentrated  after  being  dried  over  MgSO4.  Purification  by  flash  column  
chromatography (Hexane-EtOAc, 3:1)  gave  a  light  yellow  colored  oil (1.41 g, 90 %).  
1
H  
NMR (400 MHz, CDCl3):    1.46  (s, 9 H),  1.47  (s, 9H),  1.80-1.82  (m, 1H),  1.91-1.93  
(m, 2H),  2.05-2.07  (m, 1H),  3.32-3.34  (m, 2H),  3.52-3.54  (m, 1H),  3.60-3.63  (m, 1H),  
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3.87-3.89  (m, 1H),  3.96  (s, 2H);  
13
C 
 
NMR  (400 MHz, CDCl3):  27.86,  28.04,  28.34,  
28.76,  56.58,  69.25,  175.3;  HRMS: m/z calcd  for  C16H29NO5  [M + H
+
],  316.2046;  found,  
316.2007. 
 
3.3.2.2. Benzyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-carboxylate 
N-methylmorpholine  (1.3 ml,  12.1  mmol)  and  isobutylchloroformate  (1.6 ml,  12.1 
mmol)  were  added  to  a  solution  of  Cbz-proline  (3.01 g,  12.1 mmol)  in  30 ml at  0 .  
After  10  minutes,  a  white  precipitation  was  removed  by  filteration  and  filtrate  was  
transferred  to  three  neck  flask.  Solution  of  NaBH4  (0.69 g,  18.1 mmol)  in  10  ml  water  
was  mixed  slowly  to  the  cool  filtrate   while  purging  Ar  gas.  TLC  indicated  the  
completion  of  reduction  after  l  hour.  THF  was  removed  under  reduced  pressure  and  
water  was  added  to  destroy  excess  of  NaBH4.  Product  was  extracted  with  ethyl  
acetate  (3  10 ml),  washed  with  brine,  and  dried  over  Na2SO4.  After  evaporation  of  
ethyl  acetate,  light  yellow  oil  was  obtained.  N-Cbz-D-prolinol (2.84 g, 12.1 mmol)  was  
dissolved  in  20 ml  of  toluene  and  cooled down   to  0 °C.  Tetrabutylammonium iodide 
(2.23 g, 6.05 mmol),  30 % NaOH  solution (29 ml, 218 mmol),  and  tert-butylbromoacetate 
(3.6 ml, 24.2 mmol)  were  added  subsequently  into  the  cooled  solution.  The  reaction  
mixture  was  brought  to  room  temperature  after  5  hours  and  left  overnight.  20 ml  of  
toluene  was  added  and  the  mixture  was  extracted.  The  organic  layer  was  washed  with  
1 N HCl (15 ml)  and  brine (15 ml).  The  organic  layer  was  concentrated  after  dried  over  
MgSO4.  Purification  by  flash  column  chromatography (Hexane-EtOAc, 4:1)  gave  a  light  
yellow  colored  oil (2.96 g, 70 %).  
1
H  NMR  (400 MHz, CDCl3):    1.47 (s, 9H),  1.81-
1.84 (m, 1H),  1.90-1.96  (m, 2H),  2.07-2.11  (m, 1H),  3.39-3.42  (m, 2H),  3.57-3.58 (m, 
1H),  3.58-3.59  (m, 1H),  3.89  (s,  1H),  3.97  (s,  1H),  4.01-4.02  (m, 1H),  5.08-5.18  (m, 
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2H),  7.28-7.38  (m, 5H);  
13
C 
 
NMR (400 MHz, CDCl3):  23.15,  24.08,  28.17,  28.34,  
28.94,  46.98,  47.26,  56.59,  57.24,  66.81,  67.02,  68.70,  69.24,  71.76,  72.38,  76.73,  
76.94,  77.04,  77.26,  77.36,  77.46,  77.57,  81.76,  82.10,  128.01,  128.15,  128.68,  137.16,  
155.19,  169.92;  HRMS: m/z calcd for C16H29NO5  [M + H
+
],  ;  found,  . 
 
3.3.2.3. Tert-butyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-1-carboxylic acid 
Tert-butyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-carboxylate (1.41g, 4.47 
mmol)  in  10 ml  of  DCM  was  cooled  down  to  0 °C and  3 ml  of trifluoroaceticacid  was  
added  to  the  cooled  solution.  Reaction  mixture  was kept  at 0 °C for  5 hours.  Mixture  
was  extracted  by  DCM (10 ml x 3)  after  excess  TFA  was  neutralized  by  6 M  KOH.  
The  combined  organic  layers were  washed  with  brine  (10 ml)  and  dried  over  MgSO4.  
After  concentration,  light  yellow  oil  was  obtained (0.91g, 95 %).   
 
3.3.2.4. 2-((1-((benzyloxy)carbonyl)pyrrolidin-2-yl)methoxy)acetic acid 
i)  Benzyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-carboxylate  (2.96g, 8.46 
mmol)  in  10 ml  of  DCM  was  cooled  down  to  0 °C and  3 ml  of trifluoroaceticacid  was  
added  to  the  cooled  solution.  Reaction  mixture  was kept  at 0 °C for  5 hours.  After  
concentration,  a  light  yellow  oil  was  obtained. 
1
H  NMR  (400 MHz, CDCl3):    1.54-
1.58 (m, 1H),  1.79-2.00  (m, 3H),  3.33-3.47  (m, 4H),  4.05  (s, 2H),  4.24-4.28 (m, 1H),  
4.96-5.09  (dd, J = 0.05, 2H),  7.27-7.35  (m, 5H);  
13
C 
 
NMR (400 MHz, CDCl3):  24.02,  
27.89,  29.97,  46.71,  56.79,  67.74,  68.33,  75.31,  76.93,  77.24,  77.56,  114.15,  117.02,  
127.90,  128.37,  128.70,  136.14,  157.23,  161.89,  162.28,  162.27,  163.06,  175.80;  
HRMS: m/z calcd for C15H19NO5  [M + H
+
],  294.1336;  found,  294.1344. 
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  ii)  Benzyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-carboxylate  (0.70 g, 1.99 
mmol)  in  1 ml  of  toluene  was  added  to  l ml  of  85 %  phosphoric  acid  of  another  
flask.  Reaction  mixture  was kept  overnight.  5 ml  of  water  added  to  reaction  mixture  
and  product  was  extracted  with  ethyl  acetate.  The  combined  organic  layer  was  washed  
with  brine  and  dried  over  Na2SO4.    After  concentration  and  flush  column  
chromatography  (Hexane:ethyl acetate=1:2),  a  viscous  light  yellow  oil  was  obtained  
(0.41 g,  70%). 
 
3.3.3. Recognition  strand  synthesis 
3.3.3.1. -turn promoter(O-t-Bu)-Trp-NH(Cbz) 
Solution  of  Tert-butyl-2-((2-tert-butoxy-2-oxoethoxy)methyl)pyrrolidine-1-carboxylic 
acid  (1.19 g, 5.53 mmol)  and  DIEA  (2.3 ml, 13.83 mmol)  was  prepared  in  anhydrous  
DCM  (10 ml)  under  argon  gas.  N-Cbz-Trp-OH  (1.87 g, 5.53 mmol)  and  
Propylphosphonic  Anhydride  (T3P, 3.52 g, 11.06 mmol)  were  added  to  previously  
prepared  solution.  Leave  the  reaction  mixture  at  room  temperature  overnight  while  
purging  argon  gas.  The  reaction  was  quenched  with  water (10 ml)  and  extracted  with  
DCM (10 ml x 3).  The  combined  organic  layers  were  washed  with  brine (10 ml),  dried  
over  MgSO4,  and  concentrated.  After  flash  column  chromatography  (Hexane-EtOAc, 
1:1),  a  light  yellow  crystal  was  obtained  (2.375 g, 80 %).  
1
H  NMR  (400 MHz, CDCl3):  
  1.44  (s, 9 H),  1.66-1.73  (m, 2H),  1.82-1.93  (dd, J = 0.09, 0.02, 2H),  2.48-2.55  (dd, J 
= 0.05, 0.02, 1H),  3.06-3.12  (dd, J = 0.05, 0.02, 1H),  3.12-3.19  (m, 2H),  3.44-3.47  (m, 
1H),  3.58-3.59  (m, J = 0.01, 0.01, 1H),  3.66-3.68  (m, 1H),  3.89  (s, 2H),  4.67-4.73  (q, J = 
0.02, 1H),  5.10  (s, 2H),  7.04-7.38(m, 10H);  
13
C
  
NMR  (400 MHz, CDCl3):    23.63,  2.51,  
28.33,  42.25,  47.07,  53.96,  57.18,  66.97,  69.10,  70.90,  76.68,  81.78,  110.93,  111.26,  
 139 
 
111.37,  119.90,  122.47,  128.21,  128.28,  128.33,  128.71,  136.19,  136.26,  169.89,  
170.91;  HRMS:  m/z  calcd  for  C16H29NO5  [M + H
+
],  536.2682;  found,  536.2755. 
 
3.3.3.2. -turn promoter(O-t-Bu)-Trp-NH2 
Lin-Trp-NH(Cbz)  (2.375 g, 4.43 mmol)  and  palladium  carbon  powder  (10 %)  was  
added  to  methanol  (20 ml).  Leave  mixture  under  high  H2  pressure (48 psi)  for  20  
hours.  Excess  palladium  carbon  powder  was  removed  over  diatomaceous  earth.  White  
crystal  was  obtained  after  methanol  removal   under  reduced  pressure  (1.677 g, 94 %). 
 
3.3.3.3. -turn promoter(O-t-Bu)-Trp-Ala-NH(Cbz) 
Lin-Trp-NH2  ( 2.375 g, 4.43 mmol)  was  dissolved  in  10 ml  of  anhydrous  DCM  under  
argon  gas.  Subsequently,  Cbz-Ala-OH  (0.99 g, 4.43 mmol),  DIEA  (1.8 ml, 11.08 mmol),  
and  Propylphosphonic  Anhydride (T3P, 5.64 g, 8.86 mmol)  were  added  to  previous  
solution.  Reaction  mixture  was  stirred  for  22 hours  while  purging  argon  gas.  The  
crude  product  was  extracted  with  DCM  (10 ml x 3)  after  10 ml  of  water  was  added  
for  quenching  excess  T3p. The  combined  organic  layers  were  washed  with  brine  (10 
ml),  dried  over  MgSO4,  and  concentrated.  Purification  by  flash  column  
chromatography (Hexane-EtOAc, 1:2)  gave  a  light  yellow  crystal  (1.935 g, 72 %).  
1
H  
NMR (400 MHz, CDCl3):  =  1.33-1.35  (d, J = 0.02, 3H),  1.44  (s, 9 H),  1.66-1.73  (m, 
2H),  1.82-1.93  (dd, J = 0.09, 0.02, 2H),  3.16-3.18  (d, J = 0.02, 2H),  3.28-3.30  (m, 2H),  
3.50-3.51  (m, 1H),  3.56-3.57  (m, 1H),  3.89  (s, 2H),  3.99-4.01  (m, 1H),  6.96-7.36  (m, 
10H);  
13
C
  
NMR (400 MHz, CDCl3):  23.63,  2.51,  28.33,  42.25, 47.10,  47.12,  52.51,  
57.24,  69.04,  70.82,  81.82,  110.87,  111.28,  118.95,  119.89,  122.46,  123.28,  128.42,  
128.76,  136.15,  170.28 ;  HRMS  :  m/z  calcd  for  C33H42N4O7  [M + H
+
],  607.3053;  
found,  607.3120. 
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3.3.3.4. -turn promoter(O-t-Bu)-Trp-Ala-NH2 
Lin-Trp-Ala-NH2 ( 1.935 g, 3.19 mmol)  and  10 %  palladium  carbon  powder   were  
added  to  methanol  and  kept  under  high  H2  pressure  (53 psi)  overnight.  Excess  
palladium  carbon  powder  was  filtered  over  diatomaceous  earth.  Concentration  of  
filtrate  gave  a white crystal  (1.357 g, 90 %). 
  
3.3.3.5. -turn promoter(O-t-Bu)-Trp-Ala-Val-NH(Cbz) 
Solution  of  Lin-Trp-Ala-NH2  ( 2.68 g, 5.67 mmol)  was  prepared  in  anhydrous  DCM  
(10 ml)  while  purging  argon  gas.  Cbz-Val-OH  (1.14 g, 4.54 mmol),  DIEA  (1.5 ml, 9.08 
mmol),  and  Propylphosphonic  Anhydride  (T3P, 5.77 g, 9.08 mmol)  were  added  to  
previously  prepared  solution.  Reaction  mixture  was  under  dry  condition  overnight  and  
quenched  with  water  (10 ml).  Crude product  was  extracted  with  DCM  (15 ml x 3),  
washed  with  brine  (15 ml),  and  dried  over  Na2SO4.  Purification  by  column  flash  
chromatography  (pure ethylacetate)  gave  a  white  crystal  (3.207 g, 80 %).  
1
H  NMR  (400 
MHz, CDCl3):  =  0.89-0.91  (d, J = 0.02, 6H),  1.44  (s, 9 H),  2.05-2.07  (d, J = 0.02, 3H),  
2.62-2.68  (m, 2H),  3.01-3.03  (m, 1H),  3.16-3.17  (d, J = 0.01, 2H),  3.29-3.31  (m, 2H),  
3.50-3.51  (m, 1H),  3.89  (s, 2H),  3.95-4.01  (m, 2H),  4.48-4.52  (t, J = 0.02, 1H),  4.87-
4.92  (q, J = 0.02, 1H),  5.12  (s, 2H),  5.44-5.46  (d, J = 0.02, 1H),  7.06-7.36  (m, 10H);  
13
C 
 
NMR  (400 MHz, CDCl3):  19.50,  23.77,  27.23,  28.33,  29.02,  31.44,  47.12,  49.15,  
52.52,  57.25,  60.53,  67.34,  69.03,  70.84,  76.68,  81.84,  110.68,  111.35,  118.85,  119.84,  
122.43,  123.38,  128.29, 128.41,  128.77,  136.18,  169.88,  170.17,  171.38;  HRMS  :  m/z  
calcd  for   C38H51N5O8  [M + H
+
],  706.3771;  found,  706.3975. 
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3.3.3.6. -turn promoter(O-t-Bu)-Trp-Ala-Val-NH2 
Lin-Trp-Ala-Val-NH(Cbz)  ( 3.207 g, 4.54 mmol)  was  dissolved  in  methanol  (20 ml)  
and  palladium  carbon  powder  was  added.  The  reaction  mixture  was  left  under  H2  (53 
psi)  overnight  and  filtered  over  diatomaceous  earth.  A  white  crystal  ( 2.464 g, 95 %)  
was  obtained  after  filtrate  was  concentrated. 
 
3.3.3.7. -turn promoter(O-t-Bu)-Trp-Ala-Val-Val-NH(Cbz) 
Lin-Trp-Ala-Val-NH2  ( 2.169 g, 3.80 mmol)  and  DIEA  (1.3 ml, 7.60 mmol)  were  
dissolved  in  10 ml  of  anhydrous  DCM  under  argon  gas.  Cbz-Val-OH  (0.95 g, 3.80 
mmol)  and  Propylphosphonic  Anhydride  (T3P, 4.84 g, 7.60 mmol)  were  added  to  
previously  prepared  mixture.  The  reaction  was  left  overnight   while  purging  argon  gas.  
Excess  Propylphosphonic  Anhydride  (T3P)  was  quenched  with  water  (15 ml)  and  crude  
product  was  extracted  with  DCM  (15 ml x 3).  The  combined  organic  layers  were  
washed  with  brine  (15 ml),  dried  over  NaSO4,  and  concentrated.  Purification  by  flash  
column  chromatography  (ethylacetate-methanol; 20:1)  gave  a  white  crystal  (2.326 g, 
76 %).  
1
H  NMR  (400 MHz, CDCl3):  =  0.90-0.96  (d, J = 0.02, 12H),  1.43  (s, 9 H),  
1.46-1.48  (d, J = 0.02, 3H),  1.84-1.93  (m, 2H),  2.08-2,16  (m, 2H),  2.58-2.60  (m, 1H),  
3.15-3.17  (d, J = 0.02, 2H),  3.22-3.29  (m, 1H),  3.41-3.45  (m, 2H),   3.54-3.61  (m, 2H),  
3.55  (s, 2H),  3.99-4.01  (m, 1H),  4.11-4.18  (m, 1H),  4.34-4.38  (m, 1H),  4.74-4.76  (m, 
1H),  4.91-4.95  (q, J = 0.02, 1H),  5.10  (s, 1H),  7.04-7.53  (m, 10H);  
13
C
  
NMR  (400 MHz, 
CDCl3):  18.32,  18.34,  18.47,  18.48,  19.48,  19.49,  23.69,  24.43,  27.18,  28.33,  
29.28,  31.40,  47.12,  48.46,  56.53,  57.18,  58.81,  60.84,  67.13,  67.21,  69.00,  69.20,  
70.88,  76.67,  81.79,  110.68,  111.31,  119.80,  122.37,  127.71,  128.17,  128.33,  128.74,  
136.14,  136.62,  156.78,  169.87,  170.35,  170.84,  171.62,  171.97,  172.00;  HRMS :  m/z  
calcd  for  C43H60N6O9  [M + H
+
],  805.4455;  found,  805.4518. 
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3.3.3.8. -turn promoter(O-t-Bu)-Trp-Ala-Val-Val-NH2 
The solution of pentamer  (2.558 g, 3.18 mmol)  was  prepared  in  methanol  and 
palladium  carbon  powder  was  added.  The  reaction  mixture  was  left  under  H2  (53 psi)  
for  one  day  and  filtered  over  diatomaceous  earth.  Concentration  of  filtrate  gave  a  
white  crystal  (1.937 g, 91 %). 
  
3.3.3.9. -turn promoter(O-t-Bu)-Trp-Ala-Val-Val-Nlle-NH(Cbz) 
Lin-Trp-Ala-Val-Val-NH2  (1.937 g, 2.89 mmol)  and  DIEA  (7.23 mmol, 1.2 ml) were  
added  to  10 ml  of  anhydrous  DCM  under  argon  gas.  Cbz-Nlle-OH  (0.77 g, 2.89 
mmol)   and   Propylphosphonic   Anhydride   (T3P, 1.83.7 g, 5.78 mmol)   were  added  to  
previously  prepared  solution.  The  reaction  mixture  was  kept  overnight  while  purging  
argon  gas.  Excess  T3P  was  quenched  with  water  (15 ml)  and  crude  product  was  
extracted  with  DCM  (15 ml x 3).  The  combined  organic  layers  were  washed  with  
brine  (15 ml),  dried  over  Na2SO4,  and  concentrated.  Recrystallization  with  Et2O  gave  
a  white crystal  (2.406 g, 91 %).  HRMS  :  m/z  calcd  for  C49H71N7O10  [M + H
+
],  
918.5296;  found,  918.6535. 
 
3.3.3.10. -turn promoter(OH)-Trp-Ala-Val-Val-Nlle-NH(Cbz) 
Lin(O-t-Bu)-Trp-Ala-Val-Val-Nlle-NH(Cbz) ( 2.406 g, 2.62 mmol)  and 
trifluoroaceticacid  (TFA, 3 ml)  were  added  to  10 ml  of  DCM.  The  mixture  was  kept  
overnight,  neutralized  with  6 M  KOH,  and  extracted  with  DCM (15 ml x 3).  The  
combined  organic  layers  were  washed  with  brine  (15 ml) and  dried  over  Na2SO4.  
Evaporation  of  DCM  gave  a  white  crystal  (2.123 g, 94 %).  C45H63N7O10  [M - H
+
],  
860.4564;  found,  860.4544. 
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3.3.4. Synthesis  of  linker   
3.3.4.1. Tert-butyl-2-aminoethylcarbamate
 
Ethylenediamine  (55.6 mL, 831 mmol)  was  dissolved  in  THF  (200 mL).  A solution  of  
Boc2O  (20 g, 91.6 mmol)  in  200  ml  of  THF  was  added  dropwisely   at  0°C  overnight.  
The  resulting  solution  was  concentrated,  dissolved  in  DCM  (100 mL),  and  extracted  
water  (3x20 mL).  The  combined  water  layer  was  back-extracted  with  DCM  (100 mL),  
and  the  all  of  organic  layers  were  combined  and  dried  over  anhydrous  Na2SO4. After  
concentrated,  a  yellow oil  was  left  (14.52 g, 99%).  
 
 
3.3.4.2. Tert-butyl (2-(methylsulfonamido)ethyl)carbamate 
Tert-butyl-2-aminoethylcarbamate (11.19 g, 69.8 mmol)  was  dissolved  in  100 ml  of  
THF.  Triethylamine (11.68 mL, 83.8 mmol),  and  methanesulfonyl chloride (5.41 mL, 69.8 
mmol)  were  added   and  kept  at  room  temperature  for  one  hour.   The  reaction  mixture  
was  concentrated,  extracted  in  ethyl acetate  (EtOAc, 3 25 mL),  and  washed  with  brine  
(10 mL).  The  organic  layer  was  concentrated,   resulting  in  an  off-white solid.  
Recrtstallization  in  diethyl  ether  gave  white  solids  (15.11 g, 90.8%).  
1
H  NMR  (400 
MHz, CDCl3):  =  1.40  9s,  9H),  2.93  (s,  3H),  3.18-3.27  (m,  4H);  
13
C
  
NMR  (400 
MHz, CDCl3):   28.58,  40.35,  40.80,  40.95,  43.67,  79.62,  79.98,  156.74;  HRMS :  
m/z  calcd  for  C43H60N6O9  [M + H
+
],  239.106;  found,  239.105. 
 
3.3.4.3 Methyl 2-(N-(2-(tert-butoxycarbonylamino)ethyl)methylsulfonamido)acetate 
Tert-butyl-(2-(methylsulfonamido)ethyl)carbamate (15.11 g, 63.4 mmol)  was  dissolved  
in  100 ml  of  anhydrous  THF.  60% sodium hydride  (2.54 g, 63.4 mmol)  was  added  to  
the  previous  prepared  solution  while  purging  Ar  gas. After  15  minutes,  addition  of  
methyl  bromoacetate (5.83 mL, 63.4 mmol)  was  followed  and  the  solution  was  stirred  
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for  one  hour.  The  solution  was  quenched  with  water (10 mL).  The  resulting  solution  
was  concentrated,  dissolved  in  EtOAc  (75 mL),  and  extracted  five  times  with  water  
(10 mL).  The  organic  layer  was  concentrated,  and  the  crude  product  was   
recrystallized  in  EtOAc:Hexane (1:1),  producing  a  white  solid (14.96 g, 76.0%).  
1
H  
NMR  (400 MHz, CDCl3):  =  1.38  (s,  9H),  3,21  (s,  3H),  3.22-3.25  (m,  2H),  3,32-
3.35  (m,  2H),  3.71  (s,  3H),  4.10  (s,  2H);  
13
C
  
NMR  (400 MHz, CDCl3):   28.55,  
38.89,  39.79,  47.81,  48.57,  52.63,  79.72,  156.27,  170.54;  HRMS :  m/z  calcd  for  
C43H60N6O9  [M + H
+
],  311.127;  found,  311.128. 
3.3.4.4. Methyl-N-(2-aminoethyl)-N-(methylsulfonyl)glycinate 
Methyl-N-(2-aminoethyl)-N-(methylsulfonyl)glycinate  (2.00 g, 6.44 mmol)  was  
dissolved  in  10 ml  of  DCM.  Trifluoroacetic \acid (3 mL)  was  added  and  allowed  to  stir  
overnight.  The  reaction  mixture  was  concentrated  and  resulting  in   a  yellow  oil  (2.02 
g, 96.5%). 
 
3.3.5. Synthesis  of  non-recognition strand (Contributed  by  Dr.  Philip  Murray) 
3.3.5.1. Linker(OMe)-Lys(Boc)-NH(Cbz) 
The  deprotected  linker  (2.02 g, 6.22 mmol)  was  dissolved  in  anhydrous  DCM (40 
mL)  under  argon.  Cbz-lysine(Boc)-OH  (2.37 g, 6.22 mmol),  50% propanephosphonic 
anhydride (7.92 mL, 12.4 mmol)  and  DIEA (2.57 mL, 16.0 mmol)  were  added  
subsequently.  The  reaction  mixture  was  allowed  to  stir  overnight.  The  resulting  
solution  was  quenched  with  water  (10 mL),  concentrated  and  dissolved  in  ethyl  acetate  
(50 mL).  The  filtrate  was extracted  three  times  with  water  (10 mL).  The  organic  layer  
was  concentrated,  and  the  crude  product  was  recrystallized  in  ether (10 mL),  producing  
a  white  solid (1.93 g, 54.6%).  m/z [M+H]
+
 573.1. 
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3.3.5.2. Linker(OMe)-Lys(Boc)-NH2 
Linker(OMe)-Lys(Boc)-NHCbz  (1.93 g, 3.38 mmol)  was  dissolved  in  methanol.  10 %  
Palladium  carbon  powder  was  added,  and  the  solution  was  placed  under  high  H2  
pressure  (55 psi)  overnight.  The  palladium  carbon  powder  was  filtered  over  
diatomaceous  earth,  and  the  resulting  solution  was  concentrated,  forming  a  white  solid. 
 
3.3.5.3. Linker(OMe)-Lys(Boc)-Leu-NH(Cbz) 
The  deprotected  dimer  (1.48 g, 3.38 mmol)  was  dissolved  in  anhydrous  DCM  under  
argon.  DIEA (1.40 mL, 8.44 mmol),  Z-Leu-OH (0.896 g, 3.38 mmol),  and  50%  
propanephosphonic  anhydride  (T3P,  4.30 mL, 6.75 mmol)  were  added   and  allowed  to  
stir  overnight.  The  reaction  mixture  was  quenched  with  water,  concentrated  and  
dissolved  in  EtOAc  (50 mL).  The  organic  layer   was  washed  three  times  with  water 
(10 mL),  the  organic  layer  was concentrated,  and  the  resulting  crude  product  was  
recrystallized  in  ether  (10 mL)  overnight,  producing  a  white  solid  (1.99 g, 86.3%).  m/z 
[M+H]
+
 686.34. 
 
3.3.5.4. Linker(OMe)-Lys(Boc)-Leu-NH2 
Linker(OMe)-Lys(Boc)-Leu-NH(Cbz)  (1.99 g, 2.91 mmol)  was  dissolved  in methanol.  
10 % Palladium  carbon  powder  was  added,  and  the  solution  was  placed  under  H2  
pressure (55 psi)  overnight.  The  palladium  carbon  powder  was  filtered  over  
diatomaceous  earth,  and  the  resulting  solution  was  concentrated,  forming  a  white  
solid. 
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3.3.5.5. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NH(Cbz) 
The  deprotected  product (1.60 g, 2.91 mmol)  was  dissolved  in  anhydrous  DCM (10 
mL)  under  argon.  Z-Lys(Boc)-OH (1.11 g, 2.91 mmol),  50% propanephosphonic 
anhydride  (T3P,  3.70 mL, 5.81 mmol),  and  DIEA (1.20 mL, 7.27 mmol)  were  added  at  
0°C  and  allowed  to  stir  overnight.  The reaction  mixture  was  quenched  with  water  (5 
mL)  for  1 hr,  then  concentrated  and  dissolved  in  EtOAc  (50 mL).  The  organic  
solution  was  extracted  three  times  with  water  (10 mL).  The  organic  layer  was  dried  
over  Na2SO4  and  concentrated.  The  crude  product  was  recrystallized  in  ether  (10 mL)  
overnight,  producing  a  white  solid  (2.19 g, 82.7%).  m/z [M+H]
+
 914.49. 
 
3.3.5.6. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NH2 
Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NH(Cbz) (2.19 g, 2.40 mmol)  was  dissolved  in 
methanol (100 mL).  Palladium (10%)  carbon  powder (0.4 g)  was  added,  and  the  solution  
was  placed  under  H2  pressure  (55 psi)  overnight.  The  palladium  carbon  powder  was  
filtered  over  diatomaceous  earth,  and  the  resulting  solution  was  concentrated,  forming  
a  white  solid. 
 
3.3.5.7. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NH(Cbz) 
The  deprotected  product (1.87 g, 2.40 mmol)  was  dissolved  in  anhydrous  DCM  (15 
mL)  under  argon.  Z-Leu- OH (0.638 g, 2.40 mmol),  propanephosphonic anhydride  (T3P, 
3.06 mL, 4.79 mmol),  and  DIEA (1.04 mL, 6.00 mmol)  were   added  at  0°C  and  allowed  
to  stir  overnight.  Water (5 mL)  was  added  to  quench  the  excess  of  T3P  for  1  hour.  
The  resulting  solution was   concentrated  and  dissolved  in  EtOAc (50 mL).  The  solution  
was  extracted  three  times  with  water  (10 mL).  The  organic  layer  was  dried  over  
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Na2SO4  and  concentrated..  The  crude  product  was  recrystallized  in  ether  (10 mL)  
overnight,  producing  a  white  solid  (1.83 g, 74.5%).  m/z [M+H]
+
 1027.57.  
 
3.3.5.8. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NH2 
Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NH(Cbz)  (1.83 g, 1.78 mmol)  was  dissolved  
in  methanol  (100 mL).  Palladium (10%)  carbon  powder (0.4 g)  was  added,  and  the  
solution  was  placed  under  H2  pressure  (55 psi)  overnight.   The  palladium  carbon  
powder  was  filtered  over  diatomaceous  earth,  and  the  resulting  solution  was  
concentrated,  forming  a  white  solid. 
 
3.3.5.9. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NH(Cbz) 
The  deprotected  product  (1.59 g, 1.78 mmol)  was  dissolved  in  anhydrous  DCM (15 
mL)  under  argon.  Z-Lys(Boc)-OH (0.678 g, 1.78 mmol),  propanephosphonic anhydride  
(T3P, 2.27 mL, 3.56 mmol),  and  DIEA (0.736 mL, 4.45 mmol)  were  added  at  0°C  and  
allowed  to  stir  overnight.  The  resulting  solution  was  quenched  with  water  (5 mL)  for  
1  hour,  then  concentrated  and  dissolved  in  EtOAc (50 mL).  The  solution  was  extracted  
three  times  with  water (10 mL).  The  organic  layer  was  dried  over  Na2SO4  and  
concentrated.  The  crude  product  was  then  recrystallized  in  ether  (10 mL)  overnight,  
producing  a  white  solid (2.00 g, 89.5%).  m/z [M+H]
+
 1255.72. 
 
3.3.5.10. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NH2 
Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NH(Cbz)  (2.00 g, 1.59 mmol)  was  
dissolved  in  methanol  (100 mL).  Palladium (10%)  carbon  powder (0.4 g)  was  added,  
and  the  solution  was  placed  under  H2  pressure  (55 psi)  overnight.   The  palladium  
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carbon  powder  was  filtered  over  diatomaceous  earth,  and  the  resulting  solution  was  
concentrated,  forming  a  white  solid. 
 
3.3.6. Cyclization  of  recognition  strand  and  non-recognition  strand 
(Contributed  by  Dr.  Priyesh  Jain) 
3.3.6.1. Synthesis  of  linear  peptide  
Hexameric  recognition  strand  (0.14 mg, 0.125 mmol)  and  non-recognition  strand  (0.11 
g, 0.125 mmol)  were  dissolved  in  anhydrous  THF (10 ml).  Solution of  50%  
propanephosphonic  anhydride  (T3P, 0.16 mL, 0.25 mmol)  was  added  to  the  previous  
solution  at  0°C.  The  reaction  was  allowed  to  stir  overnight  at  room  temperature.  
Excess  T3P  was  quenched  with  water (2 mL),  concentrated,  and  dissolved  in  EtOAC.  
The  solution  was  extracted  three  times  with  water.  The  organic  layer  was  dried  over  
Na2SO4  and  concentrated.  The  crude  product  was  recrystallized  in  ether (10 mL)  
overnight, producing  a  white  solid (fully  protected  linear  peptide, 0.17 g, 68%).  The 
coupled  peptide  was  validated  by  MALDI-TOF  after  deprotecting  all  Boc groups.  m/z 
[M+H]
+
 1664.71 
3.3.6.2. Deprotection of  linear  peptide 
Protected  linear  peptide (0.17 g, 0.086 mmol)  was  dissolved  in  methanol (30 mL).  
Palladium (10%)  carbon  powder  (0.4 g)  was  added  and  the  solution  was  placed  under  
H2  pressure  (55 psi)  overnight.  The  palladium  carbon  powder  was  filtered  over  
diatomaceous  earth.  The  resulting  solution  was  concentrated  and  white solid  was  
formed (0.14 g, 88%).  Cbz-deprotected  linear  peptide (0.14 g, 0.076 mmol)  was  dissolved  
in  THF:H2O (1:1, 5 mL).  5%  LiOH  solution (2 mL)  was  added  to  the  previous  solution  
at 0
o
C.  The  reaction   was  carried  out  for  30  minutes  until  the  TLC  showed  complete  
consumption  of  the  starting  material.  The  reaction  contents  were  concentrated  and  
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freeze  dried  to  give  peptide  as  a  white  solid.    Deprotected  linear  peptide was validated 
by MALDI-TOF after deprotecting all Boc groups.  m/z [M+H]
+
 1516.47. 
 
3.3.6.3. Cyclization  of  linear  peptide 
Deprotected  linear  peptide  (0.11 g,  0.076 mmol)  was  dissolved  in  anhydrous  THF (10 
mL).  Solution  of  50%  propanephosphonic  anhydride  (0.10 mL, 0.15 mmol)   was  added  
at 0°C.  The  reaction  was  allowed  to  stir  overnight  at  room  temperature.  Excess  T3P  
was  quenched  with  water (2 mL),  concentrated,  and  dissolved  in  EtOAC.   The  solution  
was  then  extracted  three  times  with  water.  The  organic  layer  was  dried  over  Na2SO4  
and  concentrated.  The crude  product  was   recrystallized  in  ether (10 mL)  overnight,  a  
white  solid  was  formed.  The  cyclized  peptide  was  validated  by  MALDI-TOF  after 
deprotecting  all  Boc  groups.  m/z [M+H]
+
 1499.43. 
 
3.3.7. Linear  synthesis  of  MTI-101 
3.3.7.1. Linker(OMe)-Lys(Boc)-NH(Cbz) 
Cbz-N-Lys(Boc)-OH (0.77 g,  2.03 mmol)  was  dissolved  in  anhydrous  DCM (10 ml)  
and  cool  down  at  0 .  N-methylmorpholine (0.22 ml,  2.03 mmol)  and  
isobutylchloroformate (0.27 ml,  2.03 mmol)  were  added  to  the  cooled  solution.  Reaction  
mixture  was  allowed  to  stir  for  15  minutes.  Deprotected  linker  (0.43 g,  2.03 mmol)  
and  triethylamine  (0.57 ml,  4.06 mmol)  were  mixed  to  the  previous  solution.  The  
reaction  mixture  was  brought  to  room  temperature  and  stirred  overnight.  The  product  
was  extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  washed  with  
brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  after  
recrystallization  in  ether  (1.09 g,  98 %).  
1
H  NMR  (400 MHz, CDCl3):  =  1.31-1.32  (d, 
2H),  1.37  (s, 9H),  1.61-1.62  (m, 1H),  1.79-1.82  (m, 1H),  2.96  (s, 3H),  3.03-3.05  (m, 
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2H),  3.33-3.37  (m, 4H),  3.70  (s, 2H),  4.10  (s, 3H),  4.81-4.83  (m, 1H),  5.05  (s, 2H),  
7.26-7.30  (m, 5H);  
13
C  NMR  (100 MHz, CDCl3):  =  12.21,  17.56,  18.79,  22.74,  
28.63,  29.72,  32.12,  37.49,  39.61,  40.12,  42.18,  47.32,  48.37,  52.69,  53.86,  55.21,  
67.19,  77.04,  77.36,  77.68,  79.23,  128.33,  128.55,  128.70,  136.49,  156.43,  156.52,  
170.51,  172.72; HRMS :  m/z  calcd  for  C25H40N4O9S  [M + H
+
],  573.258;  found,  573.260. 
 
3.3.7.2. Linker(OMe)-Lys(Boc)-NH2 
Protected  dimeric  peptide  (1.09 g,  1.90 mmol)  was  dissolved  in  100 ml  of  methanol  
and  palladium  carbon  powder  (10 %)  was  mixed.  Triethylsilane  (1.52 ml,  9.51 mmol)  
was  added  slowly  under  the  hydrogen  gas.  The  completion  of  reaction  was  monitored  
by  TLC.  Palladium  carbon  powder  was  removed  over  diatomaceous  earth  and  the  
resulting  solution  was  concentrated  under  reduced  pressure.   
 
3.3.7.3. Linker(OMe)-Lys(Boc)-Leu-NH(Cbz) 
Cbz-N-Leu-OH (0.50 g,  1.90 mmol)  was  dissolved  in  anhydrous  DCM (10 ml)  and  
cool  down  at  0 .  N-methylmorpholine (0.21 ml,  1.90 mmol)  and  isobutylchloroformate 
(0.25 ml,  1.90 mmol)  were  added  to  the  cooled  solution.  Reaction  mixture  was  
allowed  to  stir  for  15  minutes.  Deprotected  dimeric  peptide  (0.83 g,  1.90 mmol)  and  
triethylamine  (0.53 ml,  3.80 mmol)  were  mixed  to  the  previous  solution.  The  reaction  
mixture  was  brought  to  room  temperature  and  stirred  overnight.  The  product  was  
extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  washed  with  
brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  after  
recrystallization  in  ether  (1.24 g,  95 %).  
1
H  NMR  (400 MHz, CDCl3):  =  0.82-0.84  (t, 
6H, J = 0.02),  1.18-1.21  (m, 2H),  1.34  (s, 9H),  1.40-1.42  (m, 2H),  1.46-1.49  (m, 1H),  
1.56-1.59  (m, 2H),  2.84-2.85  (m, 2H),  2.97  (s, 3H),  3.22-3.24  (m, 4H),  3.39-3.41  (m, 
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8H),  3.64  (s, 3H),  4.08  (s, 2H),  4.01-4.13  (m, 2H),  5.01  (s, 2H),  7.29-7.34  (m, 5H);  
13
C  
NMR  (100 MHz, CDCl3):  =  22.04,  23.33,  23.75,  24.85,  28.94,  29.87,  32.40,  38.04,  
39.50,  39.66,  39.71,  39.92,  40.12,  40.33,  40.44,  40.54,  40.75,  41.21,  47.50,  48.98,  
52.66,  53.17,  53.83,  66.06,  78.01,  127.67,  128.32,  128.45,  129/01,  137.68,  156.20,  
156.64,  170.76,  172.45,  172.87; HRMS :  m/z  calcd  for  C31H51N5O10S  [M + H
+
],  
686.342;  found,  686.345. 
 
3.3.7.4. Linker(OMe)-Lys(Boc)-Leu-NH2 
Protected  trimeric  peptide  (1.24 g,  1.81 mmol)  was  dissolved  in  100 ml  of  methanol  
and  palladium  carbon  powder  (10 %)  was  mixed.  Triethylsilane  (1.44 ml,  9.03 mmol)  
was  added  slowly  under  the  hydrogen  gas.  The  completion  of  reaction  was  monitored  
by  TLC.  Palladium  carbon  powder  was  removed  over  diatomaceous  earth  and  the  
resulting  solution  was  concentrated  under  reduced  pressure.   
 
3.3.7.5. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NH(Cbz) 
Cbz-N-Lys(Boc)-OH (0.69 g,  1.81 mmol)  was  dissolved  in  anhydrous  DCM (10 ml)  
and  cool  down  at  0 .  N-methylmorpholine (0.20 ml,  1.81 mmol)  and  
isobutylchloroformate (0.24 ml,  1.81 mmol)  were  added  to  the  cooled  solution.  Reaction  
mixture  was  allowed  to  stir  for  15  minutes.  Deprotected  trimeric  peptide  (1.00 g,  1.81 
mmol)  and  triethylamine  (0.50 ml,  3.62 mmol)  were  mixed  to  the  previous  solution.  
The  reaction  mixture  was  brought  to  room  temperature  and  stirred  overnight.  The  
product  was  extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  
washed  with  brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  
after  recrystallization  in  ether  (1.47 g,  89 %).  
1
H  NMR  (400 MHz, CDCl3):  =  0.88-
0.93  (dd, 6H),  1.32-1.45  (m, 4H),  1.40  (s, 9H),  1.55-1.61  (m, 5H),  1.79-1.85  (m, 3H),  
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2.98  (s, 3H),  3.05-3.10  (m, 4H),  3.38-3.48  (m, 4H),  3.72  (s, 3H),  4.14  (s, 2H),  4.28-
4.36  (m, 1H),  4.80-4.83  (m, 1H),  5.07  (s, 2H),  7.30-7.35  (m, 5H);  
13
C  NMR  (100 MHz, 
CDCl3):  =  21.95,  23.11,  23.26,  23.55,  24.51,  28.69,  29.66,  31.94,  32.08,  37.79,  
39.24,  39.44,  39.65,  39.86,  40.07,  40.18,  40.28,  40.49,  40.91,  47.24,  48.71,  51.40,  
52.42,  53.02,  55.17,  65.81,  77.80,  127.33,  128.10,  128.20,  128.76,  137.40,  155.99,  
166.43,  170.52,  172.14,  172.25,  172.43; HRMS :  m/z  calcd  for  C42H71N7O13S  [M + H
+
],  
914.490;  found,  914.494. 
 
3.3.7.6. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-NH2 
Protected  tetrameric  peptide  (1.47 g,  1.61 mmol)  was  dissolved  in  100 ml  of  
methanol  and  palladium  carbon  powder  (10 %)  was  mixed.  Triethylsilane  (1.28 ml,  
8.04 mmol)  was  added  slowly  under  the  hydrogen  gas.  The  completion  of  reaction  
was  monitored  by  TLC.  Palladium  carbon  powder  was  removed  over  diatomaceous  
earth  and  the  resulting  solution  was  concentrated  under  reduced  pressure. 
 
3.3.7.7. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NH(Cbz) 
Cbz-N-Leu-OH (0.43 g,  1.61 mmol)  was  dissolved  in  anhydrous  DCM (10 ml)  and  
cool  down  at  0 .  N-methylmorpholine (0.18 ml,  1.61 mmol)  and  isobutylchloroformate 
(0.21 ml,  1.61 mmol)  were  added  to  the  cooled  solution.  Reaction  mixture  was  
allowed  to  stir  for  15  minutes.  Deprotected  tetrameric  peptide  (1.26 g,  1.61 mmol)  and  
triethylamine  (0.45 ml,  3.22 mmol)  were  mixed  to  the  previous  solution.  The  reaction  
mixture  was  brought  to  room  temperature  and  stirred  overnight.  The  product  was  
extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  washed  with  
brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  after  
recrystallization  in  ether  (1.42 g,  86 %).  
1
H  NMR  (400 MHz, CDCl3):  =  0.87-0.95  
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(m, 6H),  1.25-1.47  (m, 10H),  1.39  (s, 9H),  1.57-1.60  (m, 8H),  1.82-1.95  (m, 2H),  2.97  
(s, 3H),  2.99-3.08  (m, 4H),  3.38-3.40  (m, 4H),  3.71  (s, 3H),  4.16  (s, 2H),  4.20-4.34  (m, 
2H),  4.75-4.89  (m, 2H),  5.09  (s, 2H),  7.29-7.40  (m, 5H);  
13
C  NMR  (100 MHz, CDCl3):  
=  14.51,  21.88,  23.46,  23.56,  28.69,  39.45,  39.66,  39.87,  40.08,  40.29,  47.23,  48.70,  
52.41,  52.84,  53.58,  60.20,  65.79,  77.77,  127.40,  128.05,  128.19,  128.76,  137.44,  
155.96,  156.37,  170.51,  170.78,  171.92,  172.11,  172.13,  172.80; HRMS :  m/z  calcd  for  
C48H82N8O14S  [M + H
+
],  1027.574;  found,  1027.576. 
 
3.3.7.8. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-NH2 
Protected  pentameric  peptide  (1.42 g,  1.38 mmol)  was  dissolved  in  100 ml  of  
methanol  and  palladium  carbon  powder  (10 %)  was  mixed.  Triethylsilane  (1.11 ml,  
6.92 mmol)  was  added  slowly  under  the  hydrogen  gas.  The  completion  of  reaction  
was  monitored  by  TLC.  Palladium  carbon  powder  was  removed  over  diatomaceous  
earth  and  the  resulting  solution  was  concentrated  under  reduced  pressure. 
 
3.3.7.9. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NH(Cbz) 
Cbz-N-Lys(Boc)-OH (0.52 g,  1.38 mmol)  was  dissolved  in  anhydrous  DCM (10 ml)  
and  cool  down  at  0 .  N-methylmorpholine (0.15 ml,  1.38 mmol)  and  
isobutylchloroformate (0.18 ml,  1.38 mmol)  were  added  to  the  cooled  solution.  Reaction  
mixture  was  allowed  to  stir  for  15  minutes.  Deprotected  pentameric  peptide  (1.23 g,  
1.38 mmol)  and  triethylamine  (0.38 ml,  2.76 mmol)  were  mixed  to  the  previous  
solution.  The  reaction  mixture  was  brought  to  room  temperature  and  stirred  overnight.  
The  product  was  extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  
washed  with  brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  
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after  recrystallization  in  ether  (1.58 g,  91 %).  MALDI-TOF :  m/z  [M + H
+
]  955.387.  
(MALDI-TOF  was  validated  after  deprotecting  all  Boc  groups) 
 
3.3.7.10. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)-NH2 
Protected  hexameric  peptide  (1.58 g,  1.26 mmol)  was  dissolved  in  100 ml  of  
methanol  and  palladium  carbon  powder  (10 %)  was  mixed.  The  reaction  mixture  was  
located  overnight  under  the  high  pressure  of  hydrogen  gas.  Palladium  carbon  powder  
was  removed  over  diatomaceous  earth  and  the  resulting  solution  was  concentrated  
under  reduced  pressure. 
 
3.3.7.11. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)--turn promoter-NH(Cbz) 
Deprotected  -turn  promoter (0.51 g,  1.26 mmol)  was  dissolved  in  anhydrous  DCM 
(10 ml)  and  cool  down  at  0 .  N-methylmorpholine (0.14 ml,  1.26 mmol)  and  
isobutylchloroformate (0.16 ml,  1.26 mmol)  were  added  to  the  cooled  solution.  Reaction  
mixture  was  allowed  to  stir  for  15  minutes.  Deprotected  hexameric  peptide  (1.41 g,  
1.26 mmol)  and  triethylamine  (0.35 ml,  2.52 mmol)  were  mixed  to  the  previous  
solution.  The  reaction  mixture  was  brought  to  room  temperature  and  stirred  overnight.  
The  product  was  extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  
washed  with  brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  
after  recrystallization  in  ether  (1.28 g,  73 %).  MALDI-TOF :  m/z  [M + H
+
]  1096.709.  
(MALDI-TOF  was  validated  after  deprotecting  all  Boc  groups) 
 
3.3.7.12. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)--turn promoter-NH2 
Protected  heptameric  peptide  (1.28 g,  0.92 mmol)  was  dissolved  in  100 ml  of  
methanol  and  palladium  carbon  powder  (10 %)  was  mixed.  The  reaction  mixture  was  
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located  overnight  under  the  high  pressure  of  hydrogen  gas.  Palladium  carbon  powder  
was  removed  over  diatomaceous  earth  and  the  resulting  solution  was  concentrated  
under  reduced  pressure. 
 
3.3.7.13. Linker(OMe)-Lys(Boc)-Leu-Lys(Boc)-Leu-Lys(Boc)--turn promoter-NH(Cbz) 
Cbz-N-Trp-OH (0.31 g,  0.92 mmol)  was  dissolved  in  anhydrous  DCM (10 ml)  and  
cool  down  at  0 .  N-methylmorpholine (0.10 ml,  0.92 mmol)  and  isobutylchloroformate 
(0.12 ml,  0.92 mmol)  were  added  to  the  cooled  solution.  Reaction  mixture  was  
allowed  to  stir  for  15  minutes.  Deprotected  heptameric  peptide  (1.16 g,  0.92 mmol)  
and  triethylamine  (0.26 ml,  1.84 mmol)  were  mixed  to  the  previous  solution.  The  
reaction  mixture  was  brought  to  room  temperature  and  stirred  overnight.  The  product  
was  extracted  with  DCM  (3  10 ml).  The  combined  organic  layers  were  washed  with  
brine,  dried  over  Na2SO4,  and  concentrated.  The  white  solid  was  obtained  after  
recrystallization  in  ether  (0.2 g,  23 %).  MALDI-TOF :  m/z  [M + H
+
]  1282.758.  
(MALDI-TOF  was  validated  after  deprotecting  all  Boc  groups) 
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CHAPTER  FOUR: 
CONSTRUCTION  OF  PEPTOID-PEPTIDE  HYBRIDS  
ADOPTING  -HAIRPIN  STRUCTURE 
 
4. 1. Introduction 
Peptides  play  an  important  role  in  biological  functions  and  therefore  promising  
candidates  in  therapeutic  development.  However,  their  natural  instability  to  proteases  
has  led  to  numerous  research  in  peptidomimetics  recently  (1).  Peptidomimetics  not  
only  have  similar  functions  and  interactions  to  the  intended  target  as  those  of  natural  
peptides  but  also  resist  to  the  proteolysis.  In  other  words,  peptidomimetics  would  have  
improved  stability  and  bioavailability. 
In  late  1990s,  the Gellman group introduced  the  field  of  foldamers  (2).  Foldamers  
are  defined  as  unnatural  oligomers  which  can  fold  in  a  certain  fashion  and  copy  the  
behaviors  known  from  biopolymers  (3  -  7).  One  example  of  a  type  of  foldamer  is  
hybrid  peptoid-peptide  ligands.  Goodman  and  colleagues  reported  the  first  cases  of  
peptoid-peptide  hybrids  in  1994  (8).  They  synthesized  and  characterized  collagen  
mimicry  with  peptide  repetition  H2N-Gly-[Gly-Pro-Hyp]n-,  which  were  covalently  
attached  to  the  Kemp  tricarboxylic  acid  (9  -  11).  In  addition  to  this,  similar  
assemblies  containing  the  N-isobutylglycine  (NIeu)  peptoid  residue  instead  of  
hydroxyproline  (Hyp)  were  investigated  in  a  series  of  the  study  (12  -  16). 
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Hamy  and  co-workers  showed  hybrid  peptoid-peptide  ligands  with  the  ability  to  
disrupt  the  interactions  between  HIV-1  transactivation  protein  (Tat)  and  the  
transactivation  response  (TAR)  RNA  domain,  which  following  HIV-1  replication  in  
primary  human  lymphocytes  (17  -  19).  After  screening  in  a  pool  of  3.2    10
6
  
ligands,  a  inhibitor  of  the  Tat-TAR  RNA  complex  with  nanomolar  activity  was  found  
(Figure  1a).  The  inhibitor  was  further  studied  and  proved  to  bind  TAR  RNA  
specifically  by  using  NMR  analysis  and  molecular  modeling  (16).  In  addition,  the  
group  of  Rocchi  reported  the  receptor  targeting  case  by  using  peptoid  substituted  
compounds  based  on  dermorphin,  deltorphin,  and  endomprohin  as  opioid  receptor  
agonists  (Figure  1b)  (20  -  22).   
Most  types  of  peptidomimetics,  including  peptoid-peptide  hybrids,  are  investigated  as  
membrane  active  cationic  anti-microbial  peptide  (AMP)  derivatives.  There  are  two  
major  strategies:  (1)  replacing  certain  residues  in  a  known  natural  product  or  peptide  
and  (2)  constructing  the  de  novo  design  of  an  amphiphilic  template.  Both  of  these  
strategies  have  been  applied  to  develop  AMP  analogues  with  peptoid-peptide  hybrids. 
Robinson  and  co-workers  displayed  a  small  series  of  peptoid-containing  analogues  of  
the  antimicrobial  -hairpin  structure  protegrin  I  by  using  the  first  strategy  (Figure  1c)  
(23).  In  a  preliminary  study,  the  disulfide  bridges  connecting  native  hairpin  were 
replaced  by  D-Pro-L-Pro  moiety  through  macrocyclization.  Two  substituted  compounds  
were  designed,  synthesized,  and  evaluated  (23).  After  deuterium  exchange  and  2D  
ROESY  NMR  spectroscopy  experiment  along  with  the  constrained  molecular  modeling,  
a  lead  compound  (Figure  1c)  maintains  a  relatively  stable  -hairpin  conformation  in  
aqueous  solution.  Also,  this  lead  compound  has  slightly  better  potency  than  that  of  its  
nonpeptoid-containing  -peptides  against  the  tested  microorganisms,  and  more  
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improtaltly,  it  showed  much  more  resistance  to  hemolysis  the  natural  product  lead 
protegrin  I  (23). 
 
 
Figure 38. Peptoid-peptide hybrids with bioactivity. 
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Ryge,  Hansen,  and  colleagues  reported  de  novo  designed  amphiphilic  peptoid-
peptide  hybrids  as  AMP  mimetics  and  optimized  their  design  via  combinatorial  
libraries  (24  -  26).  Their  most  powerful  molecule  showed  low  micromolar  range  for  
the  IC50  against  a  broad  spectrum  of  both  Gram-positive  and  Gram-negative  bacteria  
(Figure  1d).  In  order  to  investigate  the  transmembrane  segment  mimetics,  peptoid-
peptide  hybrids  interacting  membrane  have  also  been  studied  (27,  28). 
Since  Goodman  and  co-workers  introduced  the  first  examples  of  peptoid-peptide  
hybrid,  the  -amino  acid  combined  peptoid  residues  have  been  engaged  in  numerous  
biologically  active  ligands.  As  discussed  earlier,  ligands  for  inhibition  protein-protein  
interactions  and  antimicrobial  activities  are  the  examples  as  related  research  fields.  
The  research  of  peptoid-peptide  hybrid  structures  has  been  thrived  in  development  of  
peptidomimetics  and  will  provide  more  ligands  with  interesting  bioactivities  in  the  
future. 
 
4. 2. Results  and  discussion 
N-substituted  glycine  oligomers,  or  peptoids,  are  an  important  class  of  foldamers  
built  by  tertiary  amide  linkages  (29).  The  extensive  chemical  diversity  of  the  peptoid  
side  chains  promotes  the  design  strategies  which  can  be  applied  to  the  various  fields  
such  as  enenatioselective  catalysis,  molecular  recognition,  and  intracellular  delivery  (30  
-  32).  Moreover,  numerous  studies  have  been  dedicated  to  development of  folded  
peptoids  with  the  distinct  secondary  structures  by  changing  side  chains  which  control  
the  backbone  conformational  ordering.  Recently,  two  well-ordered  peptoid  secondary  
structures  were  built  using  triazole  linkages  (33,  34).  Even  though  this  discovery  
opens  up  the  possibility  of  the  peptoid  design  with  similar  structure  as  small  folded  
proteins,  we  seek  the  capability  to  craft  functional  peptoid-peptide  hybrids  adopting  
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the  -hairpin  structure.  -hairpin  structure  is  one  of  the  extended  peptide  secondary  
structures,  that  two  functional  strands  are  connected  through  a  linkage.  Depending  on  
side  chains,  -hairpin  can  improve  the  target  recognition  ability  as  well  as  the  
pharmacokinetic  properties. 
Peptoid  oligomers  can  be  prepared  efficiently  via  submonomer  solid-phase  synthesis  
strategy.  The  strategy  is  to  elongate  the  main  chain  by  an  acylation  reaction  with  a  
haloacetic  acid  and  then  attach  the  side  chain  with  a  primary  amine.  Because  of  its  
high  efficiency,  the  similar  approach  was  applied  in  this  experiment. The  whole  
peptoids  were  constructed  on  2-chlorotrityl  chloride  resins.  Before  the  synthesis  was  
initiated,  the  resins  were  reactivated  by  using  thionyl  chloride  in  DCM.  For  the  
acylation  step,  bromoacetic  anhydride  was  used  instead  of  haloacetic  acid  due  to  its  
high  reactivity.  Also,  2,4-dimethoxybenzyl  amine  was  selected  rather  than  ammonia  to  
introduce  the  secondary  amide,  hydrogen  bonded  to  the  carbonyl  group  on  the  
opposite  strand,,  because  ammonia  can  cleave  the  peptoids  on  the  resins.  Also,  2,4-
dimethoxytoluene  was  able  to  be  removed  with  TFA  at  the  last  stage  of  synthesis.  
One  of  critical  elements  in  -hairpin  structure  is  turn  promoter.  For  this  experiment,  
D-Pro-L-Pro  template,  type  II´  turn,  was  chosen  as  a  -turn  promoter. 
In  order  to  observe  the  structure  changes  or  differences  between  acyclic  and  cyclic  
peptoid-peptide  hybrids,  the  resins  were  divided  in  half  before  the  cleavage  from  the  
resins.  The  divided  resins  were  deprotected  separately  and  processed  in  different  ways.  
For  the  construction  of  acyclic  peptoid-peptide  hybrids,  the  resulting  compounds  after  
deprotection  were  purified  by  HPLC.  To  build  the  cyclic  peptoid-peptide  hybrids,  the  
resulting  compounds  after  deprotection  were  cyclized  in  the  presence  of  HCTU  in  
DCM  and  then  purified  by  HPLC.  Based  on  this  strategy,  three  sets  of  acyclic  and  
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cyclic  peptoid-peptide  hybrids  were  prepared  (Figure  2).  Three  sets  of  peptoid-peptide  
hybrids  were  different  in  sizes  and  the  number  of  turn  promoters. 
NMR  study  was  employed  to  check  the  formation  of  -hairpin  structures  based  on  
the  hypothesis:  if  the  -hairpin  structure  is  formed,  glycine  -protons  of  an  acyclic  
peptoid-peptide  hybrid  in  the  4  ppm  ranges  will  shift  to  5  ppm  ranges  after  
cyclization.  Deturated  acetonitrile  or  chloroform  were  used  as  NMR  solvents.  After  
NMR  studies,  there  was  no  indication  of  the  -hairpin  structure  formation  from  three  
sets  of  peptoid-peptide  hybrids  because  there  was  no  chemical  shift  changes  from  -
protons  in  acyclic  and  cyclic  peptoid-peptide  hybrids. 
 
Figure 39. Structures of three sets of acyclic and cyclic peptoid-peptide hybrids. 
 
  In  this  study,  the  possibility  of  -hairpin  structure  in  peptoid-peptide  hybrids  was  
investigated.  NMR  studies  were  performed  based  on  the  hypothesis:  glycine  -protons  
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of  an  acyclic  peptoid-peptide  hybrid  in  the  4  ppm  ranges  will  shift  to  5  ppm  ranges  
after  cyclization  due  to  the  -hairpin  structure  formation.  However,  the  NMR  study  
results  displayed  that  there  was  no  indication  of  the  -hairpin  structure  formation  in  
peptoid-peptide  hybrids.  These  results  suggested  that  the  peptoid-peptide  hybrid  
structures  were  still  flexible  despite  of  the  introduction  of  intra  hydrogen  bonding  and  
-turn  promoters.  According  to  this  finding,  it  is  necessary  to  develop  the  components  
which  provide  the  more  rigid  structure  in  peptoid-peptide  hybrids  such  as  
incorporations  of  ring  moieties  in  the  main  chain  or  development  of  staple  peptoid-
peptide  hybrids. 
 
4. 3. Experimental section 
4.3.1. General  comments 
All  reaction  intermediates  were  monitered  by  mass  spectral  analysis  (Agilent).  The  
complete  peptoid-peptide  hybrids  were  purified  by  using  HPLC  (DIONEX)  and  
purified  compounds  were  studied  via  
1
H  NMR  (INOVA-400). 
 
4. 3. 2.  General  procedure 
All  the  cyclic  peptoid-peptide  hybrids  were  prepared  using  solid-phase  peptide  
synthesis  (Figure  2).  On  the  2-chlorotrityl  chloride  resin,  Fmoc-D-Proline  was  attached  
via  SN2  reaction  and  typical  submonomer  strategy  was  performed  to  add  different  
peptoid  residues.  The  treatment  with  TFA  provided  not  only  cleavage  of  linear  
peptoid-peptide  hybrids  on  the  resin  but  also  deprotection  of  2,4-dimethoxytoluene,  
transferring  tertiary  amine  into  secondary  amine.  The  resulting  peptoid-peptide  hybrids  
were  cyclized  in  solution  and  purified  by  HPLC  for  further  study. 
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Scheme 13. General  procedure  for  peptoid-peptide  hybrids  in  SPPS. 
 
4. 3. 2.  Synthesis  of  acyclic  and  cyclic  peptoid-peptide  hybrids  1 
  2-Chlorotrityl  chloride  resins  (0.3  g;  capacity:  0.79  mmol/g)  were  swelled  with  3  
ml  of  anhydrous  DCM  at  room  temperature  for  20  minutes.  Fmoc-D-proline  (0.1  g,  
0.95  mmol)  and  DIEA  (0.28  ml,  1.58  mmol)  in  2  ml  of  DCM  were  added  to  the  
synthesis  reaction  vessel.  After  30  minutes,  the  solution  was  drained  and  the  same 
washing step  was  repeated.  The  beads  were  washed  with  anhydrous  DCM.  Then the  
beads  were  deprotected  using  2  ml  of  2  %  DBU  in  DMF  for  5  minutes  at  room  
temperature.  This  step  was  repeated,  and  the  beads  were  washed  with  DCM.  The  
acylation  step  was  carried  out  at  room  temperature  for  20  minutes.  All  the  beads  
were  incubated  in  a  mixture  of  bromoacetic  anhydride  (0.41  g,  1. 58  mmol),  DIEA  
(0.56  ml,  3.16  mmol),  and  2  ml  of  DCM. After, that step the  beads  were  washed  with  
DCM.  Depending  on  the  side  chain  sequences,  different  primary  amines  (3. 16  mmol)  
in  2  ml  of  DCM  were  added  to  the  beads  and  the  reaction  mixture  was  stirred  at  
room  temperature  for  20  minutes  before  the  beads  were  washed  with  DMF.  These  
acylation  and  SN2  by  primary  amines  (e.g.  2,4-dimethoxybenzyl  amine,  isopropyl  
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amine,  benzyl  amine  and  et  al)  were  repeated  until  the  intended  sequences  are  done.  
In  order  to  complete  -turn  template  (D-Pro-L-Pro),  Fmoc-L-Proline  (1.07  g,  3.16  
mmol),  HCTU  (1.31  g,  3.16  mmol),  and  DIEA  (1.12  ml,  6.32  mmol)  in  3  ml  of  
DCM  were  mixed  for  1  hour,  and  this  step  was  repeated.  The  beads  were  washed  
with  DCM.  Before  the  linear  peptoids  were  cleaved  from  the  resin,  Fmoc  group  was  
deprotected  using  2  %  DBU  in  DMF  and  the  beads  were  washed  with  DCM.  Based  
on  the  mass,  the  resins  were  divided  by  in  half  for  the  preparation  of  acyclic  and  
cyclic  peptoids.  Both  of  peptoids  on  the  resins  were  cleaved  with  TFA  and  the  
resulting  solution  was  collected  in  the  flask.  For  the  complete  deprotection  (2,4-
dimethoxytoluene),  the  resulting  solution  was  stirred  for  2  days.  After  removing  TFA  
under  the  reduced  pressure,  one  of  batches  were  purified  using  HPLC  to  collect  the  
acyclic  peptoid  (Figure  2).  The  peptoids  in  the  other  batch  were  cyclized  in  the  
mixture  of  HCTU  (0.65  g,  1.58  mmol),  DIEA  (0.56  ml,  3.16  mmol)  in  5  ml  of  
DCM.  After  proper  work-up,  the  cyclic  peptoids  were  obtained  after  HPLC  
purification  (Figure  2).  HRMS:  m/z [M+H]
+
   (acyclic  version).  HRMS: m/z [M+H]
+
   
(cyclic  version). 
 
Figure 40. Structures of acyclic and cyclic peptoid-peptide hybrids 1. 
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4. 3. 3.  Synthesis  of  acyclic  and  cyclic  peptoid-peptide  hybrids  2 
2-Chlorotrityl  chloride  resins  (0.3  g;  capacity:  0.79  mmol/g)  were  swelled  with  3  
ml  of  anhydrous  DCM  at  room  temperature  for  20  minutes.  Fmoc-D-proline  (0.1  g,  
0.95  mmol)  and  DIEA  (0.28  ml,  1.58  mmol)  in  2  ml  of  DCM  were  added  to  the  
synthesis  reaction  vessel.  After  30  minutes,  the  solution  was  drained  and  the  same  
step  was  repeated.  The  beads  were  washed  with  anhydrous  DCM.  The  beads  were  
deprotected  using  2  ml  of  2  %  DBU  in  DMF  for  5  minutes  at  room  temperature.  
This  step  was  repeated,  and  the  beads  were  washed  with  DCM.  The  acylation  step  
was  carried  out  at  room  temperature  for  20  minutes.  All  the  beads  were  incubated  in  
a  mixture  of  bromoacetic  anhydride  (0.41  g,  1. 58  mmol),  DIEA  (0.56  ml,  3.16  
mmol),  and  2  ml  of  DCM.  The  beads  were  washed  with  DCM.  Depending  on  the  
side  chain  sequences,  different  primary  amines  (3. 16  mmol)  in  2  ml  of  DCM  were  
added  to  the  beads  and  the  reaction  mixture  was  stirred  at  room  temperature  for  20  
minutes  before  the  beads  were  washed  with  DCM.  These  acylation  and  SN2  by  
primary  amines  (e.g.  2,4-dimethoxybenzyl  amine,  isopropyl  amine,  benzyl  amine  and  
et  al)  were  repeated  until  the  intended  sequences  are  done.  In  order  to  complete  -
turn  template  (D-Pro-L-Pro),  Fmoc-L-Proline  (1.07  g,  3.16  mmol),  HCTU  (1.31  g,  
3.16  mmol),  and  DIEA  (1.12  ml,  6.32  mmol)  in  3  ml  of  DCM  were  mixed  for  1  
hour,  and  this  step  was  repeated.  The  beads  were  washed  with  DCM.  Before  the  
linear  peptoids  were  cleaved  from  the  resin,  Fmoc  group  was  deprotected  using  2  %  
DBU  in  DMF  and  the  beads  were  washed  with  DCM.  Based  on  the  mass,  the  resins  
were  divided  by  in  half  for  the  preparation  of  acyclic  and  cyclic  peptoids.  Both  of  
peptoids  on  the  resins  were  cleaved  with  TFA  and  the  resulting  solution  was  
collected  in  the  flask.  For  the  complete  deprotection  (2,4-dimethoxytoluene),  the  
resulting  solution  was  stirred  for  2  days.  After  removing  TFA  under  the  reduced  
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pressure,  one  of  batches  were  purified  using  HPLC  to  collect  the  acyclic  peptoid  
(Figure  3).  The  peptoids  in  the  other  batch  were  cyclized  in  the  mixture  of  HCTU  
(0.65  g,  1.58  mmol),  DIEA  (0.56  ml,  3.16  mmol)  in  5  ml  of  DCM.  After  proper  
work-up,  the  cyclic  peptoids  were  obtained  after  HPLC  purification  (Figure  3).  
MALDI-TOF:  m/z [M+H]
+
   (acyclic  version).  MALDI-TOF:  m/z [M+H]
+
  929.57  (cyclic  
version). 
 
Figure 41. Structures of acyclic and cyclic peptoid-peptide hybrids 2. 
 
4. 3. 3.  Synthesis  of  acyclic  and  cyclic  peptoid-peptide  hybrids  3 
2-Chlorotrityl  chloride  resins  (0.3  g;  capacity:  0.79  mmol/g)  were  swelled  with  3  
ml  of  anhydrous  DCM  at  room  temperature  for  20  minutes.  Fmoc-D-proline  (0.1  g,  
0.95  mmol)  and  DIEA  (0.28  ml,  1.58  mmol)  in  2  ml  of  DCM  were  added  to  the  
synthesis  reaction  vessel.  After  30  minutes,  the  solution  was  drained  and  the  same  
step  was  repeated.  The  beads  were  washed  with  anhydrous  DCM.  The  beads  were  
deprotected  using  2  ml  of  2  %  DBU  in  DMF  for  5  minutes  at  room  temperature.  
This  step  was  repeated,  and  the  beads  were  washed  with  DCM.  The  acylation  step  
was  carried  out  at  room  temperature  for  20  minutes.  All  the  beads  were  incubated  in  
a  mixture  of  bromoacetic  anhydride  (0.41  g,  1. 58  mmol),  DIEA  (0.56  ml,  3.16  
mmol),  and  2  ml  of  DCM.  The  beads  were  washed  with  DCM.  Depending  on  the  
side  chain  sequences,  different  primary  amines  (3. 16  mmol)  in  2  ml  of  DCM  were  
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added  to  the  beads  and  the  reaction  mixture  was  stirred  at  room  temperature  for  20  
minutes  before  the  beads  were  washed  with  DCM.  These  acylation  and  SN2  by  
primary  amines  (e.g.  2,4-dimethoxybenzyl  amine,  isopropyl  amine,  benzyl  amine  and  
et  al)  were  repeated  until  the  intended  sequences  are  done.  In  order  to  complete  -
turn  template  (D-Pro-L-Pro),  Fmoc-L-Proline  (1.07  g,  3.16  mmol),  HCTU  (1.31  g,  
3.16  mmol),  and  DIEA  (1.12  ml,  6.32  mmol)  in  3  ml  of  DCM  were  mixed  for  1  
hour,  and  this  step  was  repeated.  The  beads  were  washed  with  DCM.  The  Fmoc  
group  was  deprotected  by  using  2  %  DBU  in  DMF  and  the  beads  were  washed  with  
DCM.  In  order  to  construct  the  other  strand,  the  same  procedure  such  as  SN2  
reaction  with  Fmoc-D-Proline,  acylation,  SN2  reaction  with  primary  amines,  and  SN2  
reaction  with  Fmoc-L-Proline  was  performed.  Before  the  linear  peptoids  were  cleaved  
from  the  resin,  Fmoc  group  was  deprotected  using  2  %  DBU  in  DMF  and  the  beads  
were  washed  with  DCM.  Based  on  the  mass,  the  resins  were  divided  by  in  half  for  
the  preparation  of  acyclic  and  cyclic  peptoids.  Both  of  peptoids  on  the  resins  were  
cleaved  with  TFA  and  the  resulting  solution  was  collected  in a flask.  For  the  complete  
deprotection  (2,4-dimethoxytoluene),  the  resulting  solution  was  stirred  for  2  days.  
After  removing  TFA  under  the  reduced  pressure,  one  of  batches  were  purified  using  
HPLC  to  collect  the  acyclic  peptoid  (Figure  4).  The  peptoids  in  the  other  batch  were  
cyclized  in  the  mixture  of  HCTU  (0.65  g,  1.58  mmol),  DIEA  (0.56  ml,  3.16  mmol)  
in  5  ml  of  DCM.  After  proper  work-up,  the  cyclic  peptoids  were  obtained  after  
HPLC  purification  (Figure  4).  MALDI-TOF:  m/z [M+H]
+
  1677.99  (acyclic  version).  
MALDI-TOF:  m/z [M+H]
+
  1659.97  (cyclic  version). 
 
 171 
 
 
Figure 42. Structures of acyclic and cyclic peptoid-peptide hybrids 3. 
 
4. 3. 4.  NMR  study  of  peptoid-peptide  hybrids 
  In  order  to  investigate  the  chemical  shift  change  of  -protons  in  acyclic  and  cyclic  
peptoid-peptide  hybrids,  the  proton  NMR  study  was  performed  (INOVA-400  and  
INOVA-500).  Compounds  were  dissolved  in  deturated  chloroform  and  acetonitrile. 
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APPENDIX:  1H,  13C  NMR  SPECTRA,  MASS  SPECTRA 
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(The sample was checked after three Boc-groups were deprotected with TFA.) 
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(The sample was checked after three Boc-groups were deprotected with TFA.) 
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(The sample was checked after three Boc-groups were deprotected with TFA.) 
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(The sample was checked after three Boc-groups were deprotected.) 
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(The sample was checked after three Boc-groups were deprotected.) 
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Acyclic  (top)  and  cyclic  (bottom)  peptoid-peptide  hybrid  1 
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Acyclic  (top)  and  cyclic  (bottom)  peptoid-peptide  hybrid  2 
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Acyclic  (top)  and  cyclic  (bottom)  peptoid-peptide  hybrid  3 
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